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Summary
Mouse mammary tumor virus (MMTV) is  a non-acute transforming  Betaretrovirus 
that is transmitted by viral particles present in the mother's milk. Upon digestion, the virus 
infects and replicates in the cells of the lymphatic system until it finally reaches the mammary 
gland epithelial. There, the integrated virus remains silent until its major LTR promoter, P1, is 
activated by glucocorticoid hormones.
Uniquely among retroviruses, MMTV harbours a further promoter element within its 
LTR.  The  P2  promoter  has  been  described  as  being  enhanced  in  the  presence  of 
glucocorticoids.  However,  as  yet,  no  transcriptional  product  of  P2  has  been  related to  its 
activity. To examine the regulation of P2 in more detail, we used a sensitive reporter gene 
assay based on luciferase expression. Unexpectedly, we detected another promoter during this 
analysis, P3, which is located immediately downstream of the P2 promoter. Both promoter 
elements appear to form a complex in the central part of the MMTV LTR. 
We  could  show  that  both  promoters  are  regulated  by  a  downstream  located 
enhancer. In  contrast,  only  the  activity  of  the  P2  promoter  is  influenced  by  an  upstream 
located  negative  regulatory  element  (NRE).  Furthermore,  we  were  able  to  relate  the 
constitutive transcriptional activity originating from the P2/P3 promoter complex with a DNase 
hypersensitive site at the corresponding nucleosome. Additionally, we could demonstrate that 
this open chromatin formation is associated with elevated methylation levels at lysine 4 and 
lysine  36  of  histone  H3,  respectively.  Both  modifications  are  predominantly  found  in 
transcriptionally active regions.
Independent of glucocorticoid stimulation, we were able to identify a doubly spliced 
message initiating from the complex. Moreover, we could demonstrate that the level of this 
transcript is regulated by the activities of histone deacetylases (HDACs). Incubation with the 
HDAC inhibitor trichostatin A (TSA) lead to a concentration dependent reduction of the doubly 
spliced  messenger  RNA,  which  was  accompanied  by  increasing  acetylation  levels  of  the 
corresponding  nucleosome.  Congruently,  we  detected  a  tight  association  of  the  histone 
deacetylase 1 (HDAC1) to the region of the P2/P3 promoter complex.
Finally,  we  could  show  that  the  transcription  factor  CCAAT  displacement  protein 
(CDP)  is  a  specific  regulator  of  the  promoter  complex.  By  binding  to  the  NRE,  CDP 
downregulates the transcriptional activity of the P2 promoter. Thereby, the emergence of the 
doubly spliced message is intimately linked to early stages of cell differentiation and thus to 
the latency phase of the virus. 
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Zusammenfassung
Der zur Gruppe der  Betaretroviren zählende Mouse mammary tumor virus (MMTV) 
verursacht nach einer längeren Latenzphase Tumoren in infizierten Tieren. Die Übertragung 
dieses  Erregers  erfolgt  dabei  durch  virale  Partikel,  welche  in  die  Muttermilch  erwachsener 
weiblicher Tiere abgebeben werden. Im Verdauungstrakt der neugeborenen Mäuse befällt der 
Virus  zunächst  die  Zellen  des  lymphatischen  Gewebes;  erst  danach  wird  die  Brustdrüse 
befallen. Die dort befindlichen Epithelzellen werden infiziert, jedoch werden nur marginal virale 
Proteine  gebildet.  Die  Latenzphase  endet,  sobald  der  Hauptpromoter  des  LTR,  P1,  durch 
Glucocorticoide aktiviert wird.
Im  Gegensatz  zu  anderen  Retroviren,  wurde  bei  MMTV  ein  zusätzliches 
Promoterelement  innerhalb  des  LTR  gefunden.  Dieser  P2  genannte  Promoter  wurde 
ursprünglich  als  ebenfalls  hormonabhängig  beschrieben.  Allerdings  konnte  bis  heute  kein 
transkriptionelles  Produkt  dieses  Promoters  gefunden  werden.  Um  die  Regulation  des 
Promoters P2 im Detail zu untersuchen, haben wir ein sensitives Reportersystem verwendet, 
welches auf der Expression des Luciferasegens basiert. Unerwarteterweise, haben wir dabei 
einen weiteren Promoter, P3, entdeckt, der sich in 3' Richtung in unmittelbarer Nachbarschaft 
zu P2 befindet. Bedingt durch ihre Nähe scheinen beide Promoterelemente einen Komplex im 
zentralen Teil des LTR von MMTV zu bilden.
Wir konnten zeigen, daß beide Promotoren durch einen in 3' Richtung befindlichen 
Enhancer  reguliert  werden.  Der  Promoter  P2  wird  zusätzlich  von  einem  in  5'  Richtung 
gelegenen Negativen Regulatorischen Element (NRE) beeinflußt. Weiters konnten wir zeigen, 
daß die konstitutive transkriptionelle Aktivität des P2/P3 Promoter Komplexes mit einer DNase 
hypersensitiven Stelle einhergeht, welche sich am zugehörigen Nucleosome feststellen ließ. 
Damit verbunden, konnten wir einen erhöhten Methylierungszustand der Lysine 4 und 36 des 
Histonproteins  H3  (desselben  Nucleosomes)  detektieren.  Beide  Modifikationen  werden 
hauptsächlich in Zusammenhang mit transkriptinell aktiven Region gefunden.
Unabhängig von hormoneller Stimulation, konnten wir eine doppelt gesplicte mRNA 
identifizieren, welche am Promoterkomplex ihren Ausgang nimmt. Wir konnten weiters zeigen, 
daß die Menge an Transkript durch die Aktivität von Histone Deacetylasen beeinflußt wird, da 
die  Verwendung  des  Histone  Deacetylasen  Inhibitors  Trichostatin  A  (TSA)  zu  einer 
konzentrationsabhängigen Abnahme der neu entdeckten mRNA führte. Begleitet wurde diese 
Abnahme  von  einer  gleichzeitigen  Zunahme  an  Acetyl-Resten  des  entsprechenden 
Nucleosomes.  Damit  übereinstimmend,  konnten  wir  eine  hohe  Konzentration  des  Enzymes 
Histone Deacetylase 1 an der P2/P3 Promoterregion feststellen.
Schließlich  konnten  wir  zeigen,  daß  der  Transkriptionsfaktor  CCAAT  displacement 
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protein (CDP) einen spezifischen Regulator des Promoterkomplexes darstellt. Durch Bindung an 
das  NRE  vermindert  CDP  die  transkriptionelle  Aktivität  des  P2  Promoters,  wodurch  das 
Auftreten des doppelt  gesplicten Transkripts  mit  frühen Phasen der Zelldifferenzierung und 
damit mit der Latenzphase des Virus in Verbindung gebracht werden kann.
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1.Introduction
1. Introduction
Retroviruses are RNA viruses which are characterised by their ability to integrate via 
a proviral DNA intermediate into the genome of the host cell. The transcription of all viral RNA 
species as well as the synthesis of the virally encoded proteins are mediated by the host cell 
machinery. Due  to  the  integration  process,  tumour  formation  is  frequently  observed after 
retroviral  infections.  Indeed,  this  consequence  often  led  to  their  discovery.  In  the  1930s, 
Bittner related particles present in the mother's milk of laboratory mouse strains to the high 
incidence of mammary tumours in those animals (Bittner, 1936). 
Mouse mammary tumor virus (MMTV) belongs to the family retroviridae, which can 
be further divided into the subfamilies orthoretrovirinaea and spumavirinae (table 1). 
Table 1: the Family Retroviridae (according to the NCBI Taxonomy Browser) 
MMTV  is  a  non-acute  transforming  retrovirus,  causing  tumour  formation  in 
susceptible mice after a latency period of 7 to 10 month (Callahan and Smith, 2000; Ross, 
2008). So far, no oncogene has been detected within the viral genome. Thus, MMTV is believed 
to induce tumours by insertional mutagenesis, a process which is further supported by the 
multiple cycles of mammary cell replication during pregnancy and lactation (Coffin et al., 1997; 
Ross,  2008).  Moreover,  the  integrated viral  DNA  is  thought  to  influence  cellular  gene 
expression  through the action  of  tissue specific  enhancer  sequences (Callahan and Smith, 
2008).
Due to their activation in MMTV-associated tumours, several cellular proto-oncogenes 
have been identified including the  Wnt and Fibroblast growth factor (Fgf)  gene families and 
Notch-related genes (Morris  et al., 1990; Shackleford et al., 1993; van Leeuwen and Nusse, 
1995). 
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Genus Type species
Subfamily Orthoretrovirinae
Betaretrovirus Mouse mammary tumor virus
Gammaretrovirus Murine leukemia virus
Deltaretrovirus Bovine leukemia virus
Epsilonretrovirus Walleye dermal sarcoma virus
Lentivirus Human immunodeficiency virus type 1
Spumavirus Chimpanzee foamy virus
unclassified Retroviridae
Avian retroviruses Avian endogenous retrovirus EAV-HP
Subfamily Spumavirinae
1.Introduction
 1.1  Exogenous infection route
 1.1.1  Dendritic cells
Upon ingestion, the dendritic  cells (DCs) of the intestinal  tract are the first cells 
which are infected by the virus present in the mothermilk (figure 1.1) (Martin  et al., 2002; 
Vacheron et al., 2002). 
Figure 1.1 Exogenous infection route of MMTV.  Viral  particles present  in the mother's  milk are 
transmitted to the newborn pups. (1) First, the dendritic cells of the gut are infected by the virus. (2) 
Upon activation, these cells travel to the lymphatic tissue of the intestinal tract, where they express and 
present the viral encoded superantigen (Sag) to cognate B- and T-cells. In response, the lymphocytes are 
activated and start to proliferate clonally. (3) Later during infection, a Sag-mediated deletion of specific 
TCR Vß positive T-cells is observed. (Figure modified from www.icmb.utexas.edu/images/upload/Directory
ID_1528/72_mmtvcycleLG.jpg)
A first interaction is mediated by the Toll-like receptors (TLRs) on the surface of the 
DCs,  which  are  able  to  recognize  invading  organisms  by  pathogen-associated  molecular 
patterns  (PAMPs).  Ligand  binding induces  signalling  through  the  Toll/IL-1  receptor  domain 
which ultimately leads to the initiation of inflammatory responses and the activation of the 
adaptive immunity (Underhill and Ozinsky, 2002; Takeda and Akira, 2007). 
MMTV primarily interacts with TLR4, thereby inducing the differentiation of the DCs 
into major antigen-presenting cells (APCs) (Rassa  et al., 2002; Burzyn  et al., 2004). Among 
other things, this process causes the expression of higher levels of the recently identified viral 
entry receptor on the surface of the DCs, the transferrin receptor 1 (TfR1 or CD71) (Ross et 
al.,  2002). While most cells require iron and thus have the potential  to express TfR1, the 
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highest levels are found in dividing cells and cells that are highly metabolically active. Thus, 
the tissue specificity of MMTV in vivo, which includes lymphoid tissue and mammary epithelial 
cells, can be explained in part by its receptor usage (Futran  et al., 1989; Schulman  et al., 
1989; Brekelmans et al., 1994). Two segments located on the surface of the TfR1 dimer, which 
are not involved in transferrin binding, have been shown to be essential for virus attachment 
(Wang et al., 2006). 
For delivering the viral genome into the cytoplasm, MMTV requires trafficking to a 
low pH compartment (~ pH 5) (Wang et al., 2008). This process is probably mediated by re-
directing the internalized receptor-virus-complex to the late endosomes, although the trigger 
for the irreversible conformational change of the envelope protein is still unknown. No evidence 
for the involvement of enzymes located in the late endosome/lysosome compartment (such as 
cysteine proteases) could have been demonstrated so far (Wang et al., 2008).   
Upon activation, the DCs migrate to the lymphatic tissue of the gut, where they 
present viral peptides together with MHC-class II molecules to  cognate T-cells, as described 
below (Abbas et al., 2000; Vacheron et al., 2002; Jude et al., 2003). Moreover, they have been 
shown to be capable of producing infectious viral particles that can be transmitted to other cell 
types (Courreges et al., 2007).  
 1.1.2  Lymphoid cells
For the establishment of infection in lymphoid cells,  MMTV has evolved a strategy 
that takes advantage of the immune system of the host. The viral encoded superantigen (Sag), 
which is translated into a 37 kDa transmembrane glycoprotein, is expressed immediately after 
successful integration of the provirus (Choi  et al., 1991). T-cells expressing an appropriate 
variable region of the T cell receptor ß chain (Vß) show reactivity to Sag and start to expand 
clonally (Held et al., 1993). 
Thereupon, these activated T-lymphocytes provide B-cell help and produce cytokines 
that  stimulate  and  recruit  additional  B-  and  T-  cells,  resulting  in  the  establishment  of  a 
reservoir  of  infection-competent as  well  as  infected cells  (Held  et al.,  1993). Later during 
infection,  a  gradual  deletion  or anergy of  Sag-reactive  T-cells  is  observed (Nakano  et al., 
1993). 
Besides T-cells, MMTV does infect B-cells that are located in the Peyer's patches of 
the gastrointestinal tract (Beutner et al., 1994). A first unspecific interaction is mediated by the 
binding of viral envelope proteins to TLR4 molecules expressed on the surface of these APCs 
(Rassa  et  al.,  2002).  However,  early  B-cell  activation  does  require  the  presence of  DCs 
(Courreges et al., 2007). Upon infection, B-cells are stimulated and present Sag together with 
MHC class II molecules to cognate T-helper cells. In turn, these cells induce the proliferation of 
17
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infected B-cells, which is essential in order to achieve high infection levels (Beutner  et al., 
1994; Karapetian et al., 1994).
Several  groups  have  demonstrated  that  no  infection  can  be  established  in  mice 
lacking B- or T-cells (Held et al., 1993; Beutner et al., 1994; Dzuris et al., 1997). Moreover, 
both cell types are capable of shedding infectious viral particles to the mammary cells, making 
them a crucial factor for virus spread (Dzuris et al., 1997; Golovkina et al., 1998).
 1.1.3  Mammary cells
The cells of the mammary gland epithelium represent the ultimate target of MMTV, 
as their successful infection ensures that viral particles are released into the mother's milk. 
Despite ongoing research, it is not known how the virus is actually delivered from the lymphoid 
cells to the mammary gland, although MMTV is highly specialized for replicating in these cells. 
In addition to the presence of a mammary specific enhancer element within the LTR (Mink et 
al., 1990; Lefebvre et al., 1991; Gouillieux et al., 1991; Reuss and Coffin, 2000), the activity 
of its major P1 promoter is upregulated in the presence of glucocorticoids (section 1.6.1). 
Furthermore,  the  virus  is  thought  be  able  to  increase  the  potential  of  mammary cells  to 
differentiate into secretory gland cells, thereby optimizing the route of exogenous transmission 
(Squartini et al., 1983).
Although several other tissues are infected as well (e.g. testis, salivary gland, kidney 
or lung), only the mammary gland epithelium is malignantly transformed upon MMTV infection 
and replication. It is believed that its regenerative activity represents a key factor for initiating 
tumour formation (Callahan and Smith, 2000). 
 1.2  Endogenous infection route
After successful integration into the DNA of the host cell, MMTV can additionally be 
transmitted through the germ line as an endogenous provirus.  So far, more than 50 MMTV 
proviral loci (Mtv) have been identified (Hodes and Abe, 2001). Indeed, most laboratory mouse 
strains contain two to eight endogenous proviruses, although in general these do not encode 
functional viruses (Kozak  et al., 1987). In fact, only  Mtv-1 and  Mtv-2 are known to induce 
mammary tumours in mice (Moore et al., 1979; Michalides et al., 1981). However, almost all 
MMTV proviral  loci  show intact  Sag coding regions, suggesting a positive selection for  the 
retention of endogenous Sags (Ross, 2008). This idea is further supported by the finding that 
mice transgenic for the  sag gene of the C3H strain are protected against exogenous MMTVs 
encoding the same Sag specificity (Golovkina et al., 1992).
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In contrast, endogenous Mtvs seem to be a prerequisite for the successful infection 
of  viruses  originating from different  strains  (Golovkina  et  al.,  1996;  Bhadra  et  al.,  2006; 
Bhadra  et al.,  2009). For instance,  the expression of  endogenous Sags was induced upon 
infection  with  the  exogenous  MMTV  strain  C3H  (Xu  et  al.,  1996).  Accordingly,  only  mice 
harbouring  endogenous  Mtvs  (Mtv-6,  -8 and  -9)  have  been  shown  to  be  susceptible  to 
tumorigenesis  after  infection  with  C3H  MMTV  as  well  as  by  the  MMTV  variant  type  B 
leukemogenic virus (TBLV) (Bhadra et al., 2006). Hence, BALB/c-c oncogenic mice lacking all 
endogenous  Mtvs are  resistant  to  infection  and  tumorigenesis  by  exogenous  C3H  MMTV 
(Bhadra et al., 2006). Interestingly, those mice could also not be infected with TBLV, a virus 
that  lacks  any  functional  sag gene.  The  mechanism for  this  resistance  is  not  yet  known 
(Bhadra et al., 2006). 
As  a  consequence  of  the  negative  selection  during  formation  of  the  immune 
repertoire, Sags encoded by endogenous Mtvs promote the clonal deletion of reactive T-cells 
(Acha-Orbea and Palmer, 1991). Thus, mice harbouring inherited proviruses in their genome 
possess an altered T-cell repertoire. This could be demonstrated by the resistance of Mtv-null 
mice to the otherwise fatal Gram-negative bacterium,  Vibrio cholerae (Scherer  et al., 1995; 
Barnett et al., 1999; Bhadra et al., 2006). 
 1.3  Does MMTV infect human tissue?
The involvement of MMTV in human pathogenesis was proposed a long time ago. 
Several groups have reported the association of a virus similar to MMTV with human breast 
cancer (Wang et al., 1995; Etkind et al., 2000; Wang et al., 2001; Lawson et al., 2004; Mok et 
al.,  2008).  In  these  studies,  MMTV-like  env sequences  have  been  detected  by  PCR 
amplification  from isolated  DNA or  by  immunological  methods.  Others,  however,  failed  to 
reproduce those results (Witt et al., 2003; Mant et al., 2004; Bindra et al., 2007). Moreover, a 
survey performed in  almost  100 patients  suffering  from breast  cancer  did not  reveal  any 
immunological reactivity against MMTV proteins (Goedert et al., 2006). 
Recently,  Melana  and  colleagues  were  able  to  isolate  particles  resembling 
Betaretroviruses from primary cultures of patients with metastatic breast cancer (Melana et al. 
2007). Additionally, a complete human mammary tumour virus (HTMV) proviral structure was 
identified in two tumours (Liu et al., 2001). Hence, the finding that the human genome carries 
a number of distinct human endogenous retrovirus (HERV) sequences which exhibit sequence 
similarity to MMTV complicate a definite correlation (Mant and Cason, 2004).  
On the other hand, studies of MMTV infecting or viruses adapting in order to infect 
human breast  cancer  cell  lines have been reported (Lasfargues  et al.,  1979; Howard and 
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Schlom, 1980; Indik  et al.,  2005 & 2007). However, the mechanism of both events remains 
unclear, since human TfR1 does not function as an MMTV entry receptor (Ross  et al., 2002; 
Wang et al., 2006). Experiments in human cells transfected with MMTV Env and hTfR1 (CD71) 
demonstrated that although both components are required, MMTV was unable to mediate the 
internalization of hTfR1 (Wang et al., 2008). Alternatively, MMTV may use other receptors for 
entry into human cells as proposed by Indik and colleagues (Indik et al., 2007). 
Taken together, the effect of MMTV-like sequences on the aetiology of human breast 
cancer remains controversial.
 1.4  The retroviral particle
Initially,  MMTV  was  classified  as  simple  retroviruses.  Those  viruses  (e.g  Murine 
leukemia virus) are thought to encode only the minimal set of proteins and enzymes which are 
necessary  for  viral  replication.  In  contrast,  complex  retroviruses  (e.g.  HIV-1)  possess 
additional information for a variety of non-structural proteins that facilitate distinct steps of 
replication or counteract cellular and immunological anti-viral host responses. Since ongoing 
research in the field of MMTV revealed at least two additional proteins with a major impact on 
viral pathogenicity, MMTV is now considered as a complex retrovirus.
Retroviruses  are  enveloped  viruses  with  an  average  diameter  of  80  –  100  nm. 
Mature,  infectious  particles  possess  a  core  of  electrondense  material,  which  is  located 
eccentrically  in  the  subfamily  Betaretrovirus  (Coffin  et  al.,  1997).  The  protection  of  the 
genome, the interaction with the host as well as the delivery of the genome are mediated by 
the proteins of the viral particle, which is shown schematically in figure 1.2.
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Figure 1.2 The retroviral particle. The composition of a Betaretrovirus is shown. The RNA genome is 
indicated by the two black lines, which are surrounded by the nucleocapsid proteins (marked by the thin 
black lines). This ribonucleoprotein complex is protected by a shell made of the capsid protein and the 
lipid bilayer, which is derived from the host cellular membrane. The knobs symbolize the surface part of 
the virally encoded Env protein. The cellular protein APOBEC3, which is incorporated into the retroviral 
particles is indicated by the blue diamond, all other geometrical shapes represent virally encoded proteins 
(modified from Flint et al., 2009). 
 1.4.1  The retroviral genome
The retroviral genome consists of two identical linear, single-stranded RNA strands of 
positive polarity, ranging from 7 to 12 kb in size. (The genome of MMTV comprises 8.6 kb.) 
Only one integrated copy is usually detected after infection; therefore, the term pseudodiploid 
is used (Coffin  et al.,  1997).  In the mature virion, these two molecules are held together 
primarily by a sequence called the dimer linkage site, which is located in the 5' untranslated 
region of gag (Coffin et al., 1997).
Since the genomic RNAs are generated by the RNA polymerase II of the host cell, 
they  possess  a  5'  cap  structure  and  are  polyadenylated  at  their  3'  end.  A  repeated  (R) 
sequence  is  found at  both  ends  of  the viral  RNA genome, which  is  followed by  a unique 
sequence at the 5' end (U5). The untranslated region at the 3' end is referred to as U3 region 
(U3) and contains most of the transcriptional control elements (promoters and enhancers). The 
major transcriptional units of replication competent retroviruses from 5' to 3' direction are gag, 
pol and env (figure 1.3). 
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Figure 1.3 Retroviral RNA genome.  Depicted is a linear, single stranded RNA genome. The repeat 
sequence (R) and the unique regions at the 5' end (U5) and the 3' end (U3), respectively, are symbolized 
by boxes. The transcriptional units (gag, pol, env) are indicated as a black line. The 5' cap-structure as 
well as the 3' polyA tail demonstrate the mRNA nature of the retroviral genome.
As a consequence of the reverse transcription step during infection, the genomic RNA 
is copied into a double stranded proviral DNA, which possesses identical structures on both 
ends of the coding region (figure 1.4). These are referred to as long terminal repeats (LTRs). 
Figure 1.4 Proviral DNA. After reverse transcription the retroviral genome is referred to as provirus and 
comprises identical regions (long terminal repeats) on both ends of the double stranded DNA genome.
The viral DNA synthesis takes place within the cytoplasm in a large ribonucleoprotein 
structure  called  the  reverse  transcription  complex  (RTC),  which  is  believed to  result  from 
structural  rearrangements  of  the  virion  core  (Mougel  et  al.,  2009).  As  the  responsible 
enzymatic  reaction  represents  a  hallmark of  retrovirus replication,  it  is  described in  detail 
below.
Similar to DNA-dependent polymerases, the viral encoded reverse transcriptase (RT) 
cannot initiate the DNA synthesis de novo. Therefore, it requires a specific primer. This task is 
accomplished by a cellular tRNA, which has been positioned at the primer binding site (pbs) of 
the RNA genome during virus assembly (figure 1.5). 
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Figure 1.5 Retroviral reverse transcription (I). The retroviral RNA genome is shown in green. Its 
primer binding site (pbs) is occupied by the cellular tRNA, thereby allowing the initiation of (-) strand 
DNA synthesis. The initiation of the reverse transcription process until the formation of the (-) strong stop 
DNA product is shown (Flint et al., 2009).
The reverse transcription starts, but quickly (after about 100 nucleotides) runs out of 
template, since it encounters the 5' end of the RNA genome. Immediately after being copied 
into the (-) strand DNA, the template  is  digested by the RNase H domain of  the RT. The 
product including the tRNA primer accumulates and is called (-) strong-stop DNA. 
In the following step, hydrogen bonding between the R sequence of the (-) strong-
stop DNA and the complementary R sequence upstream of the poly(A) tail occurs, which allows 
the  RT  to  continue  copying.  The  substitution  of  one  end of  the  RNA for  another  or  first 
template exchange takes place prior to complete digestion of the copied 5' end of the viral RNA 
(figure 1.6). 
Figure 1.6. Retroviral reverse transcription (II). The first template exchange and the initiation of 
the (+) strand DNA synthesis are shown (Flint et al., 2009).
One  early  digestion  product  of  the  genomic  RNA  is  a  fragment  comprising  the 
polypurin tract (ppt). Resourcefully, these few nucleotides serve as primer for the initiation of 
the (+) strand DNA synthesis, which starts prior to the completion of the (-) strand DNA. 
Again, the RT is forced to arrest after several nucleotides as it encounters a modified base 
which cannot be copied. The accumulating product is called the (+) strong-stop DNA (figure 
1.7). 
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Figure 1.7. Retroviral reverse transcription (III). Generation of the (+) strong stop DNA (Flint  et 
al., 2009).
The removal of the tRNA primer by RNase H allows the single-strand 3' end to anneal 
to  complementary sequences located at  the corresponding 3'  end of  (-)  strand DNA.  This 
process is referred to as second template exchange and provides a circular DNA template for 
continued polymerization by the reverse transcriptase (Flint et al., 2009).
Subsequently, (-) strand DNA synthesis continues until it reaches the end of viral 
DNA template. Both the production of (+) strong-stop DNA and the converging (-) strand DNA 
synthesis disengage the template  ends during processing.  The resulting product  is  the (-) 
strand of viral DNA equivalent of entire genome (in permuted order) annealed to (+) strong 
stop DNA (figure 1.8). 
Figure 1.8. Retroviral reverse transcription (IV). The process from the second template exchange 
until the formation of the final linear DNA product is shown schematically (Figure modified from Flint et 
al., 2009).
 As a consequence of the whole process, the regulatory elements of the U3 region 
are now in the optimal position to direct the transcription of the viral genome.
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 1.4.1.1  M  M  TV LTR promoters  
The current model for all retroviruses implies that a promoter located immediately 
upstream of the transcriptional initiation site (which is per definition the first base of the R 
region) gives rise to the full length RNA, which is subsequently either packaged into newly 
budding virions or used for translation of viral proteins. In MMTV, the major promoter is termed 
P1  promoter  (Donehower  et  al.,  1981;  Klemenz  et  al.,  1981;  Kusk  et  al.,  1995).  The 
mechanism of its activation will be described below (section 1.6)
In close vicinity to the P1 promoter, an initiator element (Inr) has been identified 
inside  the  R  region  (Pierce  et  al.,  1993;  Fee  et  al.,  2002).  Generally,  the  Inr  motif 
encompasses the transcriptional start site and represents the probably most common occurring 
sequence  motif  in  focused  core  promoters  (Juven-Gershon  et  al.,  2008).  These  group  of 
promoters possess either a single transcriptional start site or a distinct cluster within a short 
region. In vertebrates, only one-third or less are focused promoters, while the vast majority 
are dispersed core promoters, which have a number of transcriptional start sites distributed 
over  a  region  of  50  to  100  nucleotides  (Juven-Gershon  et  al.,  2008).  Hence,  a  precise 
transcription initiation in TATA-box containing promoters generally requires both the TATA-box 
motif and an Inr-like element (Sandelin et al., 2007).
Recently, it was successfully demonstrated that an MMTV provirus carrying a deletion 
of the P1 TATA-box is able to produce the viral envelope protein in an hormone-dependent way 
as efficiently as a non-deleted provirus (Rungaldier  et al., 2005). Thus, the MMTV Inr motif 
represents  a  classical  initiator  element  that  is  able  to  direct  specific  transcription  in  the 
absence of the TATA-box in addition to its role in the start site selection process. However, the 
Inr element failed to substitute for the absence of the P1 promoter in producing full length 
genomic viral RNAs (Rungaldier et al., 2005). 
Originally, the existence of an additional promoter element located in the U3 region 
was reported by Günzburg and colleagues. They observed transcripts that include sequences 
upstream of the major P1 promoter, when they were characterizing messenger RNAs from 
either MMTV infected or transfected cells (Günzburg et al., 1993). The start site of the novel 
transcriptionally active region, which has been termed P2 promoter, was assigned to position 
696 (relative to the beginning of the LTR). The activity of the P2 promoter was shown to be 
enhanced  in  the  presence  of  dexamethasone  as  well  as  in  response  to  LPS-treatment 
(Günzburg et al., 1993). Since its putative 1.2 kb transcripts were reported to be generated by 
splicing events occurring between the splice donor site of  gag and the splicing acceptor site 
used for the ORF/Sag transcripts (Wheeler et al., 1983; van Ooyen et al., 1983), the authors 
concluded that the P2 promoter is responsible for Sag expression (Günzburg et al., 1993). 
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 1.4.2  Viral proteins
 1.4.2.1  GAG  
The gag gene is transcribed from full length, unspliced mRNA. Following translation, 
the MMTV polyprotein precursor (p77) is cleaved by the viral protease (PR) giving rise to the 
myristoylated matrix  protein  (p10),  the capsid protein (p27)  and the nucleocapsid protein 
(p14). Several other proteins are generated as well, yet their functions remain unknown (Hizi 
et al., 1987).
The nucleocapsid proteins (NCs) are highly basic nucleic acid binding proteins that 
contain  one  or  two  conserved  zinc  finger  domains.  They  have  been  shown  to  direct  the 
selection, packaging and dimerization of the genomic RNA during virion assembly. Moreover, 
their association to the genomic RNA results in the congregation of other structural molecules, 
which in turn promotes the multimerization of the capsid proteins (CA) (Thomas and Gorelick, 
2008).  During  early  infection,  the  NC  proteins  contribute  to  the  fidelity  of  the  reverse 
transcription  reaction  by  inhibiting  self-initiation  of  the  cDNA synthesis.  Furthermore,  they 
facilitate the annealing of complementary sequences as well as strand transfer and exchange 
reactions (Mougel et al., 2009). 
Upon  retroviral  infection,  two  ribonucleoprotein  complexes  are  found  within  the 
cytoplasm of target cells, the Reverse-transcription-complex (RTC) and the Pre-integration-
complex (PIC). Both complexes are encased by a protein shell built by the capsid (CA) protein, 
which represents an important scaffold protein. Accordingly, CA mutants have been shown to 
reduce viral infectivity by blocking either the process of reverse transcription or distinct steps 
during nuclear entry (most probably due to improper core disassembly events) (Thomas and 
Gorelick, 2008). 
Located in between the envelope and the viral core is an additional protein layer, 
comprised  of  the  membrane-associated  matrix  (MA)  proteins.  These  polypeptides  are  co-
translationally myristoylated. Although not sufficient, this modification is required for anchoring 
the Gag polypeptides to the plasma membrane of the host cell (Coffin et al., 1997). 
During the budding process, the Gag polyproteins are cleaved by the viral protease 
in a highly ordered cascade. Immature virions contain a roughly spherical  shell  of radially 
extended Gag molecules, whereas the N-terminal Gag (MA domain) is bound to inner viral 
membrane and the C-termini of the Gag molecules project into the centre of virus. A disruption 
of the regulated nature of these events is highly detrimental to viral maturation and infectivity 
(Adamson and Freed, 2008). 
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 1.4.2.2  P  OL  
The corresponding gene encodes for the essential enzymes protease (PR), reverse 
transcriptase  (RT)  and integrase  (IN)  (in  5'  to  3'  direction).  In  MMTV,  these  proteins  are 
translated in different reading frames from full  length, unspliced mRNA (Hizi  et al., 1987). 
Pseudoknot  structures  within  the  mRNA  induce  ribosomal  frameshifting  events  that  are 
required for the generation of the gag-pro and the gag-pro-pol precursors (Hizi  et al., 1987; 
Chamorro et al., 1992; Chen et al., 1995). As a consequence, all enzymatic proteins are fused 
to the Gag polyprotein, which provides a direct way to incorporate enzymes into the virion 
during assembly (Coffin et al., 1997). 
Pro encodes for the viral protease. The enzyme possesses a broad specificity with a 
maximum activity at pH from 4-6 and cleaves virally derived polyprotein precursors during the 
essential process of virion maturation (Menendez-Arias et al., 1992). During these events, the 
liberated  NC-RNA  complex  condenses  at  the  centre  of  the  core,  the  genome  RNA  dimer 
becomes more stable and the capsid is formed. In order to ensure that Gag proteins are not 
processed before they assemble, the protease is liberated at a very late stage of viral assembly 
from the Gag-Pol fusion polypeptide as has been recently demonstrated for the HIV protease 
(Ganser-pornillos et al., 2008).
The  translation  products  of  pol are  the  viral  enzymes  reverse  transcriptase  and 
integrase. As has been described in section 1.4.1, the RT accounts for the viral DNA synthesis. 
The end product represents a direct substrate for  the enzyme integrase, which specifically 
catalyses the insertion of the reverse transcribed viral genome into the host cell  DNA.  The 
actual reaction comprises three distinct steps (processing, joining and repair, figure 1.9), two 
of which are catalysed by the IN. 
Figure 1.9 Overview of the enzymatic reactions necessary for retroviral integration. The proviral 
DNA  represents  the  direct  substrate  for  the  viral  encoded  integrase.  First,  the  enzyme  removes 
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dinucleotides from the 3' ends of both LTRs. During the strand transfer reaction, the processed proviral 
DNA is joined covalently to staggered nicks at the target site that have been introduced by the integrase 
as well. Cellular enzymes are responsible for final repair reactions (Flint et al., 2009).
In a first step, dinucleotides are removed from the 3' ends of both LTRs, thereby 
exposing a CA 5'  overhang.  In the subsequent event,  the strand-transfer  reaction,  the 3' 
recessed ends are joined to 5' phosphates at the target site which have also been created by 
the integrase. Consequently, the proviral ends of all retroviruses are embedded by 5'-TG and 
CA-3'. (Occasionally, these dinucleotides extend into imperfect inverted repeat that can be as 
long as 20 bp for some viral genomes.) Finally, the exposed 5' dinucleotides of the LTR end are 
removed and the single-stranded region is repaired, resulting in direct repeat at each LTR-
chromosomal DNA junction. This last step is mediated by cellular repair enzymes (Thomas and 
Gorelick,  2008).  Figure  1.10  shows  schematically  the  viral  genome  before  and  after 
integration.
Figure 1.10 The retroviral genome before and after integration into the host cell DNA. Above, 
the unintegrated linear DNA is shown together with the host cell DNA. The respective target sequence is 
marked by an arrow. During integration, two base pairs on either side of the LTR are removed and a 6-bp 
duplication at  the  target  site  are  generated.  The  overall  enzymatic  process  results  in  an integrated 
proviral DNA that includes short, imperfect inverted repeats at its termini, which end with conserved 
5'TG...CA-3' sequence (middle). The integrated provirus serves as template for the generation of new 
RNA viral genomes (Flint et al., 2009).
Recently,  MMTV integration  sites  have  been  analysed  from acutely  infected  cells 
(Faschinger  et al.,  2008). The experimental  set-up was distinct form earlier studies, which 
mainly utilized tumour cells (i.e. clonally expanded cells) to determine common insertion sites 
and thereby most probably induced a bias (Gray et al., 1986; Gallahan and Gallahan, 1987; 
Clausse et al., 1993; Marchetti et al., 1995; Theodorou et al., 2007). This latest study revealed 
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that MMTV possesses the most random target sites selection among retroviruses at present 
investigated (Faschinger et al., 2008). 
The respective gene is encoded from the 3' end of pol region.
 1.4.2.3  ENV  
The outer lipid envelope of the retroviral particle is derived mainly from the host cell 
membrane, while the characteristic protrusions are built by integral viral glycoproteins. They 
are encoded by the env gene, which is translated from a single-spliced subgenomic RNA and 
proteolytically cleaved by host furin enzymes (Dudley and Varmus, 1981; Coffin et al., 1997). 
In MMTV, the surface polyprotein (SU or p52) mediates the binding to the cellular 
receptor TfR1, while the transmembrane protein (TM or p33) participates in the virion-cell 
membrane fusion process (Wang et al., 2006; Ross, 2008). As mentioned earlier, the MMTV 
Env was additionally shown to interact with antigen presenting cells via the TLR4, thereby 
facilitating initial steps of infection (Rassa  et al., 2002; Burzyn  et al., 2004).  Moreover, an 
involvement of the Env protein in tumour formation was demonstrated by ectopic expression of 
env in normal mammary epithelial cells, which resulted in a phenotypic transformation of the 
transfected  cells.  An  immunoreceptor  activation  motif  (ITAM)  was  identified  as  a  critical, 
although not sufficient factor for the cellular transformation process (Katz et al., 2005; Ross et 
al., 2006). 
Other oncogenic viruses do encode viral protein with ITAMS as well. For instance, the 
Env  protein  of  the  related  Betaretrovirus Jaggsiekte  sheep  retrovirus  (JSRV)  has  been 
demonstrated to be required for the transformation of lung epithelial cells (Maeda et al., 2001; 
Rai et al., 2001; Wootton et al., 2005). 
 1.4.3  MMTV accessory proteins
 1.4.3.1  Sag (Superantigen)  
As  mentioned  earlier,  the  superantigen  is  not  displayed  by  the  virus  itself,  but 
expressed  from the  infected  antigen  presenting  cell.  The  resulting  immune  stimulation  is 
essential for viral transmission. Sag is encoded from an ORF located within the LTR (Brandt-
Carlson and Butel, 1991; Choi et al., 1991 & 1992). Due to the low abundance of the protein 
and  difficulties  in  the  production  of  reactive  antibodies,  the  regulation  of  Sag  is  largely 
unknown. Moreover, the promoter responsible for Sag expression could not be identified with 
certainty. Several candidates have been reported to account for  sag mRNA expression (van 
Ooyen et al., 1983; Günzburg et al., 1993; Zhang et al., 1996; Reuss and Coffin, 1998). 
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An MMTV variant, Type B leukemogenic virus (TBLV), induces T-cell lymphomas in 
infected animals after a very short latency period. The analysis of isolated viruses revealed 
major alterations within the LTR (Michalides et al., 1986). Infected T-cells transcribe high levels 
of MMTV-specific RNAs due to the deletion of a negative regulatory element (Ball et al., 1988; 
Hsu et al., 1988). Besides, a substitution of 124 nucleotides is found in the U3 region of the 
virus  that  is  thought  to  function  as  a  T-cell  specific  enhancer  (Mertz  et  al.,  2001).  Both 
mutations alter  the  Sag coding region,  resulting in  the expression  of  a  truncated protein. 
However, it seemed to be dispensable for the process of tumour formation, indicating that the 
loss of the NRE and putative other  cis-acting elements are sufficient for altering the tissue 
specificity of the virus (Mustafa et al., 2003). 
To date, no B-cell malignancies induced by MMTV are known.
 1.4.3.2  R  em (Regulator of export of MMTV mRNA)  
The nuclear export of incompletely spliced RNAs is usually prevented in eukaryotic 
cells. Thus, viruses have evolved different strategies in order to circumvent these mechanisms. 
Simple retroviruses utilize cis-acting viral RNA segments like the constitutive transport element 
(CTE) of the  Betaretrovirus Mason-Pfizer monkey virus (MPMV), which directly interacts with 
cellular proteins and thereby promote the export of the full length RNA  (Bray  et al., 1994; 
Pasquinelli et al., 1997).
In contrast,  complex retroviruses encode auxiliary  trans-acting proteins. The HIV 
encoded Rev protein binds to an RNA motif termed the Rev-responsive element (RRE) which is 
located in  the  env coding region (Felber  et al.,  1989;  Hadzopoulou-Cladaras  et al.,  1989; 
Malim et al., 1989). It acts as adaptor for the full length mRNA and contains a leucine-rich 
nuclear export signal (NES), which has been shown to interact with the nuclear export factor 
Crm1/Xpo1 (chromosome region maintenance-1/exportin-1) (Lin  et al., 2005).  Rev and Rev-
like proteins shuttle between nucleus and cytoplasm (Cullen, 2003).
Similar to HIV, MMTV encodes a double spliced transcript, termed regulator of export 
of MMTV mRNA (Rem) (Indik et al., 2005; Mertz et al., 2005). The rem-coding sequences are 
derived from the entire env signal-peptide coding region as well as parts of the SU and the TU 
and give rise to a 33 kDa protein (Indik  et al., 2005; Mertz  et al., 2005). Interestingly, all 
motifs necessary for RNA export are localized at the very N-terminus, making it similar in 
structure to the related HERV-K Rec protein (Mertz et al., 2005). The binding site for Rem lies 
within a highly structured viral RNA segment at the env-U3 RNA junction and was termed Rem 
responsive element (RmRE) (Mertz et al., 2005; Müllner et al., 2008). 
Recently,  a  similar  protein  was  identified  in  the  Betaretrovirus Jaagsiekte  Sheep 
Retrovirus.  Like  Rec  and  Rem,  Rej  is  a  doubly  spliced transcript  encoded  within  the  env 
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sequence. However, the mechanism of action may differ, since Rej does not appear to facilitate 
export of unspliced viral RNA. Nevertheless, it seems to be required for the synthesis and/or 
the translation of viral Gag polyproteins (Hofacre et al., 2009). 
 1.4.3.3  D  UTPase  
Like herpesvirus, poxvirus and other retroviruses, MMTV encodes a dUTPase. This 
protein  is  generated by a  ribosomal  frameshift  at  the  gag-pro junction  (Bergmann  et al., 
1994). Its function is the hydrolysis of dUTP, which leads to an increase in cellular dTTP levels. 
Thereby, the enzyme minimizes the misincorporation of uracil into the DNA during the process 
of  reverse transcription. Since  the  expression  levels  of  the  cellular  enzyme  are  low  in 
differentiated cells (Chen et al., 2002), MMTV relies on the activity of its own protein.
 1.4.4  Cellular APOBEC3 
APOBEC3  proteins  (A3)  are  potent  host  restriction  factors  of  viruses  and 
retrotransposable endogenous mobile genetic elements (Harris and Liddament, 2004). Several 
mechanisms have been proposed for the antiviral activity of APOBEC3, among them a cytidine 
deaminase  activity.  During  the  process  of  reverse  transcription,  this  property  deaminates 
cytidine  to  uridine,  thereby  inducing  hypermutations,  which  subsequently  result  in the 
degradation of the viral DNA and the generation of nonfunctional proviral genomes (Harris et 
al., 2003). 
Mice express a single APOBEC3 (mA3) protein (Cullen, 2006). Ross and co-workers 
have demonstrated that mA3 proteins are packaged into MMTV virions in an RNA-dependent 
fashion,  thus inhibiting MMTV infection. Moreover, all tissues that are predominantly infected 
by MMTV express mA3 transcripts (Okeoma et al., 2007). Accordingly, mA3-/- mice have been 
shown to be more susceptible to MMTV infections, as viruses spread more rapidly and to an 
higher extent in these animals than in control groups (Okeoma  et al., 2007).  Interestingly, 
upon viral infection, DCs increase their intracellular mA3 levels (Okeoma et al., 2009a). These 
findings  could  explain  why  MMTV infects  mature  DCs  less  efficiently  than  immature  DCs, 
although MMTV infection leads to an upregulation of the viral entry receptor TfR1 (Vacheron et 
al., 2002). 
Recently, it was demonstrated that mA3 inhibits infection by murine leukemia virus 
(MLV).  The  effect  was  not  due  to  the  enzymatic  properties  of  the  protein;  instead,  the 
restriction seemed to depend on the mA3 allele expressed (Takeda  et al., 2008). Similarly, 
mA3  could  play  a  role  in  the  genetics  of  susceptibility  and  resistance  to  MMTV  infection 
(Okeoma et al., 2009b). Since MMTV possesses a purine-rich genome, one could hypothesize 
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that MMTV do persist in mice because the virus became in evolutionary terms less susceptible 
to the inhibition by this protein (Okeoma et al., 2007). 
 1.5  The retroviral replication cycle 
The replication cycle within a single cell can be divided into early steps, which include 
attachment and binding to the target cell,  viral  entry as well  as the processes of  reverse 
transcription and integration and late steps, which comprise the transcription and translation of 
the viral proteins, their assembly and finally the release of the virion. A summary of these 
processes is shown in figure 1.11.
Figure 1.11 Retroviral life cycle.  After binding and attachment to the cellular receptor (1), the viral 
envelope protein fuses with the cellular membranes and the viral core is released into the cytoplasma (2). 
The viral RNA genome is reverse transcribed into DNA (3) and transported via the preintegration complex 
to the nucleus (4). After integration (5), the proviral DNA is transcribed by the cellular RNA polymerase II 
(6). Unspliced (7) as well as spliced mRNAs (8) are translated and transported to the cell membrane 
(10). Some full length mRNAs are packaged into the nascent viral particles in order to serve as viral 
genomes (9). The assembly of the viral particle takes place at the cell membrane (11), from which the 
viral progeny buds off. Maturation of the viral particles is achieved by the condensation of the viral core 
(12). (Figure modified from Flint et al., 2009)
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Through interaction of the viral envelope protein with components of the cell surface, 
the envelope of the virus fuses with the plasma membrane of the host cell. Subsequently, the 
viral  core  undergoes  a  partial  and  progressive  disassembly  (uncoating),  leading  to  the 
formation of the reverse-transcription complex. It is believed that the initiation of the reverse 
transcription is coupled to the onset of uncoating, since the process depends on a sufficient 
amounts of dNTPs. Nevertheless, limited linear DNA synthesis has been observed in virions 
prior to infection (Nisole and Saïb, 2004).
Besides the double-strand proviral copy of the viral genome, smaller quantities of 
two specific circular DNA products can be detected as well; however, they are considered as 
non-functional, dead-end products (Flint  et al., 2009). One is the LTR circle, which possibly 
occurs due to a failure of strand displacement during reverse transcription; the other is the two 
LTR circle. The latter is thought to be generated by the ligation of the ends of the linear viral 
DNA by the cellular enzyme DNA ligase. As the two LTR circle can be easily detected by PCR 
amplification, it is often used as a marker for the successful transport of the viral DNA to the 
nucleus. 
The overall process of reverse transcription is very slow due to the periodic pausing 
of  the  enzyme,  reaching  only  one  tenth  of  the  speed  of  DNA-dependent  polymerases. 
Additionally,  the fidelity rate of the enzyme is low, since it lacks any editing activity,  thus 
contributing to the high mutation rates observed in vivo. Due to the utilization of the second 
RNA  genome,  genetic  recombination  events  like  misincorporations,  rearrangements  or 
deletions also occur with high probability. They are referred to as copy choice recombination 
(Flint et al., 2009).
Four to eight  hours after  viral  entry during infection,  the preintegration complex 
(PIC), containing full-length viral DNA, localizes to the nucleus of the host cell. However, it is 
poorly understood how the structure passes through the nuclear pore complex, as it is too 
large for passive diffusion (Flint el al., 2009). 
Retroviruses depend on the host cell  machinery for the transcription of their RNA 
genome as well as for the production of their proteins; therefore, several viruses including 
MMTV encode additional auxiliary proteins that modulate RNA Pol II transcription or regulate 
RNA splicing and export (see above). 
For  Beta-, Deltaretroviruses and  Spumaviruses,  the assembly of the viral  particle 
takes place within the cytoplasm of the infected cells (Coffin  et al., 1997). Besides the RNA 
genome, which is  recognized via the packaging signal, equimolar quantities of  the reverse 
transcriptase  and  the  integrase  are  incorporated  as  well  as  other  relevant  nonstructural 
proteins.  Upon release of  the viral  particles,  referred to as budding,  the immature virions 
acquire  a  lipid  envelope,  which  is  derived  from  the  cell  membrane.  Simultaneously,  the 
maturation process starts that includes the proteolytic processing of virion Gag proteins. The 
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virions are now ready to infect a new cell. 
 1.6  The MMTV major P1 promoter
 1.6.1  Stimulation by glucocorticoid hormones
The LTR of MMTV is widely used as a model system for studying hormone-dependent 
transcriptional regulation. The activity of the major P1 promoter is enhanced in the presence of 
steroid  hormones  which  include  glucocorticoids,  progestins  and  androgens  (Ringold  et  al., 
1975; Cato et al., 1987). Upon binding to their receptors, these molecules are able to pass the 
nuclear membrane and adhere to sequences which are collectively termed hormone responsive 
element (HRE). Up to five consensus binding sites, which are represented by the hexamer 
TGTTCT, are located between bps 994 and 1114 (relative to the beginning of the LTR) (Buetti 
and Diggelmann, 1983; Hynes et al., 1983). 
Additionally,  two  cellular  transcription  factors  are  required  for  proper  hormone-
induced transcription from the major P1 promoter (Mymryk et al., 1995). Nuclear factor 1 (NF-
1) binds at position 1114 to 1134 (Cordingley and Hager, 1988), while sequences recognized 
by the octamer binding factor (Oct-1) are found in the region from bps 1134 to 1156 (relative 
to  the  5'  end  of  the  LTR)  (Brüggemeier  et  al.,  1991).  In  the  absence  of  hormones,  the 
chromatin structure is thought to exclude both proteins from binding to their respective sites 
on the MMTV LTR (Hebbar and Archer, 2007).
Early studies on the chromatin organization of the P1 promoter revealed that an 
array of six phased nucleosomes covers the MMTV LTR (Richard-Foy and Hager, 1987). The 
mean centre positions of the regions between the nucleosomes were determined by MPE-Fe(II) 
cleavage as well as by micrococcal nuclease digestion of either uninduced or hormone-treated 
cells. (The centres of the cutting sites were determined by the indirect end-labelling method 
and are: 175, 368, 543, 750, 944, 1134, 1330 (relative to the beginning of the LTR) (Richard-
Foy and Hager, 1987).) 
The  phasing  was  reproduced  in  chromatin  reconstitution  experiments  comprising 
fragments  of  the  MMTV  LTR  and  core  histone  octamers  (Pina  et  al.,  1990).  In  contrast, 
transiently introduced copies of the MMTV LTR do not acquire a specific chromatin structure, 
although they are hormone inducible (Lee and Archer, 1994). 
The six positioned nucleosomes are referred to as nucleosomes A-F; nucleosome F is 
farthermost distant from the transcriptional start site of the major P1 promoter (figure 1.12). 
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Figure 1.12 The chromatin organization of the MMTV LTR. Six nucleosomes are positioned over the 
MMTV LTR,  which  are  referred  to  as  nucleosome F-A (in  5'  to  3'  direction).  The  core  histones  are 
represented by the grey cylinders, while the linker histone H1 is shown in dark grey. The TATA-box of the 
major P1 promoter (TATA) as well as the hormone responsive element (HRE) and the binding site for 
transcription factors (the nuclear factor-1 binding site (NF-1) is shown exemplarily) are indicated as blue 
boxes. (Figure modified from Vicent et al., 2008.)
In  the  presence  of  glucocorticoids,  a  hypersensitive  site  is  detectable  within 
nucleosome B  that  covers  the  HRE  (Zaret  and  Yamamoto,  1984;  Richard-Foy  and  Hager, 
1987).  The existence of  nuclease hypersensitive site  is  either interpreted as a gap in the 
nucleosomal array (also referred to as nucleosome-free region) or is thought to result from a 
temporary removal of histone proteins (Rando and Ahmad, 2007). However, the presence of 
DNase hypersensitive sites do not automatically correlate with the rate of transcription from 
the  corresponding  promoters.  Therefore,  these  sites  are  suggested  to  reflect  rather  the 
transcriptional competence than the actual promoter activity (Workman, 2006).
In MMTV, however, treatment with glucocorticoids results in the rapid induction of 
transcription driven by the P1 promoter and a concomitant remodelling of the chromatin in the 
presence of ATP (Fletcher et al., 2000). Hormone-bound steroid receptors have been shown to 
enhance the association of chromatin remodelling complexes of the SWI/SNF family to the 
MMTV P1 promoter (Fletcher  et al.,  2000; Nagaich  et al.,  2004). During the final  steps of 
promoter activation, the ATP-dependent catalytic subunit BRG1 (Brahma-related gene 1) is 
recruited together with RNA Pol II (Georgel et al., 2003). Through its activity, the histone H2A 
and H2B subunits are displaced from nucleosome B, providing a more accessible DNA (Vicent 
et  al.,  2004).  Thus,  steroid  hormone  binding  facilitates  the  association  of  other  relevant 
transcription factors (Fletcher et al., 2000). 
Furthermore, bound NF-1 has been proposed to stabilize GR/BRG1 interactions. In 
the absence of the transcription factor, the chromatin architecture of the promoter does not 
permit a strong association of the GR to the HRE, suggesting a cooperativity among these two 
DNA binding factors (Chavez and Beato, 1997; Hebbar and Archer, 2007).
This whole process is accompanied by the loss of the linker histone H1 from the 
promoter  region  (Bresnick  et  al.,  1992).  Generally,  the  histone  H1 stabilizes  higher  order 
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chromatin structures and acts as general  transcriptional repressor (Lee and Archer, 1998). 
During GR-mediated chromatin remodelling, however, the histone H1 is phosphorylated and 
thereupon lost from the promoter (Bresnick et al., 1992). Figure 1.13 summarises the essential 
steps during the MMTV P1 promoter activation.
Figure 1.13 Nucleosome remodelling at the MMTV P1 promoter.  The steps of the nucleosome B 
remodelling process are shown schematically. The binding of the glucocorticoid receptor (GR) and the 
transcription factor NF-1 promotes the association of the ATP-dependent chromatin remodelling complex 
BRG1,  which  induces  the  dislocation  of  the  H2A/H2B  dimer.  These  events  are  accompanied  by  the 
removal of the phosphorylated linker histone H1. (Figure modified from Vicent et al., 2008). 
Recently,  the binding of  the transcription  factor  forkhead box A1 (FoxA1)  to  the 
MMTV LTR was reported. It is speculated that FoxA1 replaces the linker histones from open 
chromatin and anchors nucleosomes to specific sites; therefore, the association of FoxA1 could 
alter the chromatin structure and affect transcription as well. Binding sites have been mapped 
to regions flanking the nucleosome B region (Holmqvist et al., 2005).
 1.6.2  Negative regulation
The activity of the major P1 promoter is additionally modulated by two effectors, 
which have been described to negatively influence transcription from the MMTV LTR. 
The  existence  of  a  negative  acting  factor  (Naf)  was  postulated by  Salmons  and 
colleagues  during attempts  to  establish  a  packaging cell  line  containing  full  length  MMTV 
proviral sequences under the control of the Rous sarcoma virus (RSV) promoter. Upon stable 
introduction  of  MMTV  based  retroviral  vectors,  they  observed  a  downregulation  in  the 
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expression level of Gag proteins. They proposed that this effect was due to the  trans-acting 
factor  Naf  (Salmons  et  al.,  1990).  Nevertheless,  neither  the  coding requirements  nor  the 
mechanism of its effector functions have yet been elucidated (Metzner et al., 2006). 
Several groups have described the presence of a negative regulatory element (NRE) 
within the LTR (Mink et al., 1990; Lefebvre et al., 1991; Bramblett et al., 1995). Recently, it 
was  demonstrated  by  Dudley  and  colleagues  that  the  cellular  transcription  factor  CCAAT 
displacement protein (CDP) binds to the NRE, thereby repressing MMTV transcription (Liu  et 
al., 1999; Zhu et al., 2000). 
CDP proteins are a family of transcription factors that contain a Cut homeodomain 
and one  to  three Cut  repeats  (Sansregret  and Nepveu,  2008).  (The term “Cut”  originally 
derived form the “cut  wing”  phenotype observed in a  mutant of  Drosophila  melanogaster. 
However, due to the variety of terms used for the same gene family in different species, the 
gene root of Cut-like was changed to CUX (Cut-homeobox). Accordingly, CUX1 and CUX2 refer 
to  human genes,  cux1 and  cux2 to  mouse  genes  and CUX1 and CUX2 to  the  respective 
proteins (Sansregret and Nepveu, 2008). However, for simplicity, the term CDP will be used 
throughout this thesis.) 
CDP proteins are highly conserved and involved in the control of proliferation and 
differentiation  processes  (Nepveu,  2001).  Several  isoforms  with  distinct  DNA  binding  and 
transcriptional properties are known that are generated by alternative transcriptional initiation, 
polyadenylation site selection and splicing as well as proteolytic processing (figure 1.14). 
Figure 1.14 CDP isoforms. Several CDP isoforms have been described so far. With the exception of p75 
that is generated by an transcriptional initiation site within intron 20, all proteins derive from the full 
length protein (p200). The protein domains are abbreviated as follows: Inhibitory domain (In), coiled coil 
domain (CC), Cut Repeat (CR), Homeodomain (HD), Repressing domain (R) (Sansregret and Nepveu, 
2008).
Moreover, the DNA binding activity of CDP was shown to be regulated by numerous 
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post-translational  modifications  including  phosphorylation  and  acetylation  events,  both  of 
which  inhibit  the  DNA  binding  and  transcriptional  activity  of  the  protein  (Sansregret  and 
Nepveu, 2008).
CDP exerts a double influence on MMTV driven mammary carcinogenesis. On the one 
hand, the protein possesses a pivotal role in the differentiation process of the mammary gland. 
Studies revealed that CDP negatively regulates the transcription of multiple genes that are 
expressed in  the differentiated mammary glands  (Zhu  et  al.,  2004).  Accordingly,  its  DNA 
binding activity has been shown to be high in the virgin mammary gland, whereas during 
development it continuously declined (Liu et al., 1999; Zhu et al., 2000). 
On the other hand, CDP has been identified as repressor of MMTV transcription (Zhu 
et  al.,  2000;  Zhu  and  Dudley,  2002).  Substitution  mutations  elevated  both  basal  and 
glucocorticoid-induced reporter  gene expression driven by the MMTV LTR. Furthermore,  an 
additive  effect  was  observed when combinations  thereof  were  tested,  suggesting that  the 
binding sites  contribute independently to the negative  regulation (Zhu and Dudley,  2002). 
Additionally,  mice  infected  with  proviruses  containing different  CDP binding site  mutations 
exhibited an increased expression of MMTV in the virgin mammary gland and suffered from an 
accelerated appearance of breast tumours (Zhu et al., 2004).
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2. Aim of the project
Almost twenty years ago, the CAAT- and the TATA-box as well as the transcriptional 
initiation  site  of  the  P2  promoter,  which  is  located  in  the  central  part  of  the  LTR,  were 
determined by Günzburg and colleagues (Günzburg et al., 1993). The activity of the promoter 
was shown to be enhanced upon glucocorticoid treatment and it was proposed to give rise to 
Sag mRNA in B-lymphocytes. However, difficulties in determining its putative transcriptional 
product complicated the attempts to obtain definitive proof.
The aim of the project was to investigate in more detail the regulation of the MMTV 
P2 promoter and ultimately link its activity to a transcriptional product.
Thus, in a first approach, we wanted to analyse possible regulatory elements within 
the LTR, since the influence of several regions on the major P1 promoter is controversial in the 
literature. We hypothesized that these sequences could possibly modulate the activity of the P2 
promoter as well. Moreover, the transcriptional regulator CCAAT displacement protein (CDP) 
has been shown to bind to the negative regulatory element (NRE) of the LTR (Zhu and Dudley, 
2002).  Three  binding sites  are  located  in  close  vicinity  to  the  P2  promoter  elements.  By 
mutating those CDP binding sites, we wanted to analyse whether the transcriptional activity of 
the P2 promoter is repressed by CDP.
 In general, transcriptional active regions are free of nucleosomes to facilitate the 
binding of the transcriptional machinery (Segal  et al., 2006; Rando and Ahmad, 2007). The 
major P1 promoter is known to undergo a characteristic remodelling process upon hormonal 
stimulation  (Richard-Foy  and  Hager,  1987;  Bresnick et  al.,  1992;  Vicent  et  al.,  2008). 
Therefore, in a different approach, we wanted to investigate the influence of the nucleosome 
positioning on the activity of the P2 promoter, which has also been described as hormone 
inducible (Günzburg  et al.,  1993). We asked whether the P2 promoter could be regulated 
similarly. Thus, we wanted to analyse the positioning of the nucleosome D that is covering the 
P2 promoter region both in the presence and in the absence of glucocorticoid hormones.
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3. Materials and methods
 3.1  Tissue culture
 3.1.1  Cell lines
CrFK cells  (CCL-94™), NMuMG cells  (CRL-1636™), NIH3T3 cells (CRL-1658™) and 
A20 cells (TIB-208™) were obtained from the American Type Culture Collection (ATCC). HiB5 
cells (rat neuronal progenitor cells; Renfranz  et al., 1991) and GR cells (mouse mammary 
carcinoma cells; Ringold et al., 1975) were kindly provided by the cell bank of the Institute of 
Virology. 
Two MMTV producer cell clones were established by stably transfecting CrFK cells and 
NMuMG cells with pMtv-2pAneoES (Rungaldier et al., 2005), thereby generating C2AnE15 cells 
and N2AnE5 cells, respectively. The 5' LTR of MMTV was introduced stably into CrFK cells and 
NMuMG cells giving rise to populations of CK5'LTR cells and NM5'LTR cells, respectively. 
 3.1.2  Media and solutions
Dulbecco's  Modified  Eagle  Medium  (DMEM)  containing  4,500  mg/l  glucose  and 
GlutaMAXTM-I (Gibco BRL, Invitrogen) was supplemented with 10% (v/v) Foetal Calf Serum 
(FCS) (Gibco BRL, Invitrogen). The FCS was heat inactivated for 30 min at 56°C before use. 
This medium was used for monolayer cultures of CrFK, NIH3T3, GR and NMuMG cells. Stably 
transfected cell clones of CrFK cell and NMuMG cells were maintained in medium containing in 
addition 400 µg/ml and 800 µg/ml Geneticin (G418) (Gibco BRL, Invitrogen), respectively.
HiB5 cells were cultured in DMEM containing 4,500 mg/l glucose and GlutaMAXTM-I 
(Gibco BRL, Invitrogen). The medium was supplemented with 0.11 mg/ml sodium pyruvate, 
3.7 mg/ml sodium bicarbonat and 10 % (v/v) heat inactivated FCS.
RPMI  1640  medium  containing  2  mM  L-glutamine  (Gibco  BRL,  Invitrogen)  was 
supplemented with 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 10 mM HEPES, 1.0 mM sodium 
pyruvate,  0.05 mM 2-mercaptoethanol  and 10 % (v/v) heat  inactivated FCS prior  to use. 
Suspension cultures of A20 cells were grown in this medium.
The buffer used to wash the cells was phosphate buffered saline (PBS). The 10x 
stock contains 14 mM KH2PO4, 27 mM Na2HPO4 and 1370 mM NaCl dissolved in H2Odd. The 
buffer was autoclaved before use.
The cells were detached from the culture flasks using a solution of 0.5% trypsin and 
0.53 mM EDTA (TE) (Gibco BRL, Invitrogen). 
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The synthetic glucocorticoid dexamethasone (1 mM diluted in 96 % ethanol) was 
stored at -20°C and added to the cells in a final concentration of 1 µM.
 3.1.3  Cell culture
The  cells  were  cultured  in  flasks  (Corning)  with  the  corresponding  medium 
supplemented  with  FCS  and  antibiotics  at  37°C  (33°C  for  HiB5  cells)  in  a  humidified 
atmosphere containing 5 % CO2. Before reaching complete confluence, the cells were washed 
with 1x PBS and incubated with a minimum amount of TE (see 3.1.2) at 37°C (33°C) until they 
detached from the bottom of  the flask and separated from each other.  By adding normal 
growth  medium the  enzymatic  reaction  was  stopped,  a  defined  volume  of  the  cells  was 
transferred into new flasks and supplemented with an appropriate volume of fresh medium.
A20 cells were passaged by transferring the suspension into falcon tubes, followed 
by a  centrifugation step at 1000 rpm for 5 min. After removing the supernatant containing the 
used media, the cell pellet was resuspended with fresh medium and a defined volume was 
transferred to a new flask at a suitable dilution.
 3.1.4  Cell counting
After the cells were trypsinized and detached from the flask surface, they were taken 
up in an appropriate volume of fresh medium. 100 µl of the cell suspension were loaded onto a 
haemocytometer  (Bürker-Türk  counting  chamber).  The  cells  were  counted  under  a  light 
microscope and the cell number per ml was calculated.
 3.1.5  Freezing and thawing of cells
Exponentially growing cells were washed in 1x PBS, trypsinized, taken up in fresh 
medium and centrifuged at 1000 rpm for 5 minutes at 4°C. The supernatant was discarded and 
the cells  were resuspended in freezing medium containing 75% DMEM, 20% FCS and 5% 
DMSO, transferred into  cryo tubes (Nunc) and cooled down slowly in  a  freezing container 
(Nalgene).  The  cells  were  stored  at  -80°C or  transferred to  liquid  nitrogen  for  long term 
storage. The cell density of the cryo-stocks was 5 x 106 cells/ml.
The recovery of the frozen cells was done by quickly warming the cells to 37°C and 
transferring them to 10 ml of fresh medium. After a centrifugation step at 1000 rpm for 5 
minutes, the pellet was resuspended in fresh medium and added to a new flask.
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 3.1.6  Synchronization of cells
In  order  to  enrich the cells  in  the G0/G1 phase of  the cell  cycle,  the cells  were 
synchronized by serum starvation. CK5'LTR cells and NM5'LTR cells were plated in 175 cm2 
flasks in DMEM supplemented with 10 % FCS and antibiotics. After reaching 30 % to 40 % of 
cell density, the medium was replaced with DMEM containing 0.5 % FCS. Subsequently, the 
cells were incubated at 37°C for 48 hours to allow the entire population to respond to the 
serum withdrawal. By adding normal growth medium (DMEM supplemented with 10 % FCS) 
the cells were stimulated to reenter the cell cycle and to proceed simultaneously into the G1 
phase.
 3.1.7  Fluorescence activated cell sorting (FACS) analysis
Fluorescence activated cell  sorting allows the analysis and sorting of cells on the 
basis of size, surface attributes and expression of specific genes.
 3.1.7.1  Determination of eGFP expression  
In order to determine the transfection efficiency or the infectivity of different proviral 
constructs,  FACS analysis was applied to analyse the enhanced green fluorescence protein 
marker gene (eGFP) expression. For this purpose, the cells were trypsinized and resuspended 
in growth medium. An aliquot of the cell suspension was transferred to a microcentrifuge tube 
and the cells  pelleted by centrifugation  at  1000 rpm for  5  minutes.  The supernatant  was 
discarded  and  the  cells  resuspended  in  1  ml  4  % formaldehyde  (in  PBS)  and  mixed  by 
vortexing. After incubation for 20 minutes, the cells were centrifuged as before, washed twice 
with 1 ml PBS and finally resuspended in 800 µl PBS. Just before FACS analysis, the cells were 
filtered through a nylon gauze to exclude any cell clumps. The fluorochromes were stimulated 
at 488 nm and 10,000 events (for transfections) or 100,000 events (for infections) per sample 
were analysed on a FACScalibur (Becton Dickinson) flow cytometer. The results were depicted 
using the Cell Quest Pro software (Becton Dickinson) giving the proportion of eGFP expressing 
cells and the extend of the eGFP expression in terms of mean fluorescence intensity (MFI).
 3.1.7.2  Probidium iodide staining  
The quality of synchronization was monitored by FACS analysis of cells stained with 
probidium iodide  (PI).  PI  intercalates  into  the  major  groove  of  double-stranded  DNA and 
produces upon excitation at 488 nm an highly fluorescent adduct which can be measured at 
600 nm. 
For the analysis, the trypsinized cells (see 3.1.3) were washed twice with ice-cold 1x 
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PBS. After the second centrifugation step, the pellet was resuspended in 950 µl of hypertonic 
lysis buffer (0.1 % sodium citrate, 0.2 % Triton-X 100, 20 µg/ml RNase A) and incubated at 
37°C for 30 minutes. Then, 5 µl propidium iodide of a 1 mg/ml stock solution were added and 
the cells were incubated at RT for additional 30 minutes in the dark. Subsequently, the cells 
were filtered through a nylon gauze to exclude any cell  clumps and analysed using a flow 
cytometer (FACScalibur, Becton Dickson).
A histogram plot of DNA content against cell numbers allowed the determination of 
the cell cycle phase. Cells in the G0/G1 phase of the cell cycle are thought to possess a diploid 
chromosome (DNA content: 2n), whereas cells in G2/M phase contain the doubled amount of 
DNA (4n). During the S-phase (phase of DNA synthesis), the DNA content ranges between 2n 
and 4n. 
 3.1.8  Transfection of eukaryotic cells
 3.1.8.1  Calciumphosphate co-precipitation  
24 hours prior to transfection, 2.5 x 105 cells were seeded into the wells of a 6-well 
plate and supplemented with 3 ml growth medium. On the day of transfection (70 % – 80 % 
cell  density),  per  well  2  µg of  the plasmid of  interest  were diluted in  120 µl  H2Odd  using 
polystyrol tubes (Greiner). (For the determination of the transfection efficiency, 0.5 µg of the 
plasmid peGFPc1 (encoding the enhanced green fluorescence protein) were added in parallel.) 
Subsequently, 120 µl of buffer A (0.1 M Hepes, pH 7.0; 0.5 M CaCl2; sterile filtrated) 
were added. The solution was mixed by vortexing and incubated for 10 minutes at RT. Then, 
240 µl of buffer B (0.05 M Hepes, pH 7.0; 0.28  M NaCl; 1.5 mM NaPO4, pH to 7.0; sterile 
filtrated) were added dropwise while vortexing. The whole mixture was incubated for additional 
15 minutes at RT. In the mean time, the medium of the cells was replaced with 2 ml fresh 
growth medium. Then, the transfection mix was equally distributed over the well. The plates 
were incubated at 37°C in a humidified atmosphere containing 5 % CO2. Eight hours later, the 
cells were washed with 1x PBS to remove any remaining precipitates and covered with 3 ml 
fresh growth medium.
 3.1.8.2  L  ipofectamine  
The day before transfection, the cells were plated in 6-well plates in a dilution that 
would allow a 90-95 % cell density 24 hours later. Per well, 4 µg DNA were diluted in 250 µl 
DMEM without FCS. Similarly, 10 µl of LipofectamineTM 2000 (Invitrogen) were diluted in 250 µl 
DMEM without FCS, mixed gently and incubated for 5 minutes at RT. Then, the diluted DNA 
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was combined with the LipofectamineTM 2000 mix, the solution was mixed gently and incubated 
for 20 minutes at RT to allow the formation of DNA-LipofectamineTM 2000 complexes. Next, the 
medium of the cells was removed and replaced with 2 ml growth medium. 500 µl of the DNA-
LipofectamineTM complexes were added to each well and after gently mixing the solutions, the 
plates were incubated at 37°C in a CO2 incubator. The medium was replaced with fresh growth 
medium after 6 to 8 hours.
 3.2  Bacterial culture
 3.2.1  Bacterial strains
The bacterial strain used for the amplification of plasmids was E.coli MAX Efficiency® 
DH5alphaTM (Invitrogen). For applying electroporations, we transformed ElectroMAXTM DH10BTM 
cells (Invitrogen). JC 5176 bacteria (kindly provided by Dr. Françoise Rouault) were used for 
homologous recombinations. OneShot® TOP10 chemically competent E. coli (Invitrogen) were 
transformed after TA-cloning. 
 3.2.2  Media and antibiotics
Luria-Bertani (LB) medium contained 10 g/l tryptone, 5 g/l yeast extract and 10 g/l 
NaCl. The pH was adjusted to 7.0. The medium was autoclaved before use and antibiotics were 
added. 
LB low salt medium was made by combining 10 g/l tryptone, 5 g/l yeast extract and 
5 g/l NaCl. The pH was adjusted to 7.5. LB low salt medium was used in combination with the 
antibiotic Zeocin.
SOC media (0.5 % yeast extract, 2 % select peptone, 10 mM NaCl, 25 mM KCl, 10 
mM MgCl2, 20 mM Glucose) was used for cell recovery upon transformation.
The solid bacteria medium was obtained by addition of 1.5% Bacto-agar to liquid 
media (LB) before autoclaving. After cooling down to 50°C, antibiotics were added to the final 
concentration and the solution was poured into Petri dishes.
The antibiotics used were Ampicillin sodium salt (Sigma),  Kanamycin (Sigma), and 
Zeocin (Invitrogen). The stock solutions (50 mg/ml for Ampicillin and Kanamycin; 100 mg/ml 
for Zeocin) were kept at -20°C. The final concentrations of the antibiotics were 100 µg/ml, 50 
µg/ml and 25 µg/ml, respectively.
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 3.2.3  Transformation of bacteria
 3.2.3.1  Heat shock  
An  aliquot  of  compentent  cells  (50  µl)  was  thawn  on  ice  for  approximately  10 
minutes. Then, the DNA was added (10 µl for a ligation or 1 µl for retransformation) to the 
bacteria. The suspension was incubated on ice for further 15 minutes. A heat shock was then 
applied to the cells at 42°C for 45 seconds. The cells were immediately chilled on ice for 5 
minutes, upon which 400 µl LB (or alternatively SOC medium) were added. The solution was 
incubated at 37°C for 30 to 60 minutes on an orbital shaker to allow the cells to recover and to 
induce  the expression  of  the  resistance gene.  Aliquots  thereof  were  plated in  Petri-dishes 
containing the appropriate medium and antibiotics.  After overnight incubation at 37°C, the 
plates were checked for colony formation.
 3.2.3.2  E  lectroporation  
Prior to the electroporation, the DNA (20 µl of a ligation reaction) was precipitated 
once with buthanol by adding 30 µl of H2Odd and 500 µl buthanol and centrifugating the sample 
for 15 minutes at 13,000 rpm. The supernatant was decanted and the dried pellet resuspended 
in 30 µl of sterile H2Odd. Thereof, 15 µl were added to an aliquot (25 µl) of electrocompetent 
bacteria.  The suspension was transferred into  a pre-chilled electroporation  cuvette  (1  mm 
electrode gap, Biozym). Immediately after applying the electric voltage (constant set at 1.8 kV, 
200 Ω, 25 µF; BioRad gene pulser II), the bacteria were taken up in 500 µl of prewarmed SOC-
media and incubated for one hour at 37°C while shaking. Aliquots were plated in Petri-dishes 
containing the appropriate selection medium and incubated overnight at 37°C to allow colony 
formation.
 3.3  DNA methods
 3.3.1  Preparation of plasmid DNA from bacteria
 3.3.1.1  S  mall scale preparation - 'mini prep'  
From  a  3  ml  bacterial  culture  grown  overnight,  1.5  ml  were  harvested  by 
centrifugation at 6,000 rpm for 5 min at room temperature. The cell pellet was resuspended in 
300 µl buffer P1 (50 mM glucose; 25 mM Tris-HCl, pH 8.0; 10 mM EDTA; 10% (v/v) RNase A). 
To lyse the cells, 300 µl buffer P2 (0.2 N NaOH; 1 % (w/v) SDS) were added, the suspension 
was mixed gently and incubated for maximal 5 minutes at room temperature. The precipitation 
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of proteins and chromosomal DNA was done by adding 300 µl of buffer P3 (3 M potassium 
acetate; 5 M glacial acetic acid). The solution was gentle mixed and the resulting precipitate 
separated by centrifugation at 13,000 rpm for 20 minutes at 4°C. The supernatant containing 
the plasmid DNA was transferred to a new tube and the DNA was precipitated by the addition 
of  650 µl  isopropanol.  After  a centrifugation step,  the pellet was washed in 1 ml of  70% 
ethanol.  Finally,  the  DNA pellet  was  air-dryed and resuspended  in  an  appropriate  volume 
H2Odd. The plasmid quality was suitable for restriction digests; for sequencing reactions, the 
resuspended DNA was precipitated with ethanol for a second time, followed by an additional 
washing step with 70% ethanol. Subsequently, the DNA was recovered in H2Odd.  
 3.3.1.2  L  arge scale preparation of plasmid DNA - 'maxi prep'  
Larger amounts of pure plasmid DNA (up to 1.5 µg) were obtained by growing 200 
ml of a bacterial culture overnight at 37°C. The bacterial cells were harvested by centrifugation 
at 6,000 rpm for 5 minutes at 4°C in an Avanti J-25 centrifuge (Beckman). After decanting the 
supernatant, the pellet was resuspended in 10 ml of buffer P1 (50 mM glucose; 25 mM Tris-
HCl, pH 8.0; 10 mM EDTA; 10% (v/v) RNase A; Qiagen). Then, 10 ml of buffer P2 (0.2 N 
NaOH; 1 % (w/v) SDS; Qiagen) were added, the solution mixed vigorously by inverting the 
tube several times and incubated for maximal 5 minutes at RT. Subsequently, 10 ml of ice-cold 
buffer P3 (3 M potassium acetate; 5 M glacial acetic acid; Qiagen) were added. The samples 
were incubated on ice for 20 minutes after mixing thoroughly by inversion, followed by a 30 
minutes centrifugation step at 10,000 rpm at 4°C. The supernatant was transferred into a new 
tube and centrifuged for an additional 30 minutes at 10,000 rpm at 4°C. In the mean time, a 
Qiagen tip 500 column per sample was equilibrated by applying 10 ml of equilibration buffer 
(QBT, Qiagen) onto the membrane. The supernatant was pipetted onto the column and allowed 
to pass through by gravitation. Subsequently, the column was washed twice with wash buffer 
(QC, Qiagen). The column was placed into a clean glass tube and the DNA was eluted by 
applying 15 ml elution buffer (QF, Qiagen) onto the membrane. 15 ml of isopropanol were 
immediately added to the flow-through and the solution was centrifuged at 16,000 rpm for 15 
min  at  4°C.  The  DNA  was  washed  once  with  70  %  ethanol  and  after  an  additional 
centrifugation step, the pellet was dried in a vaccum dryer (Oligo prep OP120 concentrator, 
Savant) and resuspended in 400 µl TE-buffer (10 mM Tris-HCl, pH 7.5; 1 mM EDTA).
 3.3.2  Preparation of genomic DNA from cells
Generally, the Qiagen DNeasy Tissue kit involving a silica-gel membrane for DNA 
binding was used according to the manufacturer's guidelines. 
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Approximately 5 x 106 cells were harvested by trypsinization and washed once with 
PBS. The supernatant was decanted and the pellet resuspended in 200 µl PBS. Then, 20 µl 
proteinase K (Qiagen) and 200 µl  of  buffer  AL (Qiagen) were added to each sample. The 
solution  was  vortexed  vigorously  and  incubated  at  70°C  for  10  minutes.  Afterwards,  the 
solution was mixed with 200 µl ethanol and pipetted into a DNeasy Mini spin column placed in 
a 2 ml collection tube. After a centrifugation at 8,000 rpm for one minute, the flow-through 
was discarded. To wash the DNeasy membrane, 500 µl AW1 buffer (Qiagen) were applied to 
the column, followed by a centrifugation at 8,000 rpm for one minute. As before, the flow-
through was discarded before 500 µl of buffer AW2 (Qiagen) were loaded onto the membrane. 
Each sample was centrifuged at 14,000 rpm for 3 minutes. After discarding the flow-through, 
the membranes were dried by an additional centrifugation step at 8,000 rpm for one minute. 
Subsequently, the spin column was placed onto a clean 1.5 ml Eppendorf tube and 200 µl AE 
buffer (Qiagen) were pipetted directly onto the membrane. The samples were incubated for 
one minute at RT. Finally, the DNA was eluted by centrifugating the columns at 8,000 rpm for 
one minute.
 3.3.3  DNA separation on agarose gels
The DNA diluted in H2Odd was mixed with 1/5 of the sample volume 5 x loading 
buffer (30 % glycerol; 0,25 % bromphenolblue; 0.25 % xylene cyanol; 0.25 % Orange G; 10 
mM EDTA) and separated according to size via agarose gel electrophoresis. Depending on the 
expected fragment size of the DNA of interest, the percentage of agarose dissolved in 1x TAE 
buffer (40 mM Tris-base; 40 mM acetic acid; 1 mM EDTA) was between 0.7 and 2.0 % (w/v). 
Gels were run at 80 to 120 Volt (power pac, Biorad) in 1x TAE buffer in tanks. The DNA was 
visualized after ethidium bromide staining (5 µg/ml in 1 x TAE buffer) under UV (ultraviolett) 
light. 
For gels  with  an agarose content higher  than 1.2 %, the ethidium bromide was 
added to the dissolved agarose before pouring the solution into the gel chamber. These gels 
were analysed immediately after electrophoresis under the UV light. 
The intensity of  the DNA band was compared either to a 100 bp molecular  size 
marker (Fermentas) or a 1 kb DNA ladder (Invitrogen) in order to estimate the DNA size and 
quantity.
 3.3.4  Plasmids 
The  plasmids  used  in  this  work  were  the  pCR®4-TOPO  (Invitrogen),  which  was 
supplied linearised with single 3' thymidine overhangs and a topoisomerase covalently bound 
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to  the  vector.  Due  to  the  template-independent  terminal  transferase  activity  of  the  Taq 
polymerase, PCR inserts are efficiently ligated into this vector. For longer PCR amplification 
products, the vector pCR®-XL-TOPO® (Invitrogen) was used. 
The plasmid pGR102 (Salmons et al., 1985) was used to amplify Mtv-2 and Mtv-8 
LTR sequences.
We utilized the plasmid pcDNA3.1/Zeo (Invitrogen) for the cloning and expression of 
the different CDP isoforms. 
The plasmid pLTRpAneo (Rungaldier et al., 2005) was used to study the positioning 
of the nucleosome D.
For reporter gene assays, we used the promoterless plasmid  pZluc (Brasier  et al., 
1989; Maxwell et al., 1989). 
 3.3.5  Plasmid construction
 3.3.5.1  Cloning of luciferase expression constructs  
To analyse the regulation of the LTR promoters, different fragments of the MMTV LTR 
were generated by PCRs using MMTV-specific oligonucleotides carrying a BamHI (or HindIII) 
restriction  site  at  their  respective  5'  end.  After  digestion  with  the  relevant  enzymes,  the 
fragments were gel purified and inserted upstream of the luciferase gene in the promoterless 
expression plasmid pZluc. The plasmid pGR102Cla (that was obtained after ClaI-digestion and 
self-ligation  of  the plasmid pGR102)  was used as template  for  Mtv-2 LTR sequences.  The 
plasmid  pGR102AflII,  which  have  been  generated  by  religation  of  the  previously  digested 
pGR102EGFPSac (Indik et al., 2005) with AflII, was used to amplify Mtv-8 LTR sequences.
 3.3.5.2  Cloning of the CDP binding site mutations into the MMTV LTR  
Two PCRs were performed with primer pairs m596f - m693r and m693f - HindIIIrev 
in order to introduce the CDP binding site mutations and the mutation of the P3 TATA-box into 
the LTR of MMTV. The plasmid pZ1303 containing the  Mtv-2 LTR upstream of the luciferase 
gene was used as template. Subsequently, the two fragments were used as starting material of 
a third PCR using m596f together with HindIIIrev to obtain a single fragment spanning the 
whole region. The fragment was subcloned into the TOPO-XL-Vector, and after amplification, 
digested with StuI and HindIII. In the following step, the plasmid pZ1303 was digested with 
the same enzymes,  dephosphorylated and ligated with  the above fragment,  giving rise  to 
pZP2+P1+dCDP-.
To be able  to  analyse the P2  promoter  activity  in  the absence of  the  major  P1 
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promoter,  the  LTR  harbouring  the  CDP  binding  site  mutations,  yet  lacking  the  promoter 
elements of P1, was recovered by a PCR using the oligonucleotides Z1 – X1156mtv2. The 
amplified  fragment  was  digested  with  BamHI  and  XhoI  and  ligated  with  the  vector 
pZgzP2+delR harbouring mutations of the P3 promoter and a short deletion encompassing the 
P1  promoter  and  the  Inr  element.  The  vector  was  digested  with  the  same  enzymes  and 
dephosphorylated before use. As a result, the plasmid pZgzP2+delR_dCDP- was obtained. 
 3.3.5.3  Cloning of a provirus containing the CDP binding site mutations  
The plasmid pZP2+P1+dCDP-  (see 3.3.5.2) was double-digested with AarI and SacI. 
The  fragment  of  interest  (567  bps)  was  gel-purified  and  ligated  with  vector  pLTRpAneo 
(Rungaldier  et  al.,  2005)  that  had  been  digested  with  the  same  enzymes  and 
dephorsphorylated before use. The resulting plasmid was digested with BsaI giving rise to a 
7184 bp fragment, which was subsequently introduced into the linearized and dephoshorylated 
pGR102EGFPSac (Indik et al., 2005) by homologous recombination. The resulting plasmid was 
named pMtv2pAneoESdCDPm. 
 3.3.5.4  Cloning of CDP/p110 isoform  
The transcriptionally active isoform of CDP was obtained by a long-template PCR 
using  the  Expand  high  fidelity  PCR  system  (Roche)  in  combination  with  the  primer  pair 
mCDP1815for – mCDP3987rev. As template reverse transcribed mRNA from NIH3T3 cells was 
used.  The  obtained  fragment  (~2.200  bps)  was  subcloned  into  the  plasmid  pCR-XL-TOPO 
(Invitrogen) and amplified. To introduce restriction sites on either end of the fragment, a PCR 
was performed using the primer pair p110exfor – p110NotIrev. The resulting fragment was 
again  subcloned  into  the  plasmid  pCR-XL-TOPO  (Invitrogen)  and  amplified.  After  double-
digestion  with  NheI  and  NotI,  the  fragment  was  inserted  into  the  plasmid  pcDNA3.1/zeo 
(Invitrogen) that has been digested with the same enzymes and dephosphorylated before use. 
The final construct was named pCMV110.
 3.3.6  Homologous recombination
Under  physiological  conditions,  homologous  recombination  occurs  between  two 
identical (homologous) DNA molecules during cell division. The same mechanism can be used 
for efficiently linking vector and fragment DNA in vitro, if an homologous sequence of at least 
100 bp is present on either end of each molecule.
For  the  reaction  100  ng  of  the  vector  in  combination  with  a  5  times  excess  in 
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fragment DNA were used. Taking into account the length of both sequences, the following 
calculation was applied: 100 ng x 5 / (bps of the vector / bps of the fragment) gives the 
amount of the fragment (in ng). The appropriate amounts of both, vector and fragment were 
combined  in  an  Eppendorf  tube  together  with  4  µl  of  a  5  x  ligase  buffer  containing 
polyethylenglycol (Roche). H2Odd was added to a total volume of 20 µl. The reaction was mixed 
gently and incubated two hours at  RT. Then, the mixture was used to transform JC 5176 
bacteria (Capaldo-Kimball and Barbour, 1971).
The recombination event was examined by restriction digest of corresponding mini 
preps (see 3.3.1.1 and 3.3.8.1). Since JC 5176 bacteria possess only a very low potential to 
amplify non-bacterial DNA, an aliquot of the mini prep containing the correct recombinated 
plasmid was retransformed into DH5alpha bacteria in order to achieve a sufficient amount of 
DNA.
 3.3.7  Oligonucleotide dimerization
Oligonucleotides  complementary  to  each  other  were  hybridized  according  to  the 
following protocol: In a total volume of 50 µl, 20 µM of each oligonucleotide (diluted in 250 mM 
Tris-HCl, pH 7.7) were heated for 5 minutes at 95°C using an PCR machine (Eppendorf master 
cycler). Then, the temperature was lowered to 70°C, followed by a controlled gradually cool 
down to room temperature. After one hour incubation at RT, the solution was gradually cooled 
to 4°C. The mixture containing the hybridized product was aliquoted and stored at 4°C until 
further use.
 3.3.8  Enzymatic reactions
 3.3.8.1  Restriction digestions of DNA  
Restriction  endonucleases  and  10  x  reaction  buffer  were  used  according  the 
manufacturer's instructions. Analytical digestions were performed in a total of 15 µl with 0.5 
ng to 1.0 µg DNA; preparative digestions in a total volume of 100 µl using 2 µg to 5 µg of 
DNA.
 3.3.8.2  L  igation of DNA fragments with T4 DNA ligase  
Generally, a 20 µl ligation reaction mix contained 100 ng of digested vector DNA and 
a defined amount of insert DNA in 1 mM ATP, 1x T4-DNA Ligase buffer (30 mM Tris-HCl, pH 
7.8; 10 mM MgCl2;  10 mM DTT) and 0.5 µl T4-DNA ligase (Roche, 10 U/µl).  The amount of 
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insert (in ng) was calculated in relation to the length of both, vector and fragment using the 
following formula: 100 ng vector x 10 / (size of vector (bps) / size of insert (bps)).
The reactions were incubated overnight at 16°C, before the enzyme was inactivated 
by incubating the reaction mix at 65°C for 10 minutes.
 3.3.8.3  P  hosphorylation of DNA 5' ends  
Phosphorylation of 5' ends was performed using T4 polynucleotide kinase (10 U/µg 
DNA, Roche) in the buffer supplied with the enzyme (70 mM Tris-HCl, pH 7.6; 10 mM MgCl2;  5 
mM  DTT)  and  1  mM  ATP.  The  reaction  was  incubated  for  30  min  at  37°C  prior  to 
phenol/chloroform extraction (see 3.3.9.1) and ethanol precipitation (see 3.3.9.2).
 3.3.8.4  D  ephosphorylation of DNA 5' ends  
In order to avoid self-ligation, cleaved vectors were incubated with 1 U/pmol DNA 
ends of calf intestine phosphatase (CIP) (New England Biolabs) in 20 mM Tris-HCl, pH 8.0 for 
45 minutes  at  37°C.  The  enzyme was  inactivated  by  incubation  at  65°C for  45 minutes. 
Afterwards, the reaction mixture was purified by elution from an agarose gel (see 3.3.10).
 3.3.9  Purification of DNA solutions
 3.3.9.1  Phenol/Chloroform extraction  
To purify DNA from enzymes or other proteins and to remove other contaminants, 
one volume of saturated phenol was added to the DNA. The solution was vortexed at the 
highest setting for 5 to 10 seconds. Subsequently, the phases were separated by centrifugation 
at 13,000 rpm for 5 minutes. Then, the supernatant was transferred into a new tube and 
reextracted with one volume of phenol/chloroform/isoamyl-alcohol (Invitrogen). Following an 
additional centrifugation step, the upper aqueous phase was transferred into a new tube and 
precipitated with ethanol (see 3.3.9.2).
 3.3.9.2  Ethanol precipitation  
To purify or concentrate DNA, 10% (v/v) 3 M sodium acetate, pH 5.6 and 2 volumes 
of absolute ethanol were added to the DNA solution. The mixture was incubated at -80°C for at 
least 20 minutes and subsequently centrifuged at 14,000 rpm for 15 minutes at 4°C. After 
discarding the supernatant, 500 µl of 70 % ethanol were added to the pellet. The sample was 
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incubated for at least 5 minutes at -20°C. After a centrifugation at 14,000 rpm for 5 minutes 
at 4°C the pellet was dried in a speed vac (Oligo prep OP120, Savant) and taken up in an 
appropriate volume of H2Odd or TE-buffer.
 3.3.10  Elution of DNA form an agarose gel
Elution of DNA from agarose gels was performed with the Wizard® SV Gel and PCR 
Clean-Up system kit  (Promega). Briefly,  the excised DNA band was placed into an 1.5 ml 
Eppendorf tube and 1 µl membrane binding solution (Promega) per mg of gel slice was added. 
The reaction mix was vortexed and incubated at 50°C to 65°C until the gel slice was dissolved 
completely.  The solution was transferred to a SV minicolumn (Promega) placed in  a 2 ml 
collection tube and incubated at RT for one minute. After centrifugation at 13,000 rpm for one 
minute  the  flow-through  was  discarded.  Then,  the  column was  washed once  with  700  µl 
membrane  wash  solution  (Promega),  followed  by  a  second  washing  step  with  500  µl  of 
membrane wash solution. Each time, the samples were centrifugated at 13,000 rpm for one 
minute and the flow-through was discarded. Before eluting the DNA, any residual ethanol was 
removed by an additional centrifugation at 13,000 rpm for 3 minutes. The DNA was recovered 
by  applying  50  µl  H2Odd onto  the  membrane  and  collected  after  a  short  incubation  by 
centrifugation at 13,000 rpm for one minute.
 3.3.11  DNA quantification
The concentration of DNA solutions was determined by UV spectroscopy at 260 nm in 
a spectrophotometer (Gene Quant Pro, Amersham). OD260 of 1 corresponds to 50 µg/ml of 
DNA. Dilutions of 1/40 of the DNA solutions were prepared in H2Odd and measured against a 
blank containing H2Odd. 
Alternatively, dilutions of vector or fragment DNA were loaded onto an agarose gel 
and the DNA concentrations was estimated by comparison with the ladder bands 1636 and 
506/517 of the 1 kb DNA marker (Invitrogen, Cat.-N° 1561-016) corresponding to 50 ng and 
30 ng DNA, respectively.
 3.3.12  Amplification of DNA fragments by PCR (polymerase chain reaction)
A standard PCR of 50 µl contained 10 ng of template DNA, 0.2 µg of each primer, 1x 
Taq-polymerase buffer (supplied with the enzyme), 0.2 mM dNTPs (Invitrogen) and 0.5 U Taq-
polymerase (Invitrogen). The reaction was prepared on ice and transferred to a Perkin Elmer 
GeneAmp PCR System 2400. Initially, the DNA was denaturated at 94°C and amplified in 25 to 
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35 cycles of denaturating at 94°C for 30 seconds, 30 to 90 seconds of annealing temperature 
(based  on  the  melting  temperature  of  the  primers)  and  30  to  90  seconds  of  extension 
temperature at 72°C. A final step of extension temperature was performed for 7 minutes at 
72°C. Afterwards, the reactions were cooled down to and stored at 4°C until further analysis. 
Alternatively, 1.0 U Platinum Taq-polymerase (Invitrogen) was used together with 1 
x Platium Taq PCR buffer (Invitrogen), 1.5 mM MgCl2 (Invitrogen), 0.2 mM dNTPs, 0.2 µg of 
each primer and 2.0 µl template in a total volume of 50 µl. Initially, the enzyme was activated 
by an  incubation at 94°C for 2 minutes. Then, the DNA was denatured at 94°C for 30 seconds, 
followed by an annealing step at 55°C for 30 seconds and an elongation phase at 72°C for 30 
seconds. The last three steps were repeated 25 times, followed by final extension step at 72°C 
for 7 minutes. The reactions were cooled down and stored at 4°C.  
For long template PCRs (up to 5 kb) the Expand high fidelity PCR system (Roche) 
was used according the manufacturer's instructions. Briefly, mix 1 (containing 200 µM of each 
dNTP, 300 nM of each primer and a variable amount of template DNA in a final volume of 25 
µl) was combined with mix 2 (containing 19.25 µl of H2Odd, 1x Expand high fidelity buffer and 
2.6 U Expand high fidelity enzyme mix in a final volume of 25 µl). After an initial hot start at 
94°C for  2 minutes to  activate  the polymerase enzyme, 35 cycles were carried out,  each 
containing a denaturation step at 94°C for 15 seconds, followed by an annealing step at 55°C 
for 30 seconds and a subsequent elongation phase at 68°C for 5 minutes. After 15 cycles, 5 
additional seconds of elongation time were successively added to each remaining cycle. The 
final elongation step was performed at 68°C for 7 minutes. Subsequently, the samples were 
cooled down to 4°C.
 3.3.12.1  D  IG PCR  
The PCR DIG probe synthesis kit (Roche) was used for the generation of digoxigenin 
(DIG)-dUTP  labelled  probes.  The  reaction  was  performed  according  to  the  manufacturer's 
instructions,  except  for  the  PCR  conditions  which  were  adjusted  to  the  platinum  Taq- 
polymerase (see 3.3.12). 
The synthesis of the labelled probe was checked by running an aliquot of the PCR on 
an agarose gel. The DIG-labelled probe was expected to migrate slowlier than the unlabelled 
control PCR product.
 3.3.12.2  R  eal time PCR (qRT-PCR)  
The quantitative real-time PCRs were performed with the Power SYBR® Green PCR 
mastermix (Applied Biosystems) according to the manufacturer's instructions. 
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Each  reaction  within  a  96-well  plate  contained  2x  Power  Sybr  Green  mastermix 
(Applied Biosystems), 150 nM of each primer and 5 µl template in a total volume of 25 µl. The 
polymerase was activated during a 10 minutes incubation period at 95°C, followed by 40 cycles 
of  a  denaturation  phase  at  95°C  for  15  seconds  and  a  subsequent  1  minute 
annealing/extension phase at 60°C.
The amplification steps as well as the data analysis of the generated dissociation 
curves  were  performed  on  a  7500  Real-Time  PCR  System  (Applied  Biosystems).  
 3.3.13  Sequencing reactions
The  DNA samples  were  purified  by  ethanol  precipitation  (see  3.3.9.2),  the  DNA 
concentration was determined and 10 µl aliquots were prepared containing 0.8 µg plasmid 
DNA. If other primers than the standard M13 primer was used, 1 pmol of the selected primer 
was added to the sequencing tube. For the analysis, the samples were sent to the Microsynth 
laboratory (Microsynth AG, Balgach, Suisse). 
 3.3.14  List of primers
 3.3.14.1  Primers for CDP cloning and binding site mutations  
Label                    Sequence (orientation 5' to 3')  
m596f CCTCAGGCCTAGAAGTAAAAAAGGGAAAAAAGAGTGTGTTTGTCGACGTC
GGAGACAGGTGGTGGCAACC
Sense primer for introducing point mutations of the distal CDP binding sites 
into the MMTV LTR together with StuI and AvrII restriction sites
m693f CCATATACAGGAAGATATGACCTAGGTTGGGATAGGTGGGTCACTATCAAC
GGCTAGCAAGTGTTCTACAGATCCC
Sense primer for introducing point mutation of the distal CDP binding sites 
into the MMTV LTR together with a NcoI restriction site
m693r GGGATCTGTAGAACACTTGCTAGCCGTTGATAGTGACCCACCTATCCCAAC
CTAGGTCATATCTTCCTGTATATGG
Antisense primer for introducing point mutations of distal CDP binding sites 
together with a NcoI restriction
Hindrev GGAGGAAGCTTGACCGGGATCTGCGG
Antisense primer for introducing a HindIII restriction site 130bp 
downstream of the MMTV P1 promoter
X1156Mtv-2rev TTTTTCTCGAGTTTACATAAGCATTTACATAAGACTTGG
Antisense primer for introducing a XhoI restriction site upstream of the P1 
promoter
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mCDP13for CATGTTGTGCGTAGCCGGAGCCAAGT
Sense primer for cloning of CDP (mouse origin)
mCDP77for AACAGGCAAGATGAGAGCGAACAGT
Sense primer for cloning of CDP (mouse origin)
mCDP231for AAGCAGAGGCAGCCTTCTTGACTGTG
Sense primer for cloning of CDP (mouse origin)
mCDP553for GAGAAGGAGAGAAAGCTGCAAGAGAC
Sense primer for cloning of CDP (mouse origin)
mCDP778for ACAGCTCTCATCGGCCAACCACTCTC
Sense primer for cloning of CDP (mouse origin)
AY1192for ACGCTGCGCATCTCCAACAGTGACCT
Sense primer for cloning of CDP (mouse origin)
AY1922rev AGTCTGTTCAGGCTCTGGCCTGGATT
Antisense primer for cloning of CDP (mouse origin)
mCDP1815for TCCGTGGCAAGGAGCCATTCCACAAG
Sense primer for cloning the C-terminal part of CDP (mouse origin)
mCDP2620for CTCAGCATCCGCAGAGTACTGGAA
Sense primer for cloning the C-terminal part of CDP (mouse origin)
mCDP3987rev CGGCTACTTCGAGCTGAAGGTGAGTC
Antisense primer for cloning the C-terminal part of CDP (mouse origin)
mCDP4522rev CAGGCGGTGGATGATGCTGTTCAAGT
Antisense primer for cloning the C-terminal part of CDP (mouse origin)
p110exfor AAGCTAGCACCATGGTCCGTGGCAAGGAG
Sense primer for recovering the p110/CDP isoform from the TOPO® vector 
and introducing a Nhe I restriction site
p110notIrev AAAAACGCCGGCGAACTAGCTACTTCGAGC
Antisense primer for recovering the p110/CDP isoform from the TOPO® 
vector and to introduce a Not I restriction site
__________________________________________________________________________
Table 2: List of primers used for CDP cloning and binding site mutation 
All  primers  were  designed  according  to  the  sequence  of  the  Mus  musculus CCAAT  
displacement protein CDP (Cutl1) mRNA (GenBank Accession number AY037807.1).
 3.3.14.2  Primers for sequencing  
Target                   Label                         Sequence (orientation 5' to 3')  
CDP 838zeof CCACTGCTTACTGGCTTATC
Sense oligo for analysing CDP/p110 isoform 
cloned into pcDNA3.1/zeo
1045zeor GGCAACTAGAAGGCACAGTC
Antisense oligo for analysing CDP/p110 isoform 
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cloned into pcDNA3.1/zeo
321cdp110r AGCGGATGGCATCGTCAGAG
Antisense oligo for analysing CDP/p110 isoform 
cloned into pcDNA3.1/zeo
1843cdp110f GTGACAGTCAGCCTTGTGAG
Sense oligo for analysing CDP/p110 isoform 
cloned into pcDNA3.1/zeo
702cdp110f CTCACTTCTTCCGAAGAGAC
Sense oligo for analysing CDP/p110 isoform 
cloned into pcDNA3.1/zeo
1616cdp110r GTTGTCTGTCAGCACCTCTT
Antisense oligo for analysing CDP/p110 isoform 
cloned into pcDNA3.1/zeo
TOPO®Vector M13 forward GTAAAACGACGGCCAG
Sense oligo for analysing inserts of pCR®4-TOPO 
and pCR®-XL-TOPO®
M13 reverse CAGGAAACAGCTATGAC
Antisense oligo for analysing inserts of pCR®4-
TOPO and pCR®-XL-TOPO®
__________________________________________________________________________________________________
Table 3: List of primers used for sequencing
 3.3.14.3  Primers for analysing the MMTV LTR  
Label                 proviralGR102*                  Mtv-2 LTR  **      Sequence (orientation 5' to 3')  
33for 30/49 and 8603/8622 CCGAGAGTGTCCTACACTTA
Sense oligo for the generation of the DIG-
labelled probe
510for 9080/9100 510/530 GAGACGCTCAACCTCAATTGA
Sense primer for nucleosome E region
538rev 9108/9087 538/517 CCTGCTCTTCAATTGAGGTTGA
Antisense primer for nucleosome E region
548rev 9118/9099 548/529 AGTCCTTGCACCTGCTCTTC
Antisense oligo for the generation of the DIG-
labelled probe
552for 546/565 and 9122/9141 552/571 GGCCTCAGGCCTAGAAGTAA
Sense primer for nucleosome E/D region
568rev 9138/9119 568/549 CTTCTAGGCCTGAGGCCAAT
Antisense primer for nucleosome E/D region
LM602for 599/619 and 9175/9195 605/625 GAGACAGGTGGTGGCAACCAG
Sense primer for nucleosome D
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622rev 616/595 and 9192/9171 622/601 GTTGCCACCACCTGTCTCCTAT
Antisense primer for nucleosome D region
638for 9215/9242 645/672 CATCTACAGACCAACAGATGCCCCCTTA
Sense primer for nucleosome D region
646for 9216/9235 646/665 ATCTACAGACCAACAGATGC
Sense primer for nucleosome D
666rev 9236/9214 666/644 GGCATCTGTTGGTCTGTAGATGT
Antisense primer for nucleosome D region
672for 9243/9263 673/693 CCATATACAGGAAGATATGAC
Sense primer for nucleosome D region
691for 9261/9278 691/708 GACTTAAATTGGGATAGG
Sense primer for nucleosome D region
+702 9274/9293 704/723 ATAGGTGGGTCACAATCAAC
Sense primer binding immediately 
downstream of the P2 promoter initiation site
710rev 9280/9261 710/691 CACCTATCCCAATTTAAGTC
Antisense primer for nucleosome D region
723for 9293/9313 723/743 CGGCTATAAAGTGTTATACAG
Sense primer for nucleosome D
LM723rev 9296/9273 726/703 GCCGTTGATTGTGACCCACCTATC
Antisense primer for nucleosome D
739for 733/752 and 9309/9328 739/758 TACAGATCCCTCCCCTTTCG
Sense primer for nucleosome D/C region
762for 756/775 and 9332/9351 762/781 AAGACTCGCCAGAGCTAGAC
Sense primer for nucleosome C
P2+P3mtv-2 9403/9384 833/814 ACCTGTTGTTTCATGTCGTC
Antisense oligo binding downstream of the P3 
promoter initiation site
LM772for 9342/9366 772/796 AGAGCTAGACCTCCTTGGTGTATGC
Sense primer for nucleosome C
771mtv2 9343/9365 773/795 GAGCTAGACCTCCTTGGTGTATG
Sense primer complementary to the P3 
promoter initiation site
796rev 9366/9347 796/777 GCATACACCAAGGAGGTCTA
Antisense primer for nucleosome C region
876rev 9437/9419 867/849 GTGCATTCCTGTTCCTAGA
Antisense primer for nucleosome C region
LM922rev 9492/9465 922/895 GTTCTATCAGTCCAGCCACTGCCCCTTC
Antisense primer for nucleosome C/B
980for 9553/9575 983/1005 GCGGTTCCCAGGGTTTAAATAAG
Sense primer for nucleosome B region
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1073rev 9662/9643 1092/1073 AGCTCAGATCAGAACATTTG
Antisense primer for nucleosome B region
LM1099rev 9672/9651 1102/1081 GAACACTAAGAGCTCAGATCAG
Antisense primer for nucleosome B
P1STmtv2 9767/9789 1197/1219 GCAACAGTCCTAACATTCTTCTC
Sense primer complementary to the initiator  
region of the P1 promoter
-1295mtv-2 9869/9851 1299/1281 GGATCTGCGGGGGGACCCT
Antisense primer complementary to the 
region downstream of the splice acceptor site 
of the MMTV LTR (SA1275)
-1412 1431/1409 CTTGTGATGATAGCCAGACAAGA
Antisense primer binding to the gag 
untranslated region
-1442 1443/1424 GTCCGTTCCGCTCTTGTGAT
Antisense primer binding to the gag 
untranslated region
-2754 2755/2730 CCTGCTAATACAGTCTTCTTGACTCC
Antisense primer binding within the gag gene 
-3466 3466/3446 GGTGGGTACTAGCGATATTCC
Antisense primer binding within the gag gene
-5394 5394/5373 GATAATGGCAGTTTGTAGGGTA
Antisense primer binding within the pol gene
-5535 5511/5485 CTCTTTAATTATAGGCTCCCTTCCTTG
Antisense primer binding within the pol gene
-6652 6626/6605 GGCGTTGCTTCTTTCCGCTCAG
Antisense primer binding downstream of the  
splice acceptor of the env gene (SA6554)
6890R 6763/6746 CTCCTCCGCTTCGGAGAT
Antisense primer binding at the 3' end of the 
pol polyprotein (within the leader sequence of 
the env gene) 
-7803 7803/7781 GCTGCATAGTCGTAGGCAGAAGA
Antisense primer binding within the env gene 
-7933 7933/7911 AGCGACGAATCGCTTAGCTCGAA
Antisense primer binding within the env gene 
-8464 8464/8442 GACTAAAAGCAGGGCTCCAACAC
Antisense primer binding within the env gene 
delS 9140/9116 570/546 TACTTCTAGGCCTGAGGCCAATAGTCC
Antisense primer binding upstream of the 
CAAT-box of the P2 promoter within the U3  
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region
TBP2_Z  9211/9254 GATCCTTACATCTACAGACCAACAGATGCCCCCT
TACCATATACAGGA
Sense oligo for cloning the minimal P2 
promoter containing BamHI and HindIII 
restriction sites
TBP2_Zc  9254/9211 AGCTTCCTGTATATGGTAAGGGGGCATCTGTTGG
TCTGTAGATGTAAG
Antisense oligo for cloning the minimal P2 
promoter containing BamHI and HindIII 
restriction sites
TBP3_Z 9281/9310 GATCCGGTCACAATCAACGGCTATAAAGTGTTAT
ACAGATCCCTCA
Sense oligo for cloning the minimal P3 
promoter containing BamHI and HindIII 
restriction sites
TBP3_Zc 9310/9281 AGCTTGAGGGATCTGTATAACACTTTATAGCCGT
TGATGTGACCG
Antisense oligo for cloning the minimal P3 
promoter containing BamHI and HindIII 
restriction sites
Z1 3/17 and 8576/8590 AAAAAAGGATCCGCGCCTGCAGCAGAA
Sense oligo introducing a BamhI restriction site
Z2 303/319 and 8879/8895 AAAAAAGGATCCACAGCCAACTTCCTCTT
Sense oligo introducing a BamhI restriction site
Z3 9105/9125 AAAAAAGGATCCAGGTGCAAGGACTATTGGC
Sense oligo introducing a BamhI restriction site
Z3.mtv8 529/548 AAAAAAGGATCCAGGTGCAAGGACTAAGGGC
Sense oligo introducing a BamhI restriction site
Z.P2c 9251/9231 AAAAAAAGCTTCCTGTATATGGTAAGGGGGCATC
Antisense oligo introducing a HindIII restriction 
site
HenhA2 742/767 and 9318/9333 AAAAAAAGCTTCTCCCCTTTCGTGAAAGACTCGC
CAG
Sense oligo introducing a BamhI restriction site
HenhA2rev 9566/9543 AAAAAAAGCTTACCCTGGGAACCGCAAGGTTG
GGC
Antisense oligo introducing a HindIII restriction
site
d.B.mtv8 536/553 AAAAAGGATCCAAGGACTAAGGGCCTCAG
Sense oligo introducing a BamhI restriction 
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site
P2mtv8.C.H 677/661 AAAAAGCTTCCTGTATATGGTAGCGG
Antisense oligo introducing a HindIII restriction 
site
____________________________________________________________________________________
Table 4: List of primers used for analysing the MMTV LTR
*The proviralGR102 sequence corresponds to the MMTV proviral sequences of plasmid pGR102 
(Salmons et al., 1985) that harbours a 5' LTR (bp 1-1327) originating from Mtv-8 and a 3' LTR 
(8574-9900) derived from Mtv-2 flanking gag, pol and env coding regions.
** The numbers shown in italic indicate the respective sequence in relation to the first base of 
the Mtv-2 LTR.
 3.3.14.4  Primers used for selected methods  
Methode        Label                                            Sequence (orientation 5' to 3')  
LM-PCR Linker PCR1 GTAATACGACTCACTATAGGGC
Sense primer for LM-PCR analysis
Linker PCR2 AGGGCTCCGCTTAAGGGAC
Sense primer (nested) for LM-PCR 
analysis
LinkerNuc+ GTAATACGACTCACTATAGGGCTCCGCTTAA
GGGAC
Sense Oligonucleotide for generation of the 
linker-hybrid
LinkerNuc- PO4-GTCCCTTAAGCGGAG-NH2
Antisense oligonucleotide for generating the  
linker-hybrid
RLM-Race GeneRacerTM  5’ Primer CGACTGGAGCACGAGGACACTGA
Sense primer for the reverse transcribed RNA 
linker region
GeneRacerTM 5' Nested Primer GGACACTGACATGGACTGAAGGAGTA
Sense primer (nested) for the reverse 
transcribed RNA linker region
___________________________________________________________________
Table 5: List of primers used for selected methods
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 3.3.15  Southern blot hybridization
 3.3.15.1  Separation and denaturation of DNA fragments  
The integration  of  plasmid DNA into  the  genome of  stably  transfected cells  was 
analysed  by  Southern  blotting  and  subsequent  hybridization  analysis  using  a  digoxigenin-
labelled probe. Briefly, genomic DNA was isolated from the cells of interest (see 3.3.2) and 20 
µg thereof were digested overnight with selective restriction enzymes. The fragmented DNA 
was  loaded onto a 1.0  % agarose  gel  and separated by  electrophoresis  (see 3.3.3).  The 
separation of the DNA fragmentation was monitored by ethidium bromide staining. Next, the 
dye was removed by washing the gel  for  15 minutes in H2Odd.  To achieve single-stranded 
molecules suitable for the subsequent hybridization, the DNA was denatured by incubating the 
gel two times in 10 volumes of denaturation solution (1.5 M NaCl; 0.5 M NaOH) for 15 minutes 
each. The pH of the gel was lowered by washing the gel twice (each time for 15 minutes) in 10 
volumes of  neutralization  solution  (1.5  M NaCl;  0.5  M Tris-HCl,  pH 7.0)  to  ensure proper 
binding of the DNA to the membrane. Before transferring the DNA to the PVDF membrane 
(Hybond-P membrane, Amersham), the gel was equilibrated in 20x SSC buffer (3M NaCl; 300 
mM sodium citrate, pH 7.0) for 10 minutes.
 3.3.15.2  Southern blotting  
The transfer was set up by placing one sheet of Whatman filter paper soaked with 
blotting buffer (20x SSC) into a plastic tray (electrophoresis chamber), followed by the gel 
(downside up), the membrane, two additional  sheets  of  Whatman filter  paper and several 
sheets of paper towels. The blot was covered by a plastic plate and a ~ 0.5 kg weight. On the 
following  day,  the  blot  was  decomposed  and  the  membrane  UV-crosslinked  in  an  UV 
transilluminator at 254 nm wavelength to immobilize the DNA. Then, the membrane was rinsed 
shortly with H2Odd, air dried and stored at 4°C until further use.
 3.3.15.3  Hybridization  
For the hybridization, the DIG High Prime DNA labelling and detection starter kit II 
(Roche)  was  used  according  to  the  manufacturer's  instructions.  For  the  detection,  the 
membrane  was  soaked  with  2x  SSC  buffer,  followed  by  a  30  minutes  incubation  in  an 
appropriate volume (10 ml/100 cm2 filter) of prewarmed prehybridization solution (DIG Easy 
Hyb buffer, Roche) while constantly rotating (Biometra Compact Line OV4 hybridization oven). 
The optimal hybridization temperature was calculated according to the GC content and the 
percent homology of the probe to the target applying the following equitation: Toptimal = Tm – 
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20 to 25°C, whereas Tm = 49.82 + 0.41 ( % G + C) – (600/length of hybrid in base pairs). 
Meanwhile,  10 µl  of  the DIG-labelled  probe (see 3.3.12.1)  were diluted 1:5 in  H2Odd and 
denatured at 97°C for 5 minutes. Immediately thereafter, the probe was placed on ice. The 
prehybridization solution was decanted and replaced with prewarmed hybridization solution 
containing the denatured probe diluted 1:10,000 in an appropriate volume of DIG Easy Hyb 
buffer (3.5 ml/100 cm2 membrane). The membrane was incubated at the optimal hybridization 
temperature ( Toptimal) overnight during constant rotation.
 3.3.15.4  Immunological detection  
On the following day, the hybridization solution was removed and the membrane 
rinsed briefly with H2Odd,  washed twice with 50 ml of low stringency wash buffer (2x SSC; 
0.1% SDS)  at  RT  for  a  total  of  10  minutes,  followed  by  two  washing  steps  with  50  ml 
prewarmed high stringency buffer (0.5xSSC, 0.1% SDS) at 68°C. Then, the membrane was 
rinsed briefly in wash buffer (0.1 M maleic acid; 0.15 M NaCl, pH 7.5; 0.3 %(v/v) Tween 20).
For  the  subsequent  immunological  detection,  an  anti-digoxigenin  antibody 
conjugated  to  alkaline  phosphatase  (AP)  was  used.  For  this  purpose,  the  membrane  was 
incubated for 30 minutes with 1x blocking solution (Roche; 10x stock diluted in maleic acid 
buffer (0.1 M maleic acid; 0.15 M NaCl, pH 7.5)). The blocking solution was removed and 
replaced  with  an  appropriate  volume  of  an  anti-digoxigenin-AP  antibody  solution  (diluted 
1:10,000 in 1x blocking solution). After incubation at RT for 30 minutes, the membrane was 
washed twice  for  a  total  of  30 minutes  with  100  ml  of  wash buffer.  The membrane  was 
equilibrated in 20 ml detection buffer (0.1 M Tris-HCl, 0.1 M NaCl, pH 9.5) for 5 minutes at RT. 
Then, 1 ml of CSPD ready-to-use (Roche) containing the substrate for the chemiluminescent 
reaction was applied onto a plastic slide and covered immediately by the DNA side of the 
membrane. The membrane was incubated for 5 minutes at RT, followed by 10 minutes at 37°C 
in  order  to  enhance  the  luminescent  reaction.  Finally,  the  membrane  was  exposed  to  an 
autoradiography film (Hyperfilm MP high performance, Amersham).
 3.4  RNA methods
 3.4.1  Extraction of total RNA
For extraction of total RNA, the RNeasy mini kit from Qiagen was used according the 
manufacturer's instructions. Briefly, 5 x 106 cells were harvested by trypsinization, washed 
once with 1x PBS and pelleted by centrifugation prior to lysis. The cells were resuspended in 
600  µl  RLT  buffer  (Qiagen).  Subsequently,  each  sample  was  pipetted  directly  onto  a 
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QIAshredder  spin  column  (Qiagen)  in  order  to  homogenize  the  lysate  and  centrifuged  at 
13,000 rpm for 2 minutes. 600 µl of 70 % ethanol were added, the solutions were mixed by 
pipetting and transferred to an RNeasy mini column (Qiagen). After a short centrifugation at 
10,000 rpm for 15 seconds, the flow-through was discarded. The membrane containing spin 
column was washed once with 700 µl of RW1 buffer (Qiagen), followed by two washing steps 
with 500 µl of RPE buffer (Qiagen). After discarding the last flow-through of RPE buffer, the 
spin column was centrifugated for an additional minute to remove any traces of the buffer. The 
RNA was recovered by adding 50 µl H2Odd onto the membrane and by centrifugation at 10,000 
rpm for one minute. Finally, the concentration of the RNA was determined photometrically.
 3.4.2  Extraction of mRNA
5 x 106 cells were harvested by trypsinization and washed once in ice-cold PBS. The 
cells  were transferred into a 1.5 ml Eppendorf  tube, pelleted by centrifugation and placed 
immediately on ice. In the following step, each sample was resuspended in 400 µl extraction 
buffer (Quickprep micro mRNA purification kit, Amersham Biosciences). Then, 800 µl elution 
buffer (10 mM Tris-HCl, pH 7.5; 1 mM EDTA) were added and the solutions mixed thoroughly 
by vortexing. 
In order to prepare a cleared cellular homogenate the cell lysate was centrifuged at 
13,000 rpm for one minute at  RT. Similarly,  for  each sample, 1 ml  aliquots  of  Oligo(dT)-
cellulose (Quickprep micro mRNA purification kit,  Amersham Biosciences) were centrifuged. 
The buffer of the Oligo(dT)-cellulose was removed and replaced by 1 ml of the cell lysates. The 
tube was mixed gently for 3 minutes and then centrifugated at 13,000 rpm for 10 seconds. 
The  supernatant  was  discarded  and  the  mRNA  bound  to  the  oligo(dT)-cellulose  was 
resuspended in 1 ml high salt buffer (10 mM Tris-HCl, pH 7.5; 1 mM EDTA; 0.5 M NaCl) and 
centrifuged for 10 seconds at maximum speed. This washing step was repeated four times. 
Then, the pellet was washed twice with 1 ml of low salt buffer (10 mM Tris-HCl, pH 7.5; 1 mM 
EDTA;0.1  M  NaCl).  Subsequently,  the  pellet  was  resuspended  in  300  µl  low  salt  buffer, 
transferred  to  a  MicroSpin  column  (Quickprep  micro  mRNA  purification  kit,  Amersham 
Biosciences) and centrifuged for 5 seconds at maximum speed. The column was washed three 
times with 500 µl low salt buffer. After the last centrifugation, the mRNA was recovered in 100 
µl of prewarmed (65°C) elution buffer and eluted by centrifugating each sample at top speed 
for 5 seconds. The concentration of the mRNA was determined photometrically.
 3.4.3  DNase digestion of RNA samples
DNA contamination  of  RNA  samples  was  eliminated  by  incubating  200  µl  (or  a 
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multiple) of the RNA sample with 20 µl of 10x DNase buffer (Roche) and 1 µl of DNase I (10 U/
µl; Roche). The digest was incubated for 30 minutes at RT, followed by additional 30 minutes 
at 37°C. Subsequently, the enzyme was inactivated by incubating the solution at 75°C for 5 
minutes. The samples were precipitated with 96 % ethanol (see 3.3.9.2), washed with 70 % 
ethanol and resuspended in an appropriate amount of DEPC H2Odd.
Alternatively, the samples were treated with 1 µl TURBO DNase (2 U/µl; Ambion) 
together with 1x TURBO DNase buffer (Ambion) in a 50 µl reaction. After 30 minutes at 37°C, 
0.1 volumes of the DNase inactivating reagent (Ambion) were added in order to remove the 
DNase enzyme as well as divalent cations, which would otherwise catalyse RNA degradation. 
The solution was incubated for two minutes at RT and mixed occasionally. Subsequently, the 
tubes were centrifugated at 10.000 rpm for 90 seconds. The supernatant containing the DNA-
free RNA was transferred into a new tube and used immediately for downstream analysis or 
stored at -80°C.
 3.4.4  Generation of first strand cDNA
For the reverse transcription reaction, 200 ng of DNase treated mRNA (see 3.4.2 and 
3.4.3)  or  2 µg of  total  RNA (see 3.4.1) were combined with  4 µl  dNTP (10 mM, Applied 
Biosystems), 200 pMol primer and  H2Odd in a final volume of 15 µl. (If mRNA was used as 
starting  material,  either  a  poly-(dT)  primer  composed  of  50  % dTTTV  and  50  % dTTTG 
oligonucleotides or a gene-specific primer was used.)
 The reaction was incubated for 5 minutes at 65°C and placed on ice for at least one 
minute. Then, 4 µl  DTT (0.1 M Stock), 6 µl  of  a 5 x buffer  (reverse transcriptase buffer, 
Invitrogen)  and  80  U  of  RNaseOUTTM ribonuclease  inhibitor  (Invitrogen)  were  added,  the 
reaction  was  mixed  gently  and  incubated  for  two  minutes  at  42°C.  Afterwards,  1  µl  of 
SuperscriptTM II reverse transcriptase (Invitrogen) was added to the solution. The reaction was 
mixed gently and incubated at 42°C for additional 50 minutes. 
Finally, the enzyme was inactivated at 70°C for 15 minutes and 2 µl RNase H (1U/µl) 
(Invitrogen) were added. The solution was incubated for 20 minutes at 37°C  to allow the 
removal of any RNAs complementary to the cDNA. The first strand cDNA was immediately 
placed on ice and stored at -20°C until further use.
 3.4.5  RNA ligase-mediated rapid amplification of 5' and 3' ends (RLM-RACE)
This method ensures the exclusive amplification of full-length transcripts which are 
then, in the second step, used for  the RACE (rapid amplification of  5'  and 3' cDNA ends) 
analysis. Truncated mRNAs and non-mRNAs are eliminated by a preliminary dephosphorylating 
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reaction which is followed by the removal of the 5' cap structure from full-length mRNAs. As a 
consequence, the 5' phosphate that is required for the subsequent ligation to the GeneRacerTM 
RNA-oligonucleotide ('linker') is exclusively present on previously capped mRNA. After reverse 
transcription, either the 5' end or the 3' end of the generated first strand DNA can be analysed. 
Per sample, 200 µg of mRNA were gently mixed with 1x CIP buffer (GeneRacerTM kit, 
Invitrogen), 40 U of RNase Out (Invitrogen), 10 U CIP (GeneRacerTM  kit,  Invitrogen) and a 
variable volume of DEPC water for a total volume of 10 µl. The solution was incubated at 50°C 
for  one  hour.  Then,  the  RNA was  purified  by  a  phenol/chloroform extraction  and  ethanol 
precipitated. After a washing step with 70 % ethanol, the pellet was resuspended in 7 µl DEPC 
water. The 5' cap structure was removed by adding 1x tabacco acid pyrophosphatase (TAP) 
buffer (GeneRacerTM  kit,  Invitrogen), 40 U of RNaseOUTTM and 0.5 U of TAP (GeneRacerTM  kit, 
Invitrogen). The reaction was incubated for one hour at 37°C. Again, the RNA was precipitated 
as  above  and  recovered  in  7  µl  DEPC  water.  For  the  ligation  to  the  linker,  the 
dephosphorylated, decapped RNA was added to one aliquot of lyophilized GeneRacerTM  RNA 
Oligo (GeneRacerTM  kit,  Invitrogen) and incubated for  5 minutes at  65°C to  denature RNA 
secondary structures. Then, the reaction was placed on ice and 1x ligase buffer (GeneRacerTM 
kit,  Invitrogen),  1  mM ATP,  40  U  of  RNaseOUTTM (Invitrogen)  and  5  U  of  T4  RNA ligase 
(Invitrogen) were added. After incubation for one hour at 37°C, the RNA was precipitated as 
above, resuspended in 10 µl DEPC water and reverse transcribed (see 3.4.4) using a gene-
specific primer. 
The generated first  strand cDNA was then used for  the subsequent amplification 
step.  The PCR products were purified by agarose gel electrophoresis (see 3.3.3 and 3.3.10) 
and subcloned into the pCR®-TOPO vector. Upon amplification in bacteria and purification of 
the plasmid DNA, the sequence of the inserts was analysed.
 3.5  Protein methods
 3.5.1  Extraction of cellular proteins
Whole cell lysates were generated 48 hours after transfection of cells grown in a 6-
well plate. Briefly, the plates were put on ice, the medium was removed and the cells washed 
once with ice-cold PBS. Upon addition of 200 µl lysis buffer (25 mM KPO4, pH 7.8; 8 mM MgCl2, 
1 mM DTT, 1 mM EDTA, 1 % (v/v) Triton X-100, 15 % (v/v) glycerol), the cells were scraped 
from the bottom of the well, transferred into a pre-chilled Eppendorf tube and placed on ice. 
During  the  following  incubation  step  (15  minutes  on  ice),  the  samples  were  vortexed 
vigorously several times. Thereafter, the tubes were centrifuged at 14,000 rpm for 5 minutes 
at 4°C and the supernatant containing the cellular proteins transferred into a new tube and 
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either analysed immediately or stored at -80°C.
 3.5.2  Extraction of nuclear and cytoplasmic protein fractions
Approximately 5 x 106 cells were harvested by trypsinization, washed once with ice-
cold PBS and centrifuged at 4°C for 5 minutes at 1,000 rpm. The supernatant was removed 
and 200 µl of ice-cold CER I (Cytoplasmic extraction reagent I, Pierce) supplemented with 5 µl/
ml of proteinase inhibitor cocktail (Sigma) was added to the cells. After resuspending the pellet 
by vigorously vortexing for 15 seconds, the solution was transferred into a 1.5 ml Eppendorf 
tube and incubated on ice for 10 minutes. Subsequently, 11 µl of ice-cold CER II (Cytoplasmic 
extraction reagent II, Pierce) were added and the mixture was again vortexed for 5 seconds. 
After one minute incubation on ice, the solution was again vortexed and centrifuged at 13,000 
rpm for 5 minutes at 4°C in a microcentrifuge. The supernatant containing the cyctoplasmic 
extract was immediately transferred into a new, pre-chilled tube and stored at -80°C.
The remaining pellet (containing the nuclei) was resuspended in 100 µl of ice-cold 
NER (Nuclear extraction reagent, Pierce) supplemented with 5 µl/ml of proteinase inhibitor 
cocktail (Sigma). The solution was intensively vortexed on the highest setting for 15 seconds 
and immediately placed on ice for 10 minutes. The last two steps were repeated five times for 
a total period of 50 minutes. Then, the mixture was centrifuged at 13.000 rpm for 10 minutes 
at 4°C. The supernatant representing the nuclear extract was immediately transferred into a 
new pre-chilled tube and placed on ice. The nuclear protein fraction was stored at -80°C until 
further use.
 3.5.3  Western blot analysis
 3.5.3.1  SDS-PAGE  
SDS-Polyacrylamide gel  electrophoresis  (PAGE) was performed in a SE 260 Mini- 
vertical  gel  electrophoresis  unit  (Hoefer),  assembled  according  to  the  instructions  of  the 
manufacturer. The separation gel (1.5 M Tris-base, pH 8.8; 10 % (v/v) Acrylamide, 0.1 % SDS, 
0.05 % APS, 1  µl/ml  gel  Temed)  was poured in  a  dual  gel  caster (Hoefer),  overlaid with 
isopropanol and rinsed with water after polymerization. Then, the stacking gel (0.5 M Tris-HCl, 
pH 6.8; 5 % (v/v) Acrylamide, 0.4 % SDS, 0.05 % APS, 1 µl/ml gel Temed) was prepared. 
After polymerization, the gel unit was assembled and the gel submerged with in 1x Laemmli-
buffer (25 mM Tris-base, 0.19 M glycine, 0.1 % (w/v) SDS; pH 8.3). Protein samples mixed 
with 2x protein sample buffer (100 mM Tris- base, pH 6.8; 5 % (w/v) SDS, 20 % glycerol, 0.02 
% bromphenolblue, 10 % (v/v) ß-mercaptoethanol) were denaturated for 5 minutes at 95°C 
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and  loaded  onto  the  gel.  The  separation  of  protein  samples  including  a  protein  marker 
(PageRulerTM Prestained protein Ladder, Fermentas) was performed at 95 volt (Power Pac 300 
electrophoresis power supply, Biorad). 
 3.5.3.2  W  estern blotting  
For  Western  blot  analysis,  protein  samples  were  separated  by  SDS-PAGE  (see 
3.5.3.1). The proteins were then transferred to  a PVDF membrane (Hybond-P membrane, 
Amersham).  For  this  purpose,  the  membrane  was  presoaked  with  methanol  and  placed 
together with the gel and 3 pieces of WhatmanTM 3MM paper in a semi-dry electric blotter 
device (Hoefer). The transfer was performed in transfer buffer (25 mM Tris-base, pH 8.3; 0.19 
M  glycine; 20 % (v/v) methanol) at 1.1 mA/cm2 for 1-2 hours depending on the expected size 
of the protein to be analysed. The transfer efficiency was verified by Coomassie staining of the 
polyacrylamid gels (see 3.5.3.3).
 3.5.3.3  C  oomassie staining of polyacrylamide gels  
After the blotting was completed the SDS-PAGE were removed from the transfer unit 
and stained for 1 hour in Commassie light staining buffer (50 ml isopropanol, 20 ml acetic acid 
and 0.1 g Commassie Brilliant blue R250 in 200 ml H2Odd, filtered before use). Then, the gel 
was rinsed shortly in water and destained by in 10 % acetic acid for approximately two hours 
on a shaker. The intensity of the protein bands should indicate equal loading of the samples 
and the running quality of the gel.
 3.5.3.4  I mmunological detection  
To saturate the non-specific binding sites the membrane was incubated in blocking 
buffer (5 % milk powder solution in 1x TTBS buffer (20 mM Tris, pH 8.0; 0.9 % NaCl; 0.1 % 
Tween 20) at constant agitation overnight at 4°C. On the following day, the membrane was 
incubated with the primary antibody diluted in 1x TTBS buffer for at least one hour at room 
temperature. After two washing steps with 1 x TTBS at RT for a total  of  30 minutes, the 
membrane was incubated with an horseradish peroxidase (HRP) labelled secondary antibody 
(DAKO; diluted 1:10,000 in  1x  TTBS)  for  one hour  at  RT.  To  minimize  unspecific  binding 
events,  the  membrane  was  washed  three  times  (10  minutes  each)  with  1x  TTBS  buffer, 
followed by one washing step with 1x TBS buffer (20 mM Tris, pH 8.0; 0.9 % NaCl).
ECL plus Western blotting detection reagents (Amersham) were used to visualise the 
HRP-labelled secondary AB. 2 ml solution “A” and 50 µl solution “B” were mixed together and 
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immediately applied to the membrane for a maximum of 5 minutes. The blot was placed into a 
plastic foil and exposed to an autoradiography film (Hyperfilm ECL, Amersham).
 3.5.4  Luciferase assay
The luciferase assays were performed 48 hours post transfection. After extraction of 
the cellular proteins (see 3.5.1), the protein concentration of each sample was determined 
using a colorimetric assay (see 3.5.5). 20 µg of the protein lysate was pipetted into a plastic 
tube  and  transferred into  the  luminometer  (AutoLumat  LB  953).  By  automatic  injection  a 
defined amount of reaction mix (100 mM KPO4, pH 7.8; 125 µM luciferin, 0.4 mM Mg ATP) 
containing the luciferase substrate was added to each sample and the amount of emitted light 
was measured.  The quantity  of  emitted light  is  directly  proportional  to  the activity  of  the 
regulatory elements that were responsible for the enzyme production.
 3.5.5  Protein quantification
The protein content of samples was determined using a colorimetric assay according 
to the Lowry method. For the generation of the standard curve, 5-6 dilution of bovine serum 
albumine (BSA; New England Biolabs) ranging from 0.2 mg/ml to 2.0 mg/ml protein were 
prepared. Then,  5 µl of each standard and each sample were pipetted into a 96-well flate 
bottom microtiter plate in dublicate. Subsequently, 25 µl of working reagent A' (20 µl reagent 
S per 1000 µl reagent A, BioRad DC protein assay kit II) and 200 µl of reagent B (BioRad DC 
protein assay kit II) were added. After the plate was incubated for 15 minutes at RT in the 
dark, the absorbance was read at 630 nm by a microplate reader (ElX  800, Bio Tek). The 
protein concentration of the samples was determined based on the standard curve.
 3.6  Chromatin methods
 3.6.1  Isolation of chromatin
CK5'LTR cells and NM5'LTR cells, respectively, were seeded in 6x 175 cm2 culture 
flasks and synchronized (see 3.1.6). Two hours after reentering the cell cycle simultaneously in 
the G1 phase, the medium was replaced with 5 ml of 1 % formaldehyde (in 1x PBS) to fix the 
cells. After incubating the cells for 5 minutes at RT, the formaldehyde was removed. The cells 
were washed twice with ice-cold 1x PBS, scraped, collected in prechilled 15 ml falcon tubes and 
placed on ice. After a brief centrifugation at 1000 rpm for 5 minutes at 4°C, the supernatant 
was removed. The pellet was resuspended in 5 ml homogenization buffer (10 mM Tris-HCl, pH 
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7.4; 15 mM NaCl; 60 mM Kcl; 1 mM EDTA; 0.1 mM EGTA; 0.1 % (v/v) NP-40; 5 % (w/v) 
sucrose; 0.15 mM spermine; 0.5 mM spermidine), transferred to a Dounce homogenizer and 
incubated for 5 minutes on ice. In order to disrupt the cell membrane, 10 to 15 strokes with 
the Dounce pestles were performed. The lysis was controlled by observing an aliquot of the 
cells suspension under a light microscope. Then, the mixture was transferred carefully onto a 
layer of wash buffer containing 10 % sucrose (10 mM Tris-HCl, pH 7.4; 15 mM NaCl; 60 mM 
Kcl; 10 % (w/v) sucrose; 0.15 mM spermine; 0.5 mM spermidine) and centrifugated at 1000 
rpm for 20 minutes at 4°C. The supernatant was removed and the pellet gently resuspended in 
5 ml wash buffer (10 mM Tris-HCl, pH 7.4, 15 mM NaCl, 60 mM KCl, 0.15 mM spermine, 0.5 
mM spermidine).  The samples  were  centrifugated at  800  rpm for  5  minutes  at  4°C.  The 
supernatant was removed and the pellet containing the isolated nuclei was kept on ice for 
further downstream manipulations.
 3.6.2  MNase digestion
When nuclei (or permeabilized cells) are exposed to micrococcal nuclease (MNase) in 
the presence of a divalent cation, the enzyme introduces double-strand cuts within the inter-
nucleosomal region. This property was used to achieve mononucleosomal particles for either 
the determination of nucleosomal positions or for the chromatin immunoprecipitation (ChIP) 
experiments.
Briefly, the pelleted nuclei (see 3.6.1) were gently resuspended in either 375 µl (for 
determining the nucleosomal borders) or 250 µl (for ChIP analysis) MNase buffer (25 mM KCl; 
4 mM MgCl2; 1 mM CaCl2; 12.5 % (v/v) glycerol; 50 mM Tris-HCl, pH 7.4; 0.1 µM Aprotinin, 10 
µM  Leupeptin;  0.2  mM PMSF)  and  transferred  to  an  1.5  ml  Eppendorf  tube.  Micrococcal 
nuclease (Sigma, diluted in 0.1 M NaPO4 buffer, pH 7.0; 2.5 µM CaCl2) was added at a final 
concentration of 2 U/ml (for determination of the nucleosome position) or 40 U/ml (for ChIP 
experiments). The samples were incubated at 37°C for 5 minutes while shaking slowly, before 
the enzymatic reaction was stopped by adding 0.5 M EDTA to a final concentration of 50 mM. 
 3.6.3  Determination of nucleosomal borders
In order to remove any associated proteins from the MNase-digested chromatin, the 
solution was diluted (1:2) in proteinase K buffer (20 mM EDTA, 200 mM NaCl, 1 % (w/v) SDS, 
0.25 mg/ml glycogen) and 1/10 of the sample volume proteinase K (2.5 mg/ml; Sigma) was 
added.  The reaction  was incubated at  37°C for  up to  two hours.  In  order  to  reverse the 
protein-DNA  crosslinks,  the  whole  digest  was  then  incubated  for  6  hours  (alternatively 
overnight) at 60°C while gently shaking slowly. Subsequent to a phenol-chloroform extraction 
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(see 3.3.8.1),  the  DNA was ethanol-precipitated (see 3.3.9.2)  and resuspended in  100  µl 
H2Odd. To avoid any RNA contamination, the samples were treated with 20 µg RNase A (10 mg/
ml;  Sigma)  at  37°C  for  10  minutes.  Again,  the  DNA  was  purified  via  phenol-chloroform 
extraction, precipitated by ethanol and recovered in 100 µl H2Odd. 
For the determination of the nucleosomal borders, the fragmented DNA originating 
from MNase digested chromatin (see 3.6.2) was loaded onto a 2 % agarose gel and separated 
via electrophoresis. The band corresponding to ~147 bp (i.e the DNA protected by a single 
nucleosome) was extracted from the gel (see 3.3.10) and recovered in 40 µl H2Odd. In the 
following step, the DNA fragments were treated with T4 polynucleotide kinase (see 3.3.8.3) in 
order to phosphorylate the cleaved double-stranded substrate. After an ethanol-precipitation, 
0.2 µg of each sample were ligated to (~ 60 pmol) the linker-hybrid (see 3.3.7 and 3.3.8.2). 
The ligated fragments were precipitated by ethanol, resuspended in 20 µl H2Odd and stored at 
4°C.  Ligation-mediated PCRs were performed with an oligonucleotide  corresponding to the 
linker-hybrid and a gene specific primer. 
 3.6.4  Chromatin immunoprecipitation (ChIP)
This method is used to determine the association of proteins or protein modifications 
to  specific  genomic  regions.  Briefly,  fragments  of  cross-linked  chromatin  are 
immunoprecipitated with an antibody against a desired protein or protein modification. Thus, 
DNA sequences that directly or indirectly cross-link with the protein of interest are selectively 
enriched in the immunoprecipitated sample. The subsequent reversal  of  the cross-links by 
heating permits the recovery and quantitative analysis of the immunoprecipitated DNA. The 
amounts  of  specific  genomic  regions  in  control  and  immunoprecipitated  samples  are 
determined individually by quantitative PCR.
In  order  to  examine  the  MMTV  LTR  region,  ChIP  was  performed  on  single 
nucleosomes that  were generated by enzymatic  digestion  using micrococcal  nuclease  (see 
3.6.2). Immediately after terminating the enzymatic reaction with EDTA, the chromatin was 
diluted (1:1) in 250 µl FA lysis buffer (50 mM HEPES, pH7.5 with KOH, 150 mM NaCl, 1 mM 
EDTA, 1 % (v/v) Triton X-100, 0.1 % (w/v) sodium deoxycholate, 0.1 % SDS (v/v); 0.2 mM 
PMSF; 10 µl/ml protease inhibitor cocktail, Sigma). Simultaneously, an aliquot was subjected 
to proteinase K treatment and analysed via electrophoresis to determine the quality of the 
MNase digestion. 
In order to reduce any non-specific associations of any material to the protein G 
beads  that  were  used  for  the  subsequent  immunopreciptiaton,  a  preclearing  step  was 
performed by adding 40 µl ChIP-grade protein G agarose beads (Cell Signaling) to the digested 
chromatin.  The  solution  was  incubated  for  two  hours  at  4°C  during  constant  rotation. 
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Subsequent to a centrifugation at 14,000 rpm for 10 minutes, the supernatant was transferred 
into  a  new  eppendorf  tube.  Additionally,  an  aliquot  (50  µl)  labelled  as  'Input-DNA'  was 
removed from the isolated, MNase digested chromatin and transferred into a new pre-chilled 
tube. All samples including the 'Input-DNA' were stored at -80°C until further use.
For each immunoprecipitation, 100 µl of the precleared chromatin were thawn on ice 
and diluted in 400 µl FA lysis buffer. 10 µl of the antibody of interest were added and the 
samples  were  incubated overnight  at  4°C with  constant  rotation.  Normal  rabbit  IgG  (Cell 
Signaling) was used as negative control. On the following day, 40 µl protein G beads were 
added, followed by an additional incubation step of two to four hours at 4°C during constant 
rotation. Then, the samples were centrifugated at 6,000 rpm for 90 seconds at 4°C and the 
supernatant discarded.
Next, the beads were washed twice with 1 ml of FA lysis buffer and twice with 1 ml 
of FA lysis buffer containing 0.5 M NaCl, followed by an additional washing step with ChIP wash 
buffer (10 mM Tris-HCl, pH8.0; 0.25 M LiCl; 1 mM EDTA; 0.5 % (v/v) Nonidet P-40; 0.5 % (w/
v) sodium deoxycholate.) Each washing step included 10 minute of constant rotation in the 
cold, followed by a centrifugation at 6,000 rpm for 90 seconds at 4°C. Then, 150 µl  ChIP 
elution buffer (50 mM Tris-HCl, pH 7.5; 10 mM EDTA; 1 % (v/v) SDS) were added to each 
sample. At this point the 'Input-DNA' sample was thawn on ice and diluted in 250 µl ChIP 
elution  buffer.  The  chromatin-antibody  complexes  were  dissociated  from  the  beads  by 
incubating the samples for 30 minutes at 65°C while gentle rotating. The protein G agarose 
beads were pelleted by a centrifugation at 6,000 rpm for one minute and the supernatant 
containing the immunoprecipitated chromatin was carefully transferred to a new tube. Then, 5 
M NaCl was added to a final concentration of 20 mM. Finally, the samples were treated with 2 
µl proteinase K and incubated at 65°C for two hours (or alternatively overnight) to remove the 
protein-DNA crosslinks. Then, the DNA was extracted by phenol-chloroform and precipitated 
with ethanol. After resuspending the samples in an appropriate volume of  H2Odd, they were 
subjected to qRT-PCR analysis (3.3.12.2).
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4. Results
The aim of the present study was to characterise in more detail the central LTR of 
MMTV,  which  harbours  the  P2  promoter  element.  Moreover,  we  wanted to  investigate  the 
conditions under which transcription initiation is allowed to occur upstream of the major P1 
promoter. The Mtv-2 and Mtv-8 sequences used in this work are derived from the plasmid 
pGR102 (Salmons et al., 1985).
 4.1  Two elements located within the MMTV LTR influence P2 activity
The P2 promoter is located in the central part of the proviral MMTV LTR (Günzburg et 
al., 1993). Within this region, a number of regulatory elements have been identified that were 
shown to modulate the activity of the major P1 promoter. We wanted to investigate whether 
these  regulatory  sequences  exert  a  similar  influence  on  the  P2  promoter.  Preliminary 
experiments revealed that the transcriptional potential of the P2 promoter is extremely low 
(data not shown). Therefore, we decided to use the promoterless luciferase expression plasmid 
pZluc for the analysis (Brasier et al., 1989; Maxwell  et al., 1989). This vector contains three 
polyadenylation signals (one for each reading frame) upstream of the multiple cloning site that 
impede  any  readthrough  from  the  plasmid  backbone.  We  started  by  testing  Mtv-2  LTR 
sequences,  because  this  provirus  is  known  to  be  responsible  for  the  high  incidence  of 
mammary tumors in GR mice (Golovkina et al., 1996). 
The activity of a 40 bp fragment containing the minimal P2 core promoter including 
the  TATA-box (pTBP2,  construct  1)  was  compared  with  the  luciferase  expression  of  other 
fragments  that  additionally  possess  defined  regions  located  immediately  upstream  of  the 
minimal P2 promoter. Either the complete U3 region (pZ678, construct 2), the region from 
position  301  (relative  to  the  beginning  of  the  LTR)  up  to  the  minimal  promoter  (pZ370, 
construct  3)  or  the  region ranging from position  557  until  the  P2  core  promoter  (pZ151, 
construct 4) were linked individually to luciferase coding regions. Several independent cell lines 
from different  species  (feline  kidney CrFK cells,  mouse  mammary tumor  GR cells,  mouse 
fibroblast NIH 3T3 cells, mouse lymphocyte A20 cells, and rat hippocampal HiB5 stem cells) 
were transfected and transient luciferase activity was measured 48 hours later. 
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Figure 4.1 Influence of upstream located U3 sequences on P2 promoter activity. The U3 region 
is shown schematically on the top. Numbers indicate the position relative to the beginning of the LTR. The 
P2 and P1 core promoter elements are represented by filled boxes. The hormone-responsive element 
(HRE) is symbolized by the hatched box. On the left, the sequences used in the four different constructs 
are indicated. On the right, the corresponding luciferase expression levels are shown. The expression of 
the  minimal  P2  promoter  was  taken  as  100%.  All  transfections  were  performed  in  the  absence  of 
dexamethasone.  Each  bar  reflects  the  mean  value  of  at  least  three  independent  experiments  with 
standard errors of less than 5% of the mean values. 
Figure 4.1 shows the result of one representative analysis which was performed in 
CrFK cells, although similar luciferase expression patterns were obtained in all cell lines tested 
(data not shown).  Here, the transcriptional activity of the minimal P2 promoter was set to 
100%. A decrease in P2 promoter activity in all  three constructs tested can be observed, 
indicating the existence of an upstream located negative regulatory element (NRE). As the 
smallest fragment (pZ151, construct 4) is sufficient to attenuate P2 activity, the location of the 
NRE can be narrowed down to the region from position 557 to 638, immediately adjacent to 
the P2 promoter. We observed the inhibitory effect in all cell lines tested, indicating a tissue 
unspecific mechanism of repression.
Next, we analysed the effect of immediately downstream located LTR sequences on 
the basal activity of the P2 core promoter. As for the previous set of constructs, we inserted 
various downstream located fragments into the promoterless luciferase reporter plasmids, all 
of which include the region from bp 744 to bp 995 (constructs 5 to 8, figure 4.2). The influence 
of this region on the transcriptional activity of the major P1 promoter is controversial in the 
literature, because the presence of a possible enhancer (Gouilleux  et al., 1991; Reuss and 
Coffin, 2000) as well as several NREs (Mink et al., 1990; Lefebvre et al., 1991; Bramblett et 
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al., 1995) have been described.
Figure 4.2 Influence of downstream located U3 sequences on P2 promoter activity. The U3 
region is shown schematically above. Numbers indicate the position relative to the beginning of the LTR. 
The P2 and P1 core promoter elements are represented by filled boxes, while the HRE is symbolized by 
the hatched box. The lines on the left indicate the regions used and analysed in luciferase reporter gene 
assays. The bars represent the relative reporter gene expression levels of the tested constructs after 
transient transfection of CrFK cells in the absence of dexamethasone. Each bar reflects the mean value of 
at least three independent experiments with standard errors of less than 5% of the mean values. 
As can be seen in figure 4.2, a 6-fold induction of luciferase expression was observed 
when  the  region  from bp  744  to  bp  993  was  linked  to  the  P2  promoter  core,  (pZP2a2, 
construct 5, figure 4.2). This positive effect is caused by a true enhancer element, as the 
region on its own does not possess any transcriptional potential (pZa2, construct 6). When 
both the upstream located NRE and the enhancer were present in the same construct, the 
activity  of  the  promoter  was  again  downregulated,  indicating  that  the  NRE abrogates  the 
influence of the downstream enhancer element (pZ151.a2, construct 7). Interestingly, when 
the entire region from the beginning of the NRE up to the end of the enhancer (bp 557 to bp 
995,  pZd-a2,  construct  8)  was  analysed,  an  even  higher  luciferase  expression  level  was 
observed  than  that  previously  obtained  from  the  P2  promoter  under  the  influence  of  its 
enhancer (pZP2a2, construct 5). We conclude that the region between bps 678 and 744 does 
contain an element with a strong positive effect on transcription. 
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To find out more about the properties of this region, we analysed the corresponding 
sequence in different MMTV variants and found two potential TATA-boxes and one CAAT-like 
motif (underlined sequences, figure 4.3). 
Figure 4.3 Alignment of the central LTR promoter complex.  The sequences of Mtv-8 and Mtv-2 
correspond to the 5' LTR and 3' LTR of the plasmid pGR102, respectively (Salmons  et al., 1985). The 
TATA-box of P2 is shown in boldface type, while potential CAAT- and TATA-boxes for the P3 promoter are 
underlined.  The  P2  transcriptional  initiation  site  is  indicated  by  an  arrow.  The  GeneBank  accession 
numbers are as follows: AF228552 for C3H exo, AF228551 for CeH/HeJ, AF136900 for RIII and AF228550 
for Mtv-1.
Only one of  these motifs  is  conserved within  the Mtv-8 provirus;  therefore, this 
element was tested first for its transcriptional activity. To this end, different fragments of the 
central LTR (encompassing the region from bp 557 to bp 995) were amplified from an Mtv-8 
background and analysed in transient transfection assays. The results are summarized in figure 
4.4. 
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Figure 4.4 The central LTR Promoter region is functional in Mtv-8.  A scheme of the MMTV  U3 
region is presented above. The core promoter elements are symbolized by filled boxes, while the hatched 
box represents the HRE. The lines on the left side indicate the regions used and analysed in luciferase 
reporter gene assays, whereas the bars on the right represent the relative reporter gene expression 
levels  of  the  tested  constructs.  The  analysis  was  performed  in  CrFK  cells  in  the  absence  of 
dexamethasone. The transcriptional  activity of  the minimal P2 promoter was set to 100%. Each bar 
reflects the mean value of at least three independent experiments with standard errors of less than 5% of 
the mean values. 
The activity of the P2 promoter originating from the Mtv-8 isolates followed the same 
pattern  of  regulation  as  the  previously  tested  Mtv-2  sequences.  The  upstream  located 
regulatory element abrogated its activity (pZdP2mtv8, construct 11 versus minimal Mtv-8 P2 
promoter,  construct  10),  irrespective  of  the  presence  of  the  downstream  enhancer 
(pZ150.a2mtv8,  construct  13).  However,  in  the  absence  of  the  NRE,  the  same  enhancer 
increased  P2  activity  up  to  10-fold  (pZP2.a2,  construct  12).  The  level  of  reporter  gene 
expression remained elevated when the complete region from the beginning of the NRE up to 
the end of the enhancer was analysed, reflecting the transcriptional activity of the short region 
between the P2 promoter core (bp 638-678) and position 744 (pZd-a2mtv8, construct 14). We 
conclude  that  the  TATA-motif  present  in  Mtv-8  represents  the  promoter  core  of  the 
transcriptional  active element.  In accordance with previous MMTV nomenclature, the novel 
promoter was termed P3. 
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 4.2  The P3 promoter is regulated by a downstream enhancer
To further characterise the novel promoter, we tested its transcriptional potential and 
possible influencing sequences of the LTR using the same transient reporter gene assays as 
described above. The results of the analysis are summarized in figure 4.5. 
Figure 4.5 Influence of immediately upstream and downstream located regions on the activity 
of the P3 core promoter. A scheme of the MMTV U3 region is presented on the top. The core promoter 
elements are symbolized by filled boxes, while the HRE is indicated by the hatched box. The sequences 
used and analysed are indicated by the thin lines. The bars represent the relative luciferase expression 
levels of the tested constructs after transient transfection of CrFK cells in the absence of dexamethasone. 
The transcriptional activity of the minimal P3 promoter was set to 100%. Each bar reflects the mean 
value of at least three independent experiments with standard errors of less than 5% of the mean values. 
This time, the activity of the minimal P3 promoter was set to 100% and compared to 
the  relative  activities  of  the  other  constructs  tested.  Both  minimal  core  promoters  show 
comparable transcriptional potential (pZTBP2, construct 1, compared with pZTBP3, construct 
15, figure 4.5). The presence of the downstream regulatory element increased the relative 
luciferase  expression  (pZP3-a2,  construct  16,  compared  to  construct  15).  However,  the 
addition of the NRE did not affect P3 activity (pZdP3, construct 17, compared to construct 15). 
The two promoters do not work in synergy, as no increase in reporter gene expression is 
observed in the fragment encompassing both promoters (pZTBP2P3, construct 18, compared 
to  construct  1  and  construct  15).  As  expected,  high  levels  of  luciferase  expression  were 
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observed  when  the  complete  region  from bp  638  up  to  bp  995  was  analysed  (pZP2-a2, 
construct 19 compared to construct 15 and 16). 
Summarizing  these  transient  transfection  experiments,  two  transcriptional  active 
promotor elements are located within the central LTR of MMTV, whose TATA-boxes are only 47 
bp apart from each other. Both are regulated by the same enhancer element, while the activity 
of the more upstream situated P2 promoter is additionally influenced by an NRE. 
 4.3  A transcriptional initiation site is located downstream of the P3 
promoter
For the characterization of the novel P3 promoter, we decided to utilize the plasmid 
pGR102 which carries the complete coding information of an integrated provirus (Salmons et 
al., 1985). Originally, the 5'LTR and the beginning of  gag was derived from Mtv-8, while the 
remaining sequences were comprised of Mtv-2 based elements. In order to ensure that both 
LTRs carry the same sequence in their central part, we replaced the former 5' LTR with Mtv-2 
based sequences to generate an Mtv-2/Mtv-8/Mtv-2 hybrid. Additionally, a CMV-driven EGFP 
expression cassette was introduced into the 3' LTR to facilitate the detection of integrated 
copies. NMuMG cells, which are derived from the mammary glands of an adult Namru mouse 
(Owens et al., 1972) and thus represent a natural reservoir of MMTV, and CrFK cells, which are 
permissive to MMTV yet lack any endogenous murine retroviral sequences, were transfected 
and stable  clones,  referred  to  as N2AnE5 and C2AnE15,  respectively,  were produced.  The 
ability to produce infectious viral particles was monitored periodically by FACS analysis (data 
not shown).
In  order  to  determine  the  respective  transcriptional  initiation  site  of  transcripts 
originating from the P3 promoter, we performed an RLM-RACE (RNA ligase-mediated rapid 
amplification of 5' and 3' cDNA ends). This method allows the specific amplification of capped 
transcripts and, in consequence, the determination of their respective 5' or 3' ends. In brief, 
this method starts by dephosphorylating the pool of isolated RNAs. Thereby, truncated mRNA 
and non-mRNA are  eliminated from the subsequent  ligation step while  full-length,  capped 
mRNA would remain unaffected. In the following step, the cap-structure is removed leaving a 
5' phosphate that is required for the subsequent ligation to the provided GeneRacerTM  RNA 
oligonucleotide. Then, the ligated RNAs are reverse transcribed. In order to obtain the 5' ends, 
the first strand cDNAs are amplified with the GeneRacerTM 5' Primer and a sequence specific 
reverse primer. 
For the analysis, we isolated messenger RNAs from GR cells, a productively infected 
mouse mammary cell line, as well as from clone N2AnE5, both of which have been grown in 
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the absence of dexamethasone. After dephosphorylation, decapping and ligation, the RNAs 
were reverse transcribed with a reverse primer corresponding to the gag 5' untranslated region 
(1443/1424) (figure 4.6A). Subsequently, RT-PCRs were performed with the GeneRacerTM 5' 
Primer and a nested reverse primer (1431/1409). 
 In both MMTV producer cell lines, we obtained a PCR product of approximately 240 
bp  in  length  (figure  4.6B,  lane  1  and  2).  The  size  of  the  amplicon  indicates  that  the 
corresponding transcript represents a spliced message. (In contrast, the expected length of an 
unspliced product would be ~700 bps.)  A splice donor (SD825) and splice acceptor site (SA1275) 
within the LTR have been described previously (Xu et al., 1997).
A
B
Figure 4.6 Determination of the transcriptional initiation site. Messenger RNA was isolated from 
GR cells and N2AnE5 cells, decapped and ligated to the GeneRacerTM  RNA oligonucleotide. After reverse 
transcription, PCRs were performed with the GeneRacerTM 5' Primer and a gene-specific reverse primer 
(1431/1409). (A) The 5' LTR and the beginning of the gag gene of MMTV are shown. The known splice 
donor and splice acceptor sites are indicated as well as the sequence specific primer binding site used for 
the generation of  first  strand cDNAs.  (B) The amplification products obtained from GR (lane 1) and 
N2AnE5 (lane 2) first strand cDNA are shown. PCRs performed in the absence of any template are shown 
in lane 3. The arrow points to the MMTV-specific 5' RACE PCR product.  
The sequence analysis of the gel purified and subcloned GeneRacer PCR products 
revealed a corresponding transcriptional initiation site at position 760 relative to the beginning 
of  the  LTR,  which  is  therefore  61  nucleotides  downstream of  the  initiation  site  of  the  P2 
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promoter  that  has been determined by Günzburg and colleagues (Günzburg  et al.,  1993) 
(figure 4.7). 
Figure 4.7 Transcriptional initiation sites in the central LTR of MMTV. The P2/P3 promoter region 
derived from the Mtv-2 proviral sequence is shown. The TATA-boxes of both promoters are displayed in 
bold face. The arrows indicate the transcriptional start sites of the P2 promoter (Günzburg et al., 1993) 
and the P3 promoter, respectively. The numbers refer to the beginning of the LTR. 
Thus,  the  central  LTR of  MMTV harbours  two core  promoters  elements  and  two 
defined  transcriptional  start  sites  in  close  vicinity.  Moreover,  the  RLM-RACE  revealed  that 
messages initiating downstream of the P3 promoter utilize the splice donor and acceptor sites 
of the LTR at position 825 and 1275, respectively. 
 4.4  In the absence of dexamethasone the P2/P3 promoter complex is 
more potent than the major P1 promoter 
To determine the strength of the MMTV LTR Promoter complex, the activity of the LTR 
promoter complex was compared to the basal  transcription initiation rate of  the major P1 
promoter. To this end, mRNA was isolated from the MMTV-producer cell  clone N2AnE5 and 
reverse transcribed with the oligonucleotide complementary to the gag 5' untranslated region 
(1443/1424). The use of this primer allows the detection of transcripts initiating from both 
promoter  regions  (P2/P3  promoter  and P1  promoter,  respectively).  Subsequently,  the  first 
strand cDNAs were subjected to semi-quantitative RT-PCR analysis. Two primer pairs were 
used simultaneously,  which  either  amplify  a  short  region downstream of  the P3  promoter 
(expected length of 62 bps) or the very 5' end of transcripts originating from the major P1 
promoter (expected length of 76 bps). (The primer binding sites are indicated in figure 4.8A). 
Aliquots were withdrawn from the reaction tube after 15, 20, 25, 30, 35 and 40 cycles. Figure 
4.8B shows the amplification products separated on a 2.5% agarose gel. 
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    B
Figure 4.8 Semi-quantitative analysis of transcriptional initiation from the LTR promoters. (A) 
The 5' LTR and the gag 5' untranslated region is shown schematically. The primer binding sites used for 
determining the initiation rate from both promoter regions of the MMTV LTR are indicated as arrows. (B) 
First  strand  cDNA  from  isolated  mRNA  of  N2AnE5  cells  that  had  been  grown  in  the  absence  of 
dexamethasone were used for semi-quantitative PCR analysis (lane 1 to 6). Two primer pairs, specific 
either for transcripts originating from the P2/P3 promoter complex or form the major P1 promoter were 
used simultaneously. 10 µl aliquots were taken at the end of the following cycles: 15 (lane 1), 20 (lane 
2),  25 (lane 3), 30 (lane 4),  35 (lane 5) and 40 (lane 6-9).  The PCR performed in the absence of 
template cDNA is shown in lane 7 (negative control). As positive control, a plasmid template was used for 
the amplification of the P2/P3 transcripts (lane 8) and for the P1 transcripts (lane 9). 
While the amplification products of the promoter complex are visible after cycle 25 
(lane 3, figure 4.8B), those of the P1 promoter do not emerge until cycle 30 (lane 4, figure 
4.8B). Thus, in the absence of glucocorticoide hormones relatively more mRNA is transcribed 
from the P2/P3 promoter region than from the major P1 promoter.  
 4.5  A doubly spliced transcript originates from the promoter complex
In order to facilitate the detection of the putative full length transcript of the central 
LTR promoter complex, we analysed CrFK cell clones that have been stably transfected with a 
full-length provirus harbouring a short deletion of the P1 promoter in its 5'LTR. Total RNA was 
extracted from cells  that  have been grown in the absence of dexamethasone and reverse 
transcribed with poly(dT)-primers. Subsequently, first strand cDNA PCRs were performed with 
a forward primer located immediately downstream of the identified transcription initiation site 
at position 760 and a collection of reverse primers homologous to the proviral sequence. While 
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no product was obtained with primers complementary to gag- or pol coding regions, a strong 
signal emerged with primers located downstream of the  env splice acceptor site (SA6554). All 
amplification products were subcloned and revealed a double spliced message after sequence 
analysis (figure 4.9). 
    A
    B 
Figure 4.9 A double spliced message originates from the P2/P3 promoter complex. (A) The 
newly identified transcript is shown in relation to the genome of the MMTV provirus. The active splice 
donor and acceptor sites are indicated by coloured dots. Exons are shown in blue, while introns are 
represented by dashed lines. (B) The ORFe reading frame (highlighted in blue) differs from the coding 
information of the envelope gene (marked in light red). Utilized splicing sites of the ORFe transcript are 
indicated by coloured dots. 
As already shown, the first intron of the amplified transcript is placed within the LTR. 
The second intron starts at position 1482 (SD1482) and extends until position 6554 (SAenv). The 
complete message was easily recovered using the forward primer in combination with reverse 
primer (7255/7238). Moreover, we could demonstrate that the message does not depend on 
the deletion of the major P1 promoter, since the same product was detected in cDNA from GR 
cells as well as from the MMTV producer clones N2AnE5 and C2AnE15 (data not shown). The 
sequence carries an ORF of 459 nucleotides, which is translated into a 20 kDa protein of yet 
unknown function (Rouault et al., 2007). Since the third exon is located within the env-coding 
region, the putative transcript was labelled ORFe.
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In summary, the LTR of MMTV harbours two transcriptional active regions, both of 
which are comprised of two promoter elements: the major promoter P1, which is accompanied 
by  an  downstream  positioned  initiator  element  (Inr),  and  the  central  promoter  complex, 
harbouring the P2 and the P3 promoter. Therefore, we asked whether the activities of the 
central LTR promoters are regulated in a similar way to that of the major P1 promoter and the 
nearby located initiator element. 
 4.6  Determination of the nucleosome occupancy over the P2/P3 
promoter complex
It  is  well  known  that  upon  hormone  stimulation,  a  characteristic  nucleosome 
remodelling  process  takes  place  at  nucleosome  B,  which  covers  the  hormone  responsive 
element and the TATA-box of the major P1 promoter. Furthermore, studies have revealed that 
the neighbouring nucleosomes C and A are involved in an extended chromatin rearrangement 
as well (Fletcher et al., 2000; Vicent et al., 2004). However, further upstream regions were not 
investigated  during  these  analyses.  We  hypothesized  that  the  activity  of  the  central  LTR 
promoters  (P2  and  P3,  respectively)  could  be  regulated  by  alternating  positions of  the 
corresponding nucleosome. Depending on the presence of glucocorticoids, a nucleosome free 
site could be generated for either of the two promoters to allow transcription to take place. 
Therefore, we decided to study the position of the nucleosome D, which covers the P2/P3 
promoter region on a base pair  level  of  resolution in the presence and in the absence of 
dexamethasone. 
In  contrast  to  regulatory  proteins,  nucleosomes  do  not  recognize  a  specific 
sequencing motif. They must be able to associate with the entire genome in order to facilitate 
the packaging of the DNA. Hence, this unspecific binding makes it difficult to predict regions 
occupied by nucleosomes. Nevertheless, genome wide studies revealed two main properties of 
the DNA that influences nucleosome binding. One characteristic feature is given by a 10 bp 
periodicity of A/T nucleotides, which facilitates the bending of the double helix around the 
nucleosome core particle (Satchwell  et al., 1986; Widom, 2001).  In addition, these studies 
demonstrated that  there  are  a  number  of  short  sequences  on the  DNA itself  that  act  as 
nucleosome disfavouring motifs  (Segal  et al.,  2006;  Field  et al.,  2008).  Current  computer 
prediction programs take advantage of both features. 
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 4.6.1  In silico analysis of the LTR allows multiple positions of nucleosome D
We  started  by  subjecting  the  LTR  of  Mtv-2  and  Mtv-8,  respectively,  to  the 
nucleosome prediction model developed by the group of Eran Segal (Segal et al., 2006; Kaplan 
et al., 2009). Mtv-2 was chosen as a representative of an integrated virus able to produce 
infectious viral particles, while Mtv-8 served as example of a defective provirus. Figure 4.10A 
shows the predicted nucleosome occupancy over the Mtv-2 LTR.
       A
       B
Figure 4.10 In silico analysis of the Mtv-2 LTR.  (A) The probability of the nucleosomal occupancy 
over the Mtv-2 LTR is shown. The numbers on the x-axis refer to the base pair position of the LTR, while 
the  corresponding probability is  indicated on the  y-axis.  (B)  The graph displays  the probability  of  a 
specific Mtv-2 LTR sequence to serve as transcriptional initiation site. 
As mentioned in section 1.6.1, the MMTV LTR is covered by an array of six positioned 
nucleosomes, termed F-A (in 5'  to 3' direction). The hormone-responsive element and the 
TATA-box of the major promoter are covered by nucleosome B, while the nucleosome D is 
occupying the central LTR including the P2/P3 promoter complex.
The calculated nucleosomal occupancy over the Mtv-2 LTR revealed distinct positions 
for the first two nucleosomes in respect to the beginning of the LTR (nucleosomes F and E, 
according to the literature), since relatively low probabilities are found around position 1-15 
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and 180-200. These are followed by a strong nucleosome disfavouring sequence of more than 
100 bp (positions 370-470). The probability increases unequivocally around bp 534, reaching 
an internal high at position 600. This is followed by a constant decrease until position 880, 
which complicate a prediction of the border between the corresponding nucleosomes D and C. 
Two local low points at bp 890 and at bp 1120, both interrupted by internal highs, indicate the 
respective positions of the nucleosomes B and A. 
Besides  the  nucleosome  occupancy,  the  model  calculates  the  probability  for 
transcriptional initiation sites of the sequence of interest. The results in regard of the Mtv-2 
LTR are shown in figure 4.10B. The highest probability for an initiation site is found at position 
1171,  which  correlates  to  the  known  transcriptional  start  of  the  major  promoter  P1.  In 
addition, a cluster of potential start sites is indicated over the central part of the U3 region 
(position  680-700),  where  the  promoters  P2  and  P3  have  been  identified.  Interestingly, 
transcriptional  initiation  sites  are  predicted even further  upstream: at  position  25,  around 
position 210-240 and within the region ranging from position 530 to 580. It is tempting to 
speculate that the very N-terminal start site indicates initiation from the open reading frame 
that encodes for Sag. However, no transcriptional activity has as yet been reported from the 
other two indicated regions.
The predicted nucleosome occupancy over the Mtv-8 LTR, which is shown in figure 
4.11A, resembles that calculated from the Mtv-2 sequence (figure 4.10A).
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       B
Figure 4.11 Analysis of the Mtv-8 LTR. (A) The probability of nucleosomal occupancy over the Mtv-8 
LTR is shown. The numbers on the x-axis indicate the base pair positions relative to the beginning of the 
LTR. (B) The graph represents the computed transcriptional initiation site distribution over the Mtv-8 LTR.
The positions of the first two nucleosomes relative to the beginning of the LTR are 
predicted with high probability, followed by a short, but strong disfavouring region of about 
100 bp around position 420. Then an almost continuous increase reaches its top level at bp 
610. The probability drops about 20 %, but stays at a constant level until position 750, before 
it decreases further. Again, it is not possible to locate the border between nucleosome D and 
nucleosome  C.  In  contrast  to  Mtv-2,  there  seems  to  be  a  second,  although  less  strong, 
disfavouring region of about 100 bps from position 820 to 920. A broad, lower peak together 
with a high, but smaller peak allow the localization of the positions of nucleosome B and A, 
respectively. 
In accordance to the nucleosome positions, the predicted transcriptional initiation 
sites of Mtv-8 resemble those of Mtv-2 (compare figure 4.11B with figure 4.10B). However, a 
prominent exception is illustrated by the predicted transcriptional start site at the very N-
terminus, which appears to be twice as high as the other ones. The viral encoded superantigen 
is known to be expressed from almost all endogenous MMTV sequences (Scherer et al., 1995). 
Therefore,  this  result  supports  our  previous assumption that  this  peak corresponds to the 
initiation site of Sag.
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In conclusion, it is possible to predict the putative 5' border of nucleosome D that is 
covering the P2/P3 promoter region, because it is strongly affected by an upstream located 
nucleosome disfavouring region. However, the nucleosome occupancy calculated merely from 
the DNA sequence does not allow the determination of the 3' border of nucleosome D. 
 4.6.2  A nuclease hypersensitive site is detectable at the P2/P3 promoter 
region
For the in vivo study, we stably transfected cells with a plasmid containing only the 
5'  LTR of  Mtv-2 in  order  to  compensate  for  possible  differences in  the distribution  of  the 
nucleosomes  over  both  LTR  regions.  Stable  populations  were  produced  in  the  mammary 
epithelial cell line NMuMG as well in the MMTV permissive feline cat kidney cells CrFK and are 
referred to as NM5'LTR cells and CK5'LTR cells, respectively. 
The successful integration of the plasmid DNA into the host cells was demonstrated 
by  Southern  blot  analysis.  Genomic  DNA was  isolated from both  populations,  blotted  and 
subsequently hybridized to digoxigenin (DIG)-labelled probe corresponding to the 5' end of the 
LTR. Figure 4.12 shows that the Mtv-2 LTR is integrated in transfected CrFK cells (lane 2, figure 
4.12) as well as in transfected NMuMG cells (lane 4, figure 4.12); the original plasmid was 
used as positive control (figure 4.12, lane 5). In contrast to the CrFK cells, which are free of 
any endogenous MMTV proviruses (lane 1, figure 4.12), a number of endogenous Mtvs could 
be detected in the parental NMuMG cell line (lane 3, figure 4.12). However, none of them is 
identical to the transfected LTR of Mtv-2 (compare lane 3 with lane 4, figure 4.12). 
Figure  4.12 Stable  integration  of  the  5'LTR into  CrFK and  NMuMG cells. Genomic  DNA was 
digested to completion with restriction enzymes BamHI, EcoRI and HindIII, separated on a 1% agarose 
gel and transferred onto a nylon membrane.  Hybridization was performed with a DIG-labelled probe 
spanning a 500 bp fragment corresponding to the 5' end of the MMTV LTR. The arrow points to the Mtv-2 
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based LTR of the transfected plasmid. The hybridization results obtained from non-transfected CrFK cells 
(lane 1), CK5'LTR cells (lane 2), non-transfected NMuMG cells (lane 3) and NM5'LTR cells (lane 4) are 
shown. Plasmid DNA was used as positive control (lane 5).
In order to ensure the functionality of the integrated single LTR, we determined the 
level of transcripts initiating from both promoter regions by semi-quantitative RT-PCR analysis. 
To compensate for differences in the nucleosome occupancy during transcription and mitosis, 
the cells were synchronized in their cell cycle. This was achieved by arresting the cells using 
serum starvation for 48 hours. At the end of the starvation period, the cells were allowed to 
reenter the cell cycle by the addition of normal growth medium, with half of the cells being 
stimulated  with  dexamethasone.  Total  RNA was  extracted after  30 min  and 120  min  and 
reverse transcribed with an oligonucleotide corresponding to the  gag 5' untranslated region 
(1443/1424);  subsequently,  RT-PCRs  were  performed.  The  forward  primers  were  located 
downstream of either the transcriptional initiation site of the major P1 promoter (1197/1219) 
or the transcriptional start site of the P3 promoter (773/795).
Figure 4.13A shows the amplification products originating from the P1 promoter. An 
increase of its transcriptional activity is found in response to hormonal stimulation after 30 min 
(lane 1) as well as after 120 min (lane 3) compared to the basal levels detected in untreated 
cells  (lane 2 and 4, respectively).  In contrast,  no differences in  the amount of  transcripts 
initiating  at  the  central  promoter  complex  are  detectable  in  response  to  glucocorticoid 
induction. Moreover, the amount of transcripts stayed constant over the whole time period 
investigated (lane 1 to 4, figure 4.13B). Results with NM5'LTR cells are shown, although similar 
pictures were also obtained with CK5'LTR cells. 
A B
Figure 4.13 Transcriptional initiation from the LTR promoters in NM5'LTR cells.  NM5'LTR cells 
were growth arrested by serum starvation for 48 hours. Total RNA was extracted after the cells were 
allowed to reenter the cell cycle for 30 min and 120 min, respectively. Half of the cells of each time point 
were stimulated for the same period with dexamethasone. After reverse transcription, RT-PCRs were 
performed with primers located downstream of the initiation site of the P1 promoter (A) or the central 
promoter  complex  (B).  The  amplification  products  of  synchronised  NM5'LTR  cells  treated  with 
dexamethasone (lane 1) or without any hormones (lane 2) for 30 min and those of NM5'LTR cells treated 
with  dexamethasone  (lane  3)  or  without  any  hormones  for  120  min  (lane  4)  are  shown.  Lane  5 
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represents RT-PCRs performed in the absence of a cDNA template.
We decided to focus on CK5'LTR cells in order to prevent any influence originating 
from endogenous  Mtv sequences  as  this  could  not  be  excluded in  a  NMuMG background. 
Moreover, the strong difference between untreated and dexamethasone induced cells regarding 
the transcriptional activity of the major promoter after 120 min prompted us to choose  this 
time point for further analysis. 
The strategy for the determination of the nucleosomal borders was adopted from 
Soutoglou and Taliandis (Soutoglou and Taliandis, 2002) and is shown schematically in figure 
4.14. 
Figure 4.14 Determination of the nucleosomal borders via LM-PCR. The steps for the analysis of 
the position of a specific nucleosome are shown schematically. First, the chromatin is isolated from the 
cells of interest (A) and treated with micrococcal nuclease (B) to achieve mononucleosomal particles (C). 
The histone proteins are digested by proteinase K treatment and the remaining DNA fragments are 
electrophoretically  separated  (D).  Finally,  those  fragments  that  have  been  protected  by  a  single 
nucleosome are extracted and ligated to the double stranded linker-oligonucleotide. The subsequent PCR 
analysis is performed with a  linker-specific primer (grey arrow) and a sequence-specific primer (blue 
arrow) (E).
The first  steps included the isolation of  the chromatin (figure 4.14A),  which was 
subsequently digested with micrococcal nuclease (MNase), an enzyme that cuts preferentially 
inter-nucleosomal  DNA  (figure  4.14B).  Then,  the  generated  mono-  and  multinucleosomal 
particles  (figure  4.14C)  were  digested  with  proteinase  K  to  remove  histone  as  well  as 
associated  non-histone  proteins.  Afterwards,  the  fragmented  DNA  (figure  4.14D)  was 
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separated  electrophoretically  and  those  fragments  that  had  been  protected  by  a  single 
nucleosome (appropriate length of 147 bps) were extracted and purified. Before ligating the 
asymmetric  linker  oligonucleotide  to  the  MNase-cleaved  substrate,  it  was  necessary  to 
phosphorylate  the  5'  hydroxyl-groups  that  were  generated  by  the  enzyme.  The  ligation-
mediated  (LM-)  PCRs  were  performed  with  a  primer  pair  comprising  of  a  linker-  and  a 
sequence-specific primer (figure 4.14E). 
Prior to the analysis, the determination of the optimal concentration of the enzyme 
was required to prevent overdigestion and thus the generation of subnucleosomal particles, 
which  would  otherwise  distort  the  interpretation  of  the  results.  Figure  4.15  shows  one 
representative agarose gel of chromatin from synchronized CK5'LTR cells treated with suitable 
amounts of micrococcal nuclease. 
Figure 4.15 Agarose gel electrophoresis of purified DNA fragments after micrococcal nuclease 
digestion of the respective chromatin. Chromatin was extracted from synchronized CK5'LTR cells and 
digested  with  micrococcal  nuclease.  The  respective  DNA  fragments  were  purified  and  separated  by 
agarose gel electrophoresis. 2 µl (lane 1), 5 µl (lane 2) and 10 µl (lane 3) of the sample were applied to 
the gel.
 A characteristic laddering of the DNA is visible, comprising of the mononucleosomal 
fragments together with their multiples. These are generated when one or more consecutive 
inter-nucleosomal  regions escaped  digestion.  In  addition,  this  analysis  allows  the 
determination of the proper quality of the nucleosomal preparation, which is guaranteed if six 
or more distinct bands are visible. 
Independent  preparations  of  mononucleosomes made from synchronized CK5'LTR 
cells that had been either stimulated with glucocorticoids or left untreated were subjected to 
LM-PCR  analysis.  The  use  of  an  MMTV-specific  forward  (645/672)  and  reverse  primer 
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(726/703),  each  in  combination  with  an  oligonucleotide  corresponding  to  the  reverse 
transcribed linker sequence, allowed the determination of the position of the nucleosome D 
that is covering the P2/P3 promoter region. 
Figure 4.16 shows the amplification products of the in vivo analysis of the position of 
nucleosome D. Irrespective whether the cells have been stimulated with dexamethasone or left 
untreated, two prominent bands appeared when the 5' border of the nucleosome was analysed 
(figure 4.16A, left picture). In contrast, a single product was amplified using a MMTV-specific 
primer for determinating the 3' end of the nucleosome (figure 4.14A, right picture).
A
B
Figure 4.16 Determination of the nucleosome D positioning in CK5'LTR cells. (A) The LM-PCRs 
results for determining the 5' border (left) and the 3' border (right) of the nucleosome D (covering the 
P2/P3 promoter region) after electrophoretic separation are shown. Lane 1: CK5'LTR cells stimulated with 
dexamethasone, preparation I; lane 2: CK5'LTR cells left untreated, preparation I, lane 3: CK5'LTR cells 
stimulated with dexamethasone, preparation II; lane 4: CK5'LTR cells left untreated, preparation II. Lane 
5 shows the LM-PCR performed in the absence of any DNA template. (B) The sequence of the P2/P3 
promoter region is shown. The arrows indicate the MNase cleavage sites obtained after sequence analysis 
of at least 30 mini-preps that were made after subcloning the LM-PCR products. Only digestion sites that 
were hit at least three times were included in the interpretation of the analysis.
The bands were extracted from the gel, purified and sequenced after an additional 
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subcloning step. The analysis is presented in figure 4.16B. The total amount of samples (each 
representing an individual clone) that contained both primer sequences and aligned to the 
MMTV LTR were set at 100 %. Only those digestion sites that occurred at least three times 
were included in the analysis of the nucleosomal borders.
Two clusters of nuclease digestion sites corresponding to the two amplified fragments 
were detected at the 5' end of the nucleosome. The upstream located site overlaps with the 
CAAT-box of the P2 promoter, while the centre of the downstream located site is found in 
between  the  CAAT-box  and  the  TATA-box  of  the  P2  promoter.  At  the  3'  border  of  the 
nucleosome,  the  nuclease  digestion  sites  were  distributed around the  TATA-box of  the  P3 
promoter. 
In  summary,  the  more  upstream located  5'  nuclease  digestion  site  corresponds 
together with the detected 3' border approximately to the theoretical size of a nucleosomal 
DNA  fragment  (147  bps).  Moreover,  both  sites  lie  in  close  vicinity  of  the  nucleosome  D 
positions that were originally identified by Richard-Foy and Hager (Richard-Foy and Hager, 
1987). Therefore, we conclude that the nuclease digestion sites around position 644 represent 
an additional hypersensitive site that indicates an open chromatin formation at nucleosome D. 
Interestingly,  both,  the  CAAT-box of  the  P2  promoter  as  well  as  the  TATA-box  of  the  P3 
promoter  are  located at  the very end of  the nucleosome, a property which  increases the 
accessibility of these sequences to be bound by putative transcription factors. 
However, we were unable to detect any difference of the nucleosomal position in 
dependence of glucocorticoid treatment. 
 4.7  Elevated methylation levels accompany transcription from the P2/
P3 promoter complex
Besides  the  positioning  of  the  nucleosomes,  post-translational  modifications  of 
histone proteins have a major impact on the transcriptional activity of the underlying DNA. 
These modifications influence the chromatin structure either directly by altering DNA-histone 
interactions or indirectly by providing binding sites for non-histone proteins (Thorne  et al., 
2009). The constant rate of transcription initiation from the P2/P3 promoter complex as well as 
the results from the nucleosome positioning analysis prompted us to investigate associated 
histone modifications by chromatin immunoprecipitation (ChIP).
Briefly, the chromatin was isolated from the cells of interest and digested with a 
suitable  enzyme  into  parts  of  appropriate  length.  After  a  preclearing  step  to  minimize 
unspecific binding events, antibodies against the modifications of interest were allowed to bind 
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to their corresponding epitopes. Then, protein G beads, which adhere to the immunoglobulins 
due to their high affinity to the Fc (Fragment crystallizable) region, were added to the solution. 
After  several  washing steps,  the bound fraction  (comprising of  the antibody associated to 
specific subgenomic regions of the chromatin) was eluted. Subsequently, the corresponding 
DNA-fragments were isolated and purified. The last step included a qRT-PCR analysis in order 
to allocate the investigated modifications to their corresponding regions on the DNA and to 
allow a comparison of their relative amounts. 
For the isolation of the chromatin and the generation of subgenomic units, the same 
protocol was used as for the determination of the nucleosomal borders with the exception that 
this time we wanted to achieve a complete digestion of the chromatin (i.e. mononucleosomal 
fragments).  Synchronized CK5'LTR cells  grown in  the  absence  of  hormones  were  used as 
starting  material  for  the  ChIP  analysis.  Figure  4.17  shows  the  digested  chromatin  after 
extraction of the DNA and separation on a 2% agarose gel. 
Figure  4.17 Mononucleosomal  DNA  fragments  obtained  after  complete  digestion  with 
micrococcal nuclease. Agarose gel electrophoresis of DNA fragments which were purified after nuclease 
digestion of isolated chromatin of CK5'LTR cells. 2 µl (lane 1), 5 µl (lane 2) and 10 µl (lane 3) of the 
sample have been loaded onto the gel.
Only  mononucleosomal  fragments  (147  bp)  are  present  in  the  preparation; 
therefore, a direct comparison of the relative amounts of the respective modifications between 
nucleosome D, which covers the P2/P3 promoter complex, and nucleosome B, which occupies 
the hormone-responsive sites of the P1 promoter, would be possible. 
A marker of choice for active chromatin represents the trimethylation of lysine 4 on 
histone H3 (H3K4m3) (Ng  et al., 2003;  Pokholok  et al., 2005). Although lysine methylation 
itself has no inherent effect on the histone charge, its predominant role lies in the recruitment 
of additional factors (Fuchs  et al., 2009).  Independently performed experiments revealed an 
equal distribution of this specific modification over the nucleosomes B, C and D. The results are 
represented in figure 4.18 as percent of the input-sample.  
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Figure  4.18  Active  chromatin  formation  is  found  equally  distributed  over  the  central 
nucleosomes of the MMTV LTR. ChIP analyses were conducted in synchronized CK5'LTR cells with an 
antibody targeting methyl-groups on histone H3 (H3K4m3 antibody, Cell Signaling Technology). The IgG 
antibody was used as control. The relative amounts of the respective DNA were determined by qRT-PCR 
with primers specific for each nucleosome. The results are represented as percentage of the input-sample 
which was set to 100%. The mean of at least three independent experiments is shown.
Although H3K4m3 is known to promote transcriptional elongation and regulate RNA 
processing events (Santos-Rosa  et al., 2002; Sims  et al., 2007), the same modification has 
been shown to be able to recruit repressing protein complexes as well (Berger, 2007). 
Therefore, we additionally investigated the distribution of trimethylation at lysine 36 
of histone 3 (H3K36m3). This modification is catalysed by the histone methyltransferase Set2, 
which specifically binds to the RNA polymerase II. Thereby, H3K36m3 is directly linked to the 
passage  of  RNA polymerase  II  and  thus  acts  as  potent  sign  of  transcriptional  elongation 
(Berger, 2007; Fuchs et al., 2009). 
The results of the ChIP analyis performed with an antibody against H3K36m3 are 
shown in figure 4.19. In the absence of glucocorticoid stimulation, the highest levels of these 
modifications are found at nucleosome D, which occupies the P2/P3 promoter region. 
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Figure 4.19 A marker for transcriptional elongation is found predominantly at nucleosome D. 
Chromatin immunoprecipitation of CK5'LTR cells was performed with an antibody targeting  H3K36m3 
(Cell Signaling Technology). The IgG antibody was used as control. The relative amount of the respective 
DNA was determined by qRT-PCR with primers specific for the nucleosome B, C or D regions. All results 
are depicted as percentage of the input-sample which was set to 100%. The mean of at least three 
independent experiments is shown.
The results correspond to the findings obtained by semi-quantitative RT-PCR (figure 
4.8), which indicated that without dexamethasone induction, relatively more RNA is transcribed 
from the promoter complex than from the major P1 promoter.
 4.8  Post-translational acetylation inversely correlates with ORFe 
transcription
Subsequent to the passage of the DNA-polymerase, the initiation signals have to be 
suppressed to prevent an otherwise constitutive activation of the respective gene. This task is 
mediated by the recruitment of enzymes that possess repressive deacetylase activities (Joshi 
and Struhl, 2005). Thus, we investigated in the following step the impact of the acetylation 
status  of  the  corresponding  histone  proteins  on  the  transcriptional  activity  of  the  central 
promoter complex.
According to the commonly accepted model, the acetylation of histones neutralizes 
their positive charge. Thereby, the tight association with the negatively charged DNA backbone 
is outweighed and gene activation is allowed to take place. However, a few exceptions (c-myc, 
cyclin D1) have been described (Van Lint et al., 1996; Lallemand et al., 1996). In regard of the 
MMTV LTR, controversial results have been reported. Several groups detected an activation 
dependent increase in histone acetylation over the MMTV LTR (Lambert and Nordeen, 2003; Li 
et al., 2003; Astrand  et al., 2009) while others notified deacetylation events upon induction 
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(Sheldon et al., 2001; Mulholland et al., 2003; Wilson et al., 2002; Aoyagi and Archer, 2007). 
As no one has separately analysed the effect of acetylation on the major promoter and the 
central  promoter  complex,  we  thought  that  this  approach  might  help  to  explain  previous 
observations. 
In a preliminary experiment, synchronized CK5'LTR cells were treated with increasing 
concentrations  of  the  deacetylase  inhibitor  trichostatin  A  (TSA).  Total  RNA  was  isolated, 
reverse transcribed and transcription  initiation was analysed either  at  the P2/P3 promoter 
complex or at the P1 promoter/Initiator region. The results of the RT-PCRs are shown in figure 
4.20.
A B
Figure 4.20 Effect of trichostatin A on the transcriptional initiation rate of the LTR promoters. 
Synchronized CK5' cells were treated for 18 hours with increasing concentrations of TSA. Subsequently, 
total RNA was reverse transcribed with poly(dT) primers and transcriptional initiation was analysed by RT-
PCR  with  oligonucleotides  specific  for  the  P2/P3  promoter  region  (A)  and  the  P1  promoter  (B), 
respectively. The amplification products of untreated cells (lane 1), cells incubated with 5 ng/ml TSA (lane 
2), cells incubated with 50 ng/ml TSA (lane 3) and cells incubated with 100 ng/ml TSA (lane 4) are 
shown. RT-PCRs performed without any cDNA template are shown in lane 5.
While no effect was observed after 2 hours of incubation (data not shown), overnight 
treatment  lead  to  a  shift  in  the  nature  of  transcriptions  initiating  at  the  P2/P3  promoter 
complex. The amount of unspliced transcripts accumulated upon increasing TSA concentrations 
(grey arrow, figure 4.20A), while at the same time the level of spliced messages decreased 
(white  arrow,  figure  4.20A).  In  contrast,  only  a  slight  change  was  detected  in  the  basal 
transcriptional activity of the P1 promoter (figure 4.20B). We concluded that transcription from 
the central promoter complex is regulated by acetylation and at least one level of regulation 
does involve the process of RNA splicing. 
In  the  following  step,  we  asked  whether  we  could  identify  the  mechanism  of 
repression by investigating the acetylation level of the corresponding nucleosomes. Chromatin 
immunoprecipitations of synchronized CK5'LTR cells were performed, which were either left 
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untreated or incubated with 100 ng/ml TSA for 18 hours, the highest tolerated repressing 
dose.  To  prevent  any deacetylation  events  during the procedure,  all  buffers  and reagents 
contained 5 mM sodium butyrate. Antibodies against the acetylated histone H3 as well  as 
antibodies recognizing acetyl-groups on either lysine 8 or lysine 12 of histone H4 were used. 
The  amount  of  immunoprecipated  DNA  was  determined  by  qRT-PCR  using  primers  for 
nucleosome B and D, respectively. Figure 4.21 shows the results obtained for nucleosome B 
(panel A) and nucleosome D (panel B).
       A
       B
Figure 4.21 Effect of TSA treatment on the acetylation level of nucleosome B and nucleosome 
D. Chromatin immunoprecipitation of CK5'LTR cells either left untreated (blue bars) or incubated with 100 
ng/ml  TSA (red bars) were performed against  acetyl-groups of  histone H3 (H3K9,4Ac antibody,  Cell 
Signaling Technology) and histone H4 (H4K8Ac antibody and H4K12Ac antibody, both from Cell Signaling 
Technology). The IgG antibody was used as control.  The relative amount of the respective DNA was 
determined by qRT-PCR with primers specific for nucleosome B (A) and nucleosome D (B), respectively. 
All results are depicted as percentage of the input-sample which was set to 100%. 
In the absence of hormones, we detected no change of the nucleosome B acetylation 
status  in  response  to  the  TSA  treatment  (figure  4.21A).  This  finding  corresponds  to  the 
constant rate of transcription initiation from the major P1 promoter under these conditions 
(figure 4.20B). In contrast, an overall increase in acetyl-groups of histone H3 as well as of 
histone H4 following the incubation with TSA was detected at nucleosome D, which occupies 
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the  P2/P3  promoter  region  (figure  4.21B).  Thus,  the  downregulation  of  ORFe  specific 
transcripts upon TSA is accompanied by increasing levels of histone acetylation. 
Consequently, their upregulation would require the presence of a histone deacetylase 
complex.  The mammalian  HDAC superfamily  consists  of  11 proteins which  share  a  highly 
conserved deacetylase domain. According to their homology with yeast proteins, they can be 
classified into four families, which differ in structure, subcellular localization and expression 
patterns  (Haberland  et  al.,  2009).  Class  I  HDACs  (HDAC1,  2,  3  and  8)  are  localized 
predominantly in the nucleus and exert a high enzymatic activity toward histone substrates. 
HDAC1 and HDAC2 are nearly identical and generally found together in repressive complexes. 
HDAC3  is  recruited  to  distinct  complexes,  while  HDAC8  possesses  no  specificity  at  all 
(Haberland et al., 2009). In contrast, class IIa (HDAC 4, 5, 7 and 9) specifically bind to the 
transcription factor myocyte enhancer factor 2 (MEF2) and to the chaperone protein 14-3-3. 
The  enzymes  of  class  IIb  (HDAC  6,10)  are  the  main  cytoplasmic  deacetylases  found  in 
mammalian cells. Little is known about HDAC11, the only member of class IV HDACs. 
Given their known association to histone proteins, we concentrated on determining 
the level of class I HDACs. We performed a chromatin immunoprecipitation with an antibody 
against the most prominent member HDAC1. The results are represented in figure 4.22. 
Figure  4.22  HDAC1  is  predominantly  associated  with  nucleosome  D.  Chromatin 
immunoprecipitation  of  CK5'LTR  cells  was  performed  with  an  anti-HDAC1  antibody  (Cell  Signaling 
Technology). The IgG antibody was used as control.  The relative amount of the respective DNA was 
determined by qRT-PCR with  primers  specific  for  the  nucleosome B,  C or  D regions.  All  results  are 
depicted as percentage of the input-sample which was set to 100%. 
Indeed, eight times more HDAC1 complexes were found associated with nucleosome 
D compared to nucleosome B or nucleosome C regions, suggesting a tight association of a 
potential  transcriptional  regulator to the P2/P3 promoter region. However, HDACs lack any 
DNA-binding domain, depending on another protein in order to exert their activities in a certain 
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genomic context.
 4.9  CDP is a repressor of the P2 promoter
Within  the  MMTV  LTR,  a  putative  binding  partner  of  these  enzymes  has  been 
identified by the group of J. Dudley (Bramblett  et al., 1995). When they were characterizing 
proteins that bind to the NRE, they identified two major complexes. These included either the 
transcription factor CCAAT displacement protein (CDP) or the special AT-rich sequence binding 
protein 1 (SATB1) (Liu et al., 1997). The latter exhibits a tissue specific expression pattern and 
has been suggested to be responsible for the suppression of MMTV expression in T-cells (Liu et 
al., 1997 & 1999); in contrast, CDP is expressed ubiquitously (Sansregret and Nepveu, 2008). 
It functions either by competing with transcriptional activators for the common binding site, 
referred to as active repression, or by recruiting the histone deacetylase HDAC1 enzyme, a 
phenomenon known as passive repression (Nepveu, 2001). 
At least seven CDP binding sites have been mapped throughout the MMTV LTR (Zhu 
et al., 2000; Zhu and Dudley, 2002). Indeed, three of those are located in close vicinity of the 
P2  promoter  elements.  Two  strong  binding  sites  overlap  with  the  CAAT-box  and  the 
transcriptional initiation site of P2, respectively, whereas a third weaker motif is found near the 
P2 TATA-box (figure 4.23).
Figure 4.23 CDP binding site distribution over the P2/P3 promoter region. The sequences of the 
P2/P3 promoter complex of the Mtv-2 provirus (top line) and of the Mtv-8 provirus (bottom line) are 
shown. The CAAT-box and the TATA-box of  the P2 promoter  as well  as the TATA-box of  the P3 are 
highlighted in blue. The P2 transcriptional start sites is represented by an arrow. CDP binding sites, 
determined by Dudley and colleagues (Zhu and Dudley, 2002) are marked with asterisks. The base pairs 
are depicted relative to the beginning of the LTR.
 From the above discussion, we assumed that CDP not only acts as global repressor 
of  MMTV  as  shown  by  others  (Zhu  et  al.,  2000  &  2004;  Zhu  and  Dudley,  2002),  but 
additionally as a specific negative regulator of the P2 promoter. To investigate this notion, the 
influence of CDP was prevented by introducing point mutations into the two strong binding 
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sites of P2 (abbreviated in figure 4.25 as m596 and m693, respectively). Furthermore, the P3 
TATA-box was  mutated  to  prevent  possible  interfering  transcription  from the  neighbouring 
promoter (figure 4.25). 
Figure 4.25 Introduced point mutations of the CDP binding site within the central U3 region. 
The sequences of the P2/P3 promoter complex of the Mtv-2 provirus before (top line) and after mutation 
(bottom line) are shown. The CAAT-box and the TATA-box of the P2 promoter as well as the TATA-box of 
the P3 promoter are highlighted in blue, while the introduced mutations are shown in red. Putative CDP 
binding sites are represented by asterisks. 
In addition, transcription from the P1 promoter was abolished by introducing a short 
deletion encompassing the P1 TATA-motif and the R initiator element. The so mutated LTR was 
inserted  upstream  of  the  luciferase  gene  in  the  pZluc  vector  (pZgzP2+delR_dCDP-).  For 
comparison, we used a plasmid containing the same promoter mutations, yet the CDP binding 
sites were left unmodified (pZgzP2+delR). The transcriptional activity of each construct was 
analysed in CrFK and NMuMG cells, respectively. After transient transfection, half of the cells 
were stimulated with dexamethasone for 24 hours, as the activity of P2 has been described to 
be enhanced by glucocorticoids (Günzburg et al., 1993). After a further 24 hours of incubation, 
the luciferase activity was measured. Figure 4.26 shows the outcome of one representative 
analysis.
Figure 4.26 Effect of the mutation of the CDP binding sites on P2 promoter activity. NMuMG cells 
were transiently transfected with the indicated plasmids. The transcriptional potential of the MMTV LTR 
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containing only a functional P2 promoter (pZgzP2+delR) was compared to the activity of the P2 promoter 
in the presence of CDP binding site mutations (pZgzP2+delR_dCDP-). Half of the cells were incubated with 
dexamethasone for  24 hours  (blue  bars)  while  the  others  were  left  untreated (turquoise  bars).  The 
luciferase  expression  was  measured  48  hours  post  transfection.  Error  bars  represent  the  standard 
deviation of three independent experiments. 
In  the  presence  of  dexamethasone,  the  luciferase  expression  driven  by  the  P2 
promoter  increased  when  the  CDP  binding  sites  were  inactivated  by  mutation  (compare 
construct  pZgzP2+delR with construct pZgzP2+delRdCDP-, blue bars, figure 4.26). The same 
effect occurred without hormonal stimulation, albeit to a much lower extent (turquoise bars, 
figure 4.26). One explanation for the low expression levels that were observed in the absence 
of dexamethasone could be that they actually reflect the transcription levels of the uninduced 
promoter. Besides, CDP has been described to lose its DNA-binding activity depending on the 
differentiation status of the cells (Zhu et al., 2000). Therefore, differences in the amount of the 
biological active form of CDP between the hormone stimulated (i.e. differentiated cells) and the 
uninduced (i.e. undifferentiated) state of the respective cell could further distort the effect of 
the introduced binding site-mutations. 
In  order  to  test  the latter  hypothesis,  we decided to  determine the endogenous 
levels of  the transcription  factor by immunodetection. We repeatedly tried to quantify  the 
amount of CDP in the cell lines used; nevertheless, we did not succeed due to the extremely 
low  sensitivity  level  of  the  antibodies.  Moreover,  the  cell  lines  we  used  for  studying  the 
regulation  of  the  P2/P3  promoter  complex  have  been  selected  due  to  their  potential  for 
expressing high amounts of viral proteins. Consequently, they should possess low endogenous 
CDP levels.
Hence, to ensure equal amounts of the transcription factor, we decided to express 
the protein exogenously. Previous studies have shown that the activity of  CDP is elevated in 
proliferating cells and decreases during terminal differentiation (Nepveu, 2001).  We started 
with  the  isolation  and  reverse  transcription  of  messenger  RNA  from  different  cell  lines. 
Numerous RT-PCRs were performed, but due to the complexity of the gene (CDP possesses 
more than 33 exons and is organized over a region of over 340 kb (Zeng et al., 2000)), we had 
to overcome major difficulties. 
Nevertheless, we were able to amplify the 110 kD isoform (p110) from NIH3T3 cells 
(mouse  embryonic  fibroblasts).  Under  physiological  conditions,  this  N-terminal  truncated 
protein is generated in a cell cycle dependent manner via proteolytic cleavage of the full length 
CDP polypeptide (p200) (Moon et al., 2001; Truscott et al., 2004; Goulet et al., 2004). Hence, 
the removal of the auto-inhibitory domain and Cut repeat (CR) 1 changes the DNA binding 
specificity and kinetics of the protein. CDP isoforms containing the CR1 domain bind rapidly but 
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only  transiently  to  DNA.  They  prefer  a  distinct  nucleotide  repeat  sequence  than  isoforms 
lacking CR1 and carry the CCAAT-displacement activity (Truscott  et al., 2004). In contrast, 
p75, p90 and p110 exhibit much slower DNA binding kinetics and, depending on the context, 
either  repress  or  activate  transcription  (Sansregret  and  Nepveu,  2008).  Moreover,  the  C-
terminal domain has been shown to recruit the HDAC1 deacetylase (Li et al., 1999).
Figure 4.27 shows a western blot detecting CDP/p110 in transfected NMuMG cells, 
demonstrating that CDP/p110 can be expressed successfully in eukaryotic cells. According to 
its function as transcription factor, it is found exclusively in the nuclear fraction.
Figure 4.27 Immunoblot showing the expression of CDP/p110 in nuclear extracts of NMuMG 
cells.  NMuMG cells  were  transfected  with  the  pCMV110 expression  vector.  Nuclear  and  cytoplasmic 
fractions  (see  methods)  were  separated  on  a  10%  SDS-PAGE.  The  protein  was  detected  by 
immunoblotting using an anti-CDP antibody (M-222, Santa Cruz Biotechnology). Lane 1: cytoplasmic 
extract of non-transfected NMuMG cells, lane 2: nuclear extract of non-transfected NMuMG cells, lane 3: 
cytoplasmic extract of NMUMG cells transfected with pCMV110, lane 4: nuclear extract of NMuMG cells 
transfected with pCMV110. The coomassie-staining of the gel is shown below.
In the following experiment, the reporter gene driven by the P2 promoter in the 
context of the full-length LTR (pZgzP2+delR) or in combination with the NRE (pZ150) was co-
transfected with equal amounts of the CDP/p110 expression vector. The luciferase expression 
was measured 48 hours later. This time, the cells were not stimulated with dexamethasone to 
avoid any influence of the hormonal treatment on the activity of CDP. Figure 4.28 shows a 
decrease  of  P2  activity  in  the  presence  of  CDP/p110  (pCMV110).  A  downregulation  was 
observed in the context of the full length LTR (figure 4.28A) as well as in the situation when 
the P2 promoter elements are solely under the control of the NRE (figure 4.28B).
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Figure 4.28 Influence of CDP/p110 on P2 promoter activity. The relative luciferase activities driven 
by the P2 promoter in the presence of the expression vector (pcDNA3.1) and under the influence of 
exogenously expressed CDP/p110 (pCMV110),  respectively,  are shown. (A) Analysis  of  the luciferase 
activity  in  the  context  of  the  full  length  MMTV  LTR.  Mutations  of  the  P3  promoter  and  a  deletion 
comprising  the  P1  promoter  and  the  R initiator  element  have  been  introduced.  (B)  Analysis  of  the 
luciferase activity of the LTR fragment comprising the minimal P2 promoter and the NRE.
In  conclusion,  this  experiment  shows  that  the  activity  of  the  P2  promoter  is 
downregulated if CDP binds to the cognate sites in the vicinity of the promoter. Consequently, 
the introduction of these binding site mutations (m596 and m693) into the proviral context 
should allow the identification of the corresponding transcriptional product of P2.
 4.10  Constitutive active P2 promoter gives rise to ORFe mRNA
We demonstrated earlier that, independent of hormonal stimulation, a double-spliced 
transcript  (ORFe)  initiates  from  the  P2/P3  promoter  complex  (Rouault  et  al.,  2007). 
Furthermore, we showed that the P3 promoter functions independently of the NRE, while under 
the same conditions, the activity of the P2 promoter decreases. Therefore, we concluded that 
ORFe is transcribed from the constitutive active P3 promoter. 
In order to identify the transcriptional product of the active P2 promoter, we inserted 
the 5' LTR containing the CDP binding site mutations (m596 and m693, respectively) and the 
mutated  P3  TATA-box into  the  full  length  proviral  Mtv-2/Mtv-8 hybrid  containing an  EGFP 
expressing cassette within the 3' LTR. The P1 promoter as well as the initiator element were 
left unmodified to ensure proper transcription of all other viral related RNA species. Two 100 % 
EGFP-expressing clones that were produced in NMuMG cells, were chosen at random and their 
total RNA was isolated and reverse transcribed with poly(dT) primers. First, the functionality of 
the P2 promoter in the proviral  context was tested by performing RT-PCRs with a forward 
primer binding immediately downstream of the P2/P3 promoter complex and a reverse primer 
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corresponding to the gag 5' untranslated region (figure 4.29A). As can be seen in figure 4.29B, 
the nature of transcripts differed in the clones analysed. While spliced messages prevailed in 
clone A, unspliced transcripts were found predominantly in clone B. 
       A
        B
Figure 4.29 Transcripts initiating downstream of the P2/P3 promoter complex after mutation 
of the P3 TATA-box and the CDP binding sites. (A) The 5'LTR and the beginning of gag are shown. 
The functional LTR promoters as well as the initiator element are symbolized by black boxes, while the 
mutated P3 promoter is  depicted as hatched box.  The numbers  indicate the position relative to the 
beginning of the LTR. The primer utilized for reverse transcription is represented by the black arrow. (B) 
Total RNA was extracted and reverse transcribed with poly(dT) primers. The transcriptional activity of the 
mutated promoter complex was analysed by RT-PCRs with oligonucleotides (773/795) and (1431/1409). 
The amplification products of clone A (lane 1) and clone B (lane 2) are shown.
For  the  identification  of  the  full  length  P2  product,  another  set  of  RT-PCRs was 
conducted utilizing the same forward primer (773/795) in combination with different reverse 
primers corresponding to gag, pol and env proviral sequences. While no specific product could 
be amplified with primers corresponding to gag or pol regions (data not shown), a specific PCR 
product was detected with an oligonucleotide (6627/6601) that binds immediately downstream 
of the env splice donor (SD6554) (figure 4.30A). Interestingly, the signal was detected solely in 
the clone A, but could not be amplified from clone B (figure 4.30B). 
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Figure 4.30 A double spliced message originates from the P2 promoter. (A) Primer binding sites 
for the identification of the putative P2 promoter transcript. The proviral DNA of MMTV is shown. The 
unmodified promoter elements of the LTR are indicated by black boxes, while the mutated P3 promoter is 
symbolized by the hatched box. The splice donor (SD) and splice acceptor (SA) sites of the LTR as well 
those utilized for the single-spliced env message are indicated. Forward and reverse primer binding sites 
are represented as arrows. (B) Total RNA was extracted from two cell clones that were stably transfected 
with the proviral  construct and reverse transcribed with poly(dT) primers.  Subsequent RT-PCRs were 
performed with  a  forward  primer  located  downstream of  the  transcriptional  initiation  site  of  the  P2 
promoter in combination with reverse primer corresponding to the env coding region (6627/6601). The 
results obtained with cDNA from clone A (lane 1) and clone B (lane 2) are shown. 
The sequencing analysis  of  the amplification  product  revealed the double  spliced 
ORFe message. Thus, ORFe mRNAs are transcribed from the intact P2/P3 promoter complex as 
well as from the active P2 promoter. In the latter situation, however, the amount of the double 
spliced transcript was almost below the detection limit, suggesting that the activity of the P2 
promoter alone is not sufficient for constitutive ORFe transcription levels. 
According to previous studies, the DNA-binding activity of CDP inversely correlates 
with the differentiation status of the mammary gland epithelial (Zhu et al., 2000). Therefore, 
in a related experiment CDP binding was prevented by a long-term dexamethasone treatment 
which should mimic the hormonal status during pregnancy and lactation. NMuMG cells that had 
been stably transfected with a Mtv-2 based provirus harbouring a mutation of the P3 TATA-box 
within the 5' LTR sequence were grown in the presence of dexamethasone for 96 hours. (The 
CDP binding sites were wild-type in the applied construct.) The doubly spliced ORFe transcript 
was successfully amplified from all tested samples (data not shown), indicating that, in the 
absence of the P3 promoter, the detection of ORFe mRNA depends on the inhibition of CDP 
binding.
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 4.11  The translated ORFe sequence harbours a transmembrane 
spanning domain and TRAF-2 binding motifs
In  order  to  obtain  a  first  impression  about  the  putative  function  of  ORFe,  we 
performed a detailed in silico analysis of its in vitro translated aminoacid sequence (152 AA). 
However,  no results  were  obtained using  BLAST (basic  local  alignment  tool)  search,  even 
though different protein databases (UniProt, Protein database Europe (PDBe), NCBI/BLAST) 
were used. The only exception was a correlation with the gag-pol polyproteins of human and 
mouse betaretroviruses, which was not surprising, since the start of env is known to overlap 
with the end of pol.
When we looked for secondary structure elements, we were however able to identify 
a  transmembrane  spanning  domain  (AA  44-61)  by  using  either  the  prediction  program 
proteinpredict or  interproScan.  The latter application utilizes the TMHMM server which is  a 
specialized prediction tool for the identification of transmembrane helices. Figure 4.31 depicts 
the out-put graph obtained with TMHMM (www.cbs.dtu.dk/services/TMHMM/). 
Figure 4.31 Probabilities of transmembrane helices within ORFe. The output graph of the applied 
prediction program TMHMM (version 2.0) is shown. The number of the ORFe AA are depicted on the x-
axis, while the probability to form a transmembrane domain is shown on the y-axis. The localization of 
the inside and outside segments of the sequence can not be calculated by the algorithm, therefore each 
of the two possibilities is indicated (compare the thin blue and pink lanes).
The program does not  include any algorithm capable  of  distinguishing outer and 
inner  compartments.  Thus,  in  terms  of  the  protein,  those  domains  are  interchangeable. 
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Furthermore,  by  applying  ELM (Eukaryotic  Linear  Motif  resource  for  functional  sites  in 
proteins), we were able to identify one major TRAF2-binding consensus motif (AA 62-65) as 
well  as  one  minor  TRAF2-binding  motif  (AA  131-136).  Tumor  necrosis  factor  receptor 
associated factors (TRAFs) belong to a family of proteins that bind to the cytoplasmic domain 
of the tumor necrosis factor receptor (TNFR) family members (Tsitsikov et al., 1997). To date, 
six members of the TRAF family have been identified, whereby TRAF2 is found associated with 
the intracellular domain of the type II TNF receptor (TNF-RII) and CD40. CD40 as well as the 
TNF-R family members are type I membrane proteins with conserved extracellular cysteine-
rich domains. 
TNF-RI and TNF-RII are present on almost all cell types. Upon ligand binding, they 
stimulate the recruitment of neutrophils and macrophages to the site of infection and activate 
these cells in order to eradicate invading microbes. Most of these physiological tasks, however, 
are mediated by TNF-RI (Abbas et al., 2000).
In contrast,  CD40 is predominantly expressed on B-cells,  macrophages, dendritic 
cells and endothelial cells. Particularly B-lymphocytes and dendritic cells are inevitable for the 
establishment of MMTV infection. Moreover, CD40 mediates the activation of the transcription 
factor NF-κB leading to the (T cell-dependent) B-cell activation as well as to the activation of 
macrophages, dendritic cells and endothelial cells (Abbas  et al., 2000). The stimulation and 
subsequent proliferation of T- and B-cells represents a hallmark of the MMTV infection. 
Taken together, this finding allows the prediction of the subcellular orientation of the 
protein (outside: AA 1-43; transmembrane: AA 44-61; inside: AA 62-152) and additionally 
suggests  a  major  role  of  ORFe  in  the  activation  of  cellular  signal  transduction  pathways. 
Further analyses of the protein are needed to verify these predictions.
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5. Discussion
Mouse mammary tumor virus accounts for the majority of mammary tumours found 
in common laboratory mouse strains as well as in wild animals. During the course of infection, 
a virally encoded superantigen excessively stimulates the immune system of the host, leading 
to an amplification of a sub-set of both B- and T-cells. The virus infects and replicates in these 
cells until it finally reaches the mammary gland epithelial tissue. There, it remains latent until 
the  hormonal  activation  during  pregnancy  and  lactation  leads  to  the  production  of  high 
amounts of viral particles. These are finally passed on via the mother's milk to the newborn 
pups. In addition to this exogenous route of infection, MMTV can be transmitted endogenously, 
if the virus infects and integrates into the cells of the germ line. As a consequence, these 
proviruses are inherited in a Mendelian fashion.
According to the current model of retroviral replication, a single promoter located at 
the boundary between the U3 and the R region is responsible for the generation of all mRNA 
species,  both full-length and spliced. In MMTV, this  major promoter, P1, has been studied 
extensively  because  its  transcriptional  activity  is  highly  enhanced  in  the  presence  of 
glucocorticoid hormones. 
However, unique among retroviruses, an additional promoter, P2, was identified in 
MMTV upstream of the P1 promoter within the central part of the U3 region (Günzburg et al., 
1993). Initially, we focused on the analysis of the regulation of the P2 promoter. However, at 
the very beginning of our studies, we detected another promoter in the close vicinity, which 
was termed the P3 promoter. The project was therefore extended to investigate the regulation 
of these two promoters and to identify possible transcripts. 
 5.1  The P2/P3 promoter complex
Using an improved luciferase reporter construct, we could demonstrate that the P2 
promoter  is  influenced  by  an  upstream  negative  regulatory  element  and  a  downstream 
enhancer. In contrast, the activity of the adjacent P3 promoter is exclusively modulated by the 
downstream enhancer element. Originally, this enhancer was thought to influence transcription 
from the MMTV P1 promoter in cooperation with the hormone responsive element (Gouilleux et 
al., 1991). However, we did not observe any hormone dependency of the P2 or of the P3 
promoter activity in connection with this region (data not shown). Neither did we detect any 
alterations in the luciferase expression levels between the different cell lines tested. Both the 
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P2 and the P3 promoter showed the same relative activities in mammary cells, lymphocytes 
and fibroblasts of murine origin as well  as in MMTV permissive feline kidney cells  and rat 
hippocampal  stem cells.  These data suggest  that  the two promoters are  not regulated by 
tissue specific factors.
The direct  comparison between Mtv-2 and Mtv-8 based sequences allowed us to 
determine the P3 promoter core, which is represented by the consensus sequence TATAAA. In 
contrast,  the P2 TATA-motif  does  contain  a cytosine at  its  fifth  position  (TATACA).  This  is 
uncommon  and,  according  to  the  literature,  indicative  of  a  less  frequent  promoter  usage 
(Bjornsdottir and Myers, 2008; Juven-Gershon et al., 2008). Nevertheless, the central part of 
the U3 region including both promoters appears to be highly conserved among different MMTV 
isolates. Moreover, by analysing the 5' ends of transcripts initiating from the central promoter 
region, we detected an additional initiation site at position 760 (relative to the beginning of the 
LTR).  This  is  in  close vicinity  (61 bp)  to  the previously  described initiation site  of  the P2 
promoter (Günzburg et al., 1993). Both promoter elements showed transcriptional activity in 
reporter  gene  assays;  we  therefore  conclude  that  the  two  promoters  together  with  their 
respective transcriptional initiation sites form a promoter complex in the central part of the 
LTR. According to our knowledge, this is the first time that a promoter complex has been 
described within the LTR of a retrovirus. 
Furthermore, we were able to show that in the absence of hormones, the complex is 
even more potent in initiating transcription than the major P1 promoter. Nevertheless, in our 
experimental system, the global amount of RNAs initiating from the central promoter complex 
did not change upon glucocorticoid stimulation. In contrast, Günzburg and colleagues reported 
an  increase  of  the  transcriptional  activity  of  the  P2  promoter  in  response  to  hormones 
(Günzburg et al., 1993). Thus, the observed constitutive level of transcripts can be explained 
by  the  inability  of  the  central  LTR  promoters  to  respond  to  the  synthetic  glucocorticoid 
dexamethasone. On the other hand, each of the two promoters may be inversely regulated, so 
that any changes would cancel themselves out.
 5.2  Associated chromatin structure
Previous analyses have shown that  the MMTV LTR is covered by an array of  six 
positioned nucleosomes termed F-A (in the 5' to 3' direction). The TATA-box of the major P1 
promoter,  the  hormone responsive  element  and the  binding sites  of  relevant transcription 
factors are covered by a single nucleosome (nucleosome B) that undergoes a characteristic 
remodelling  process  upon  hormonal  induction  (Richard-Foy and Hager,  1987;  Truss  et  al., 
1995; Nagaich  et al., 2004; Vicent  et al., 2004 & 2008). Accordingly, a single nucleosome 
(nucleosome D) has been shown to occupy the P2/P3 promoter region (Richard-Foy and Hager, 
109
5.Discussion
1987). 
In  order  to  decipher  the  hormone  dependency  of  the  central  promoters,  we 
hypothesised that a slight translational movement of the nucleosome D may allow either one 
or the other promoter to be uncovered from these basic protein complexes and thus may 
render  the  relevant  promoter  accessible  to  the  transcriptional  machinery.  Therefore,  we 
determined the  respective  borders  of  the  corresponding nucleosome (nucleosome D)  at  a 
base-pair level of resolution in the presence and absence of hormones. Our results regarding 
the  5'  and  3'  end  of  the  nucleosome  D  correlate  with  previous  low-resolution  mappings 
(Richard-Foy and Hager, 1987). However, we did not detect any difference in the positioning of 
the nucleosome upon hormone induction. This finding seems to argue against a translational 
movement (sliding) as a putative regulatory mechanism. 
However, independent of dexamethasone stimulation, we nevertheless observed a 
nuclease hypersensitive site within nucleosome D  indicating either a nucleosome free region 
(i.e.  the exchange of nucleosomes in and out of  the chromatin)  or  the partial  removal  of 
histone  proteins  (Rando  and  Ahmad,  2007).  Each  possibility  would  allow  the  underlying 
sequence  to  be  more  easily  accessible  to  DNA-binding  proteins,  thus  reflecting  the 
transcriptional  competence of the investigated region.  Interestingly, this additional site has 
been described previously using in vitro assembled chromatin on the MMTV LTR (Belikov et al., 
2000). However, due to the applied experimental system, the nucleosome positioning over the 
LTR as well as the nuclease hypersensitive sites within nucleosome B (indicating the hormone 
response of the P1 promoter) and nucleosome D (occupying the P2/P3 promoter region) were 
exclusively observed in the presence of glucocorticoids. 
By  investigating the  corresponding post-translational  histone  modifications  in  the 
absence of  dexamethasone,  we were able  to relate  the 'open chromatin'  formation at  the 
nucleosome  D  with  signs  of  active  transcription  from  the  P2/P3  promoter  region.  The 
nucleosomes D, C, and B (covering the P2/P3 promoter complex, the region in between and 
the P1 promoter, respectively) exhibit elevated methylation levels at lysine 4 of histone H3 
(H3K4me3). This peculiar methylation increases when genes become active and is known to 
specifically localize to 5' ends of ORFs (Heintzman et al., 2007). However, it has been shown 
that this modification recruits not only activating proteins, but also transcriptionally repressing 
factors (Berger, 2007). 
Furthermore,  we  detected  (in  absence  of  dexamethasone)  the  highest  levels  of 
methylation  at  lysine  36  on  histone  H3  (H3K36me3)  at  nucleosome  D  compared  to  the 
nucleosome  C  and  B  regions.  This  modification  is  known  to  be  intimately  linked  to  the 
elongation phase of the RNA polymerase II.  The CTD-phosphorylated (elongating) enzyme 
harbours  intrinsic  histone  acetyltransferase  activities  to  facilitate  its  passage  through  the 
nucleosomes.  However,  by  recruiting  the  Set2  histone  methyltransferase  (that  specifically 
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modifies H3K36), it promotes the association of the Rpd3S histone-deaceylase complex. In 
turn, the transcription elongation-induced acetyl-groups are removed (Workman, 2006). Taken 
together, the elevated methylation levels at nucleosome D provide further evidence for the 
transcriptional activity of the P2/P3 promoter complex.
During our work on the regulation of these promoters, a colleague in our laboratory 
was independently able to identify (in the proviral context) a double-spliced message carrying 
a 459 nucleotide long ORF (“ORFe”) that initiates from the promoter complex. The transcript 
comprises  sequence  elements  from the  LTR,  the  5'  untranslated  region  and  parts  of  env 
(Rouault  et al.,  2007).  Hence,  the close vicinity  of  the two promoters  complicate  a direct 
correlation between the activity of either promoter with the emergence of the double spliced 
transcript. 
 5.3  The influence of acetylation
Besides  methylation,  active  transcription  has  additionally  been  associated  with 
increased acetylation levels at histone proteins (Strahl and Allis, 2000). However, in terms of 
the  MMTV LTR,  this  modification  has  been  controversial.  The  accumulation  of  intracellular 
acetylation levels has been associated with an increase in the promoter activity as well as with 
transcriptional repression  (Bartsch  et al., 1996; Lambert and Nordeen, 1998; Wilson  et al., 
2002; Aoyagi and Archer, 2007).  
By  investigating  the  P2/P3  promoter  region  and  the  region  of  the  hormone 
dependent  P1  promoter  (i.e.  the  corresponding  nucleosomes)  separately,  we  detected 
differences in the response to the histone deacetylase (HDAC) inhibitor trichostatin A. While in 
our hands, the transcriptional activity of the major P1 promoter (in the absence of hormones) 
remained  almost  unaffected,  the  amount  of  ORFe  specific  transcripts  declined  upon  TSA 
treatment, indicating that the generation of the double spliced ORFe mRNA depends on the 
activity of histone deacetylating enzymes. Furthermore, we could demonstrate that the effect 
of TSA is accompanied by an increase of acetyl-groups at the corresponding nucleosome D, 
suggesting that this kind of regulation specifically modulates the activity of the P2/P3 promoter 
complex. In contrast, the acetylation levels of nucleosome B that is covering the P1 promoter 
did not change upon TSA treatment. 
In accordance with our observation that the generation of the double spliced ORFe 
message depends on active histone deacetylases, we could show that the highest levels of 
HDAC1, the most prominent representative of  these enzymes, are found at nucleosome D 
compared to nucleosome C and B regions. This finding indicates that these regulatory enzymes 
are intimately linked to the region containing the P2/P3 promoter complex. Interestingly, TSA 
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treatment did not change the overall  rate of transcripts initiating from the P2/P3 promoter 
complex. Instead, it increased the emergence of unspliced RNAs (in regard to the first intron). 
Although it has recently been demonstrated that TSA is able to inhibit mRNA splicing in vitro 
(Kuhn et al., 2009), no direct relationship between histone acetylation and mRNA splicing has 
as yet been reported, indicating the involvement of other proteins. 
Hence,  the idea that  this  particular  modification targets  a  non-histone protein is 
further  supported by  the  fact  that  the  response  to  TSA was  observed after  an  long-term 
(overnight) incubation period. In contrast, a shorter treatment (2 hours) failed to induce any 
detectable changes.
 5.4  Model for the transcriptional regulation of ORFe
HDACs themselves lack any DNA-binding capacity (Haberland  et al., 2009). Thus, 
they have to associate with other proteins in order to exert their function in a certain genomic 
context. Binding sites for the transcriptional regulator CCAAT displacement protein (CDP) have 
been recently mapped to the NRE of the MMTV LTR (Zhu et al., 2000; Zhu and Dudley 2002). 
This  ubiquitously  expressed  transcription  factor  is  known  to  prevent  the  transcription  of 
numerous genes during early developmental stages (Nepveu, 2001; Sansregret and Nepveu, 
2008). Moreover, it  has been demonstrated that CDP is able to recruit  HDAC1 in order to 
establish a repressing chromatin architecture (Li et al., 1999). 
Using LTR deletion  constructs,  we  could  demonstrate  in  luciferase  reporter  gene 
assays that the activity of the P2 promoter is indeed modulated by the NRE. Moreover, the co-
transfection of the exogenously expressed CDP p110 isoform resulted in a decrease of the 
transcriptional activity of the P2 promoter. This downregulation was observed in the context of 
the full length LTR as well as in situations when the P2 promoter was exclusively under the 
control of the NRE. Furthermore, by mutating the CDP binding sites as well as the TATA-box of 
the P3 promoter, we were able to detect a specific transcript of the P2 promoter in the context 
of the full-length provirus. The sequence of this transcript corresponded to the double-spliced 
ORFe message. 
However, we noticed major discrepancies in the amount of produced mRNAs. If the 
transciptional  elements of  both  promoters  (P2 and P3)  are  functional,  the level  of  double 
spliced ORFe mRNA is much higher than in the situation in which only the TATA-box of the P2 
promoter  is  left  unmodified.  This  results  in  only  marginal  amounts  of  the  transcript.  We 
conclude therefore that the P3 promoter is responsible for the generation of constitutive levels 
of ORFe mRNA. Furthermore, we propose that, by transcriptional interference, the activity of 
the upstream located P2 promoter negatively influences the neighbouring P3 promoter. 
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Thus, the overall  genomic organization of the central  promoter complex is highly 
reminiscent of a special mode of transcriptional regulation that was originally described for the 
his3 promoter  of  S.  cerevisiae.  Here,  two  TATA-boxes,  in  most  cases  one  canonical  TATA 
sequence (TATAAA) and one noncanonical  sequence, are arranged in close vicinity to each 
other. Both promoter elements are able to direct transcription, either of them from distinct 
start sites. Usually, the downstream promoter contains the canonical TATA motif and is able to 
increase its transcriptional activity upon induction, whilst the upstream one is used for low 
levels of gene expression and additionally can be repressed by specific factors (Butler and 
Kadonaga, 2002). According to this example and taking in account all our findings, we propose 
the following model for the regulation of the MMTV central promoter complex: 
Figure 5.1 Regulation of the P2/P3 promoter complex.  The TATA-boxes of  the P2 and the  P3 
promoter, respectively, are indicated as boxes, while putative regulators are depicted as circles/ovals. The 
transcriptional initiation sites are marked by arrows. The size of the transcript 'ORFe' correlates with the 
observed levels of double-spliced mRNA. (A) In differentiated cells, CDP (CCAAT displacement protein) is 
post-translationally modified by acetylation. Consequently, its DNA-binding activity is prevented, which 
allows the P2 promoter to be fully active. Simultaneously, the activity of the adjacent P3 promoter is 
downregulated by transcriptonal interference. (B) In undifferentiated cells,  CDP is able to bind to its 
cognate  sites  on the  DNA. Furthermore,  it  recruits  the HDAC1 (histone deacetylase  1)  enzyme that 
removes acetyl-groups from histones as well as other histone-associated proteins. Consequently, the P3 
promoter becomes active and transcribes constitutive levels of double spliced ORFe mRNA.
The  level  of  double  spliced  ORFe  mRNA  is  regulated  by  the  mutually  exclusive 
activity of  two adjacent promoters. The upstream located P2 promoter is  active when the 
binding of the transcriptional repressor CDP is prevented. Studies have shown that the ability 
of CDP to bind DNA is lost upon post-translational acetylation of the protein (Li et al., 2000). 
Under  these  conditions,  transcripts  are  assumed  to  initiate  predominantly  from  the  P2 
promoter. As a consequence, the activity of the P3 promoter is suppressed by transcriptional 
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interference.
In contrast, an active P3 promoter implies that the P2 promoter has to be repressed. 
CDP is known to recruit HDAC1 upon DNA binding, thus allowing the removal of acetyl-moieties 
from histone as well  as non-histone proteins.  Moreover,  CDP has been shown to be  highly 
active during early developmental stages. Consequently, the activity of the P2 promoter should 
be suppressed in undifferentiated tissues, allowing proper transcription from the downstream 
located P3 promoter. 
Taken together, the generation of constitutive levels of ORFe mRNA is dependent on 
the CDP-mediated downregulation of the P2 promoter. Hence, the amount of ORFe transcripts 
is  inversely  correlated with the differentiation  status of  the infected cell.  According to  our 
model,  the  previously  reported  increase  in  P2  transcriptional  activity  upon  glucocorticoid 
stimulation (Günzburg et al., 1993) rather represents a consequence of the diminishing DNA-
binding activity of CDP during cellular differentiation than a direct influence of the hormone 
itself. 
 5.5  Putative ORFe function
In order to further characterize the ORFe protein, we performed an in silico analysis 
of  the  translated ORFe sequence  (152 AA).  With  this  approach,  we  uncovered two major 
characteristics of the putative protein that allowed us to deduce its possible function during 
MMTV infection. 
First, we identified a transmembrane spanning domain ranging from AA 43 to AA 61. 
Interestingly, diverse viral species which do infect lymphocytes harbour the coding information 
for similar proteins within their genome. For instance, the related retrovirus HTLV-1 (Human T-
lymphotropic virus type-1) encodes for the protein p12 which contains two transmembrane 
regions. Upon expression, this protein accumulates in the ER and cis-Golgi apparatus, where it 
binds key regulatory proteins that are involved in calcium-mediated cell signalling pathways. It 
is assumed that p12 plays a role during the establishment of HTLV-1 infection through the 
activation  of  host  cells  (Michael  et  al.,  2004).  Besides,  several  members  of  the  gamma-
herpesvirus subfamily express so-called terminal membrane proteins (TMPs), which are named 
according to their  localization within the viral  genome (Brinkmann and Schulz,  2006). The 
most prominent member, the latent infection membrane protein-1 (LMP1) is expressed by the 
Epstein-Barr virus (EBV) during the latency phase of infection. This protein lacks any intrinsic 
enzymatic activity. Instead, the six transmembrane spanning domains induce the spontaneous 
aggregation of the protein within the plasma membrane (Brinkmann and Schulz, 2006). As a 
consequence, LMP1 mediates the association of cellular proteins of the tumor necrosis factor 
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receptor  (TNFR) signaling pathway,  resulting in  the nuclear  translocation of  the ubiquitous 
transcription  factor  NF-κB  (McFarland  et  al.,  1999).  These  events  finally  stimulate 
differentiation  and proliferation  processes  and additionally  protect  virus-infected cells  from 
apoptosis. In summary, the signalling pathways induced by LMP1 are remarkably similar to 
those mediated by CD40, a type I membrane glycoprotein of the TNFR-superfamily (Abbas et 
al, 2000). Under physiological conditions, CD40 is predominantly expressed by APCs which 
include B-lymphocytes, dendritic cells, macrophages and endothelial cells. Upon ligand binding, 
it provides key activation signals in T-cell dependent B-cell activation such as the upregulation 
of surface molecules, the stimulation of antibody production and isotype switching as well as 
the secretion of cytokines and protection from apoptosis (van Kooten and Banchereau,2000; 
Bishop et al., 2002). 
Interestingly,  the  same  cellular  pathway  is  also  exploited  by  HIV-1.  Martin  and 
colleagues demonstrated recently that HIV-1 incorporates CD40L (a surface molecule that is 
expressed  by  activated  helper  T-cells)  into  emerging  viral  particles  (Martin  et  al.,  2007). 
Thereby, the virus triggers an abnormal activation of B-cell lymphocytes that is supposed to 
result in a more efficient spreading of the virus to CD4+ T-cells (Martin et al., 2007). 
Furthermore, the direct interaction of CD40 with CD40L has already been shown to 
represent a critical step during early phases of MMTV infection. Mice which were defective of 
CD40L failed to induce any deletion of cognate T-cells (a hallmark of MMTV infection) after 
being exposed to infectious viruses. Furthermore, the response of T-cells in CD40L-minus mice 
was impaired in vitro, but could be reconstituted by adding B-cells that had been activated by 
recombinant CD40L (Chervonsky et al., 1995). 
Second, we were able to identify one major and one minor TRAF-2 (TNFR-associated 
factor-2) binding motif in the C-terminal part of the protein (AA 62 to AA 65 and AA 131 to 
136).  TRAFs  are  common  signal  transducers  that  associate  intracellularly  to  ligand-bound 
receptors  of  the  TNFR  superfamily.  To  date,  six  TRAFs  are  known,  the  majority  of  which 
promote cell survival via activation of protein kinase cascades (NF-κB, AP-1), leading to the 
proliferation and differentiation of the respective cell (Lee and Lee, 2002). 
Taken  together,  we  suggest  that  ORFe  mimics  CD40  activation  and  therefore  is 
supposed  to  be  expressed  during  the  establishment  of  MMTV  infection.  Furthermore,  we 
propose that upon TRAF-2 binding, ORFe induces the activation and subsequent proliferation of 
B-lymphocytes, thereby contributing to the amplification of virus infected cells. This hypothesis 
implies  that  ORFe is  predominantly  expressed from exogenous  viruses.  We have provided 
(preliminary) evidence for this assumption by demonstrating that ORFe mRNA is detectable in 
GR cells (productively infected with a Mtv-2 provirus) as well as from NMuMG cells that have 
been stably transfected with a Mtv-2 based proviral sequence (N2AnE5). In contrast, no signal 
was  obtained  from  parental  NMuMG  cells  which  harbour  three,  yet  different  endogenous 
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retroviruses (Rouault et al., 2007). Further experiments are needed to test these hypotheses. 
Indeed, a detailed characterization of ORFe might uncover additional mechanisms during the 
establishment of MMTV infection.
In conclusion, we were able to demonstrate by using an epigenetic approach that the 
P2/P3 promoter complex represents a transcriptional active region within the U3 region of 
MMTV. In contrast to the major P1 promoter, both promoters of the complex seem to work 
independently  of  hormonal  stimulation.  Hence,  the  tight  transcriptional  regulation  of  their 
product suggests a regulatory function of the corresponding ORFe protein. This idea is further 
supported  by  the  presence  of  two  TRAF-2  binding motifs  which  were  identified  in  the  C-
terminal part of the protein. Furthermore, we were able to establish a model showing that the 
amount  of  ORFe  mRNA is  dependent  on  the  activity  of  the  transcriptional  regulator  CDP. 
Accordingly,  ORFe  expression  is  supposed  to  occur  in  undifferentiated  cells  and  therefore 
during the latency phase of MMTV infection. 
Thus, the LTR of MMTV does contain two elements that are inevitable for the early 
stages of  infection;  the  coding information  for  Sag and the P2/P3  promoter  complex.  We 
propose  that  similar  to  Sag,  which  upon  expression  accounts  for  the  differentiation  and 
proliferation  of  T-cells,  the  transcriptional  product  of  the  P2/P3  promoter  complex  (ORFe) 
induces the activation of infected B-cells. 
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